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Abstract 
Introduction 
Extramural venous invasion (EMVI) is a poor prognostic factor in rectal cancer. It is 
detected by magnetic resonance imaging (MRI) and histopathological analysis. 
Neoadjuvant chemoradiotherapy (CRT) is often given to patients with locally 
advanced disease however the clinical outcomes of EMVI-positive tumours following 
such treatment remains unknown. This thesis aimed to investigate the radiological, 
pathological and molecular changes which occur in EMVI-positive tumours following 
CRT to determine whether these changes can predict prognosis.  
Methods 
Following a systematic review (SR) of EMVI in rectal cancer, a series of studies were 
conducted. Patients were identified from a prospectively maintained database of 
primary rectal cancers who were scheduled for CRT followed by curative surgery 
between 2006 and 2012. Imaging and pathology samples were reviewed and tissue 
samples were further processed for molecular profiling using micro-RNA analytical 
techniques. Data were correlated with disease-free survival (DFS), recurrence rate 
and patterns of relapse.  
Results 
SR demonstrated that EMVI is associated with locally advanced tumours, distant 
disease recurrence and worse overall survival. However there is a variation in 
technique and definitions which makes interpretation of historical studies 
problematic. EMVI is an important consideration in the multidisciplinary management 
of rectal cancer as most clinicians use it to influence treatment decisions. MRI may 
allow for improved detection rates of EMVI following CRT compared with routine 
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histopathology techniques and it is an independent prognostic factor for recurrence 
at 3 years. Patients with persistent EMVI following CRT have improved DFS if given 
adjuvant chemotherapy. Finally, EMVI-positive tumours express specific patterns of 
microRNA sequences.  
Conclusion 
 
EMVI is a poor prognostic factor following CRT. Patients with evidence of EMVI may 
be considered for intensive adjuvant chemotherapy and more frequent surveillance 
for distant disease. Unique molecular signatures may hold the key for future 
management strategies. These results have led to the development of the MARVEL 
Study. 
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Chapter 1  
Overview of rectal cancer 
1.1. Anatomical considerations of the rectum 
The embryology and anatomy of the rectum are central to the understanding of the 
staging, surgery and pathology of rectal cancer. They explain the possible routes for 
tumour spread, both for local and metastatic disease, in addition to how surgical 
treatment can be applied most effectively in order to optimise patient outcomes. 
Furthermore, direct tumour penetration through the anatomical layers of the bowel wall 
into the surrounding tissue and vasculature influences prognosis and survival. 
Therefore, knowledge of the pelvic anatomy is essential to plan curative treatment.   
1.1.1. Embryology of the hindgut and rectum 
The rectum develops from the embryological hindgut as a blind-ending tube in the 
caudal part of the embryo. The hindgut is the distal part of the alimentary canal and 
includes the distal third of the transverse colon, the sigmoid colon, the rectum and the 
upper portion of the anal canal.  
As the embryo develops the primitive alimentary canal, which is initially in broad 
contact with the posterior abdominal wall becomes suspended by a thin dorsal 
mesentery. This is the main blood supply to the primitive gut by the end of the fourth 
week of gestation. Gradually the gut rotates and positions itself such that it remains 
suspended by a central fan-shaped mesentery with three main arterial trunks 
supplying large sections of the bowel. These main arteries correspond to the foregut, 
midgut and hindgut – the inferior mesenteric artery becoming the principle vessel that 
supplies blood to the hindgut.   
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1.1.2. Anatomy of the rectum and structure of the bowel wall 
The rectum forms the distal part of the lower gastrointestinal tract. It lies in the pelvis 
and is intimately surrounded by important neurovascular structures that control sexual 
function. Proximally, it is a continuation of the sigmoid colon and terminates at the anal 
canal. The exact beginning of the rectum remains a point of contention between 
anatomists and surgeons. This possibly explains the different values given for the 
length of the rectum that is commonly stated to be 15cm but has been quoted in the 
range of 13-18cm (Salerno et al., 2006). 
Anatomically, the point at which the rectum begins can be delineated by the structure 
of the bowel wall. The colon is distinguished from the small intestine by the thickened 
bands of muscle which surround the bowel – the taeniae coli; the sacculations of the 
bowel wall between these bands – the haustra; and the fatty projections of the 
omentum – the omental appendices. These features are all absent in the rectum. The 
taeniae of the colon can be followed to the point where they spread out to form a 
continuous layer of longitudinal muscle forming the outer coat of the rectum. This point 
is sometimes called the rectosigmoid junction and lies anterior to the S3 vertebral body 
of the spinal column. It continues distally until it perforates a sheet of muscle 
comprising the floor of the pelvis – the levator ani. As the bowel exits the pelvic floor it 
becomes the anal canal. The condensation of muscle fibres forms a sling around the 
rectum creating a sharp bend of approximately 80 degrees known as the anorectal 
flexure. This sling of muscle provides an important mechanism for faecal continence. 
The portion of the rectum which lies immediately above the levator ani is known as the 
ampulla, and is supported by the anococcygeal ligament. This produces a dilatation of 
the rectum acting as a reservoir which further helps in faecal continence. Therefore, 
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disruption of the anatomy from surgical treatment can lead to significant functional 
consequences.  
Immediately below the outer longitudinal coat of muscle lies a layer of circular 
musculature. This layer helps give the rectum its characteristic appearance when 
visualised anteriorly. Three internal folds of the mucosal and sub-mucosal layers which 
overlie the circular muscle of the rectum produce lateral flexures, transverse folds or 
valves of Houston. These may be referred to as the ‘rectal shelves’ and the middle 
shelf in the male can provide an important landmark for the pelvic surgeon where the 
peritoneum reflects on to the dome of the bladder. 
As with most viscera contained within the abdominal and pelvic cavities, the rectum is 
partly covered with a thin layer of tissue called the peritoneum. This layer is in 
continuation with the lining of the abdomino-pelvic compartment. The peritoneal 
covering varies along the length of the rectum. In the upper third, it covers the anterior 
and lateral parts of the rectum; the middle third is only covered anteriorly and the distal 
third has no covering at all. The peritoneal lining reflects back on itself to become 
continuous with the pelvic wall. This reflection differs slightly between males and 
females; in males the peritoneum continues over the posterior wall of the bladder 
forming the floor of the recto-vesical pouch. However, in females the peritoneum 
passes along the posterior fornix of the vagina forming the recto-uterine pouch.   
1.1.3. Vasculature and lymphatic drainage 
The rectum is supplied by three arterial trunks - figure 1. The superior rectal artery is 
a continuation of the inferior mesenteric artery and is considered the major blood 
supply to the rectum. It predominantly supplies the proximal part of the rectum 
although there are several anastomoses which occur along its length. The two middle 
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rectal arteries are branches which arise from the internal iliac artery and supply the 
middle and distal thirds of the rectum. The inferior rectal artery comes from the internal 
pudendal artery and supplies the anorectal junction at its most distal part. These 
vessels and their tributaries produce numerous anastomoses in the submucosal layer 
of the rectum.  
 
Figure 1 – Arterial anatomy of the rectum  
The venous drainage of the rectum flows into the superior, middle and inferior rectal 
veins. These vessels drain into the inferior mesenteric, internal iliac, and internal 
pudendal veins, respectively. There are further anastomoses between the tributaries 
of these veins which flow into both the systemic and portal venous systems. The 
superior rectal vein drains into the portal system whilst the middle and inferior veins 
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drain into the systemic circulation. The importance of the venous drainage is discussed 
in relation to tumour spread in later sections. This is shown in figure 2. 
 
 
 
 
Figure 2 – Venous drainage of the rectum 
The lymphatic drainage of the rectum follows the blood vessels. Therefore, in the 
upper third, drainage is along the superior rectal vessels which drain into the inferior 
mesenteric nodes, then on to the lumbar para-aortic nodes and into the thoracic duct. 
The middle third of the rectum drain into the middle rectal vessels then on to the 
internal iliac nodes before also flowing into the lumbar para-aortic nodes and thoracic 
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duct. The lower portion of the rectum drain along the inferior rectal and pudendal 
vessels before reaching the deep pelvic nodes and the para-aortic nodes. There is 
some drainage into the inguinal nodes.  
1.1.4. The mesorectum 
The rectum displays a feature not seen in the upper part of the alimentary tract - a 
circumferential lymphovascular envelope called the mesorectum which surrounds it 
along the majority of its length – figure 3. It is derived from the dorsal root mesentery 
and includes vascular contributions from the hindgut vessels that drain into the portal 
system and the iliac vessels of the systemic circulation. The outermost boundary of 
this fatty layer is defined by the mesorectal fascia (MRF), which seems to act as an 
initial oncological barrier to the spread of tumour cells.  
Although the entire alimentary tract may be thought of as a muscular tube surrounded 
by lymphovascular mesentery and fascia, it is most pronounced and a distinct unit in 
the rectum. An avascular anatomical plane can be developed by careful and precise 
dissection in surgery of the rectum (Heald, 1988). This type of fascia is not present 
throughout the length of the gut and has been difficult to demonstrate in cadaveric 
models. This may explain the conspicuous absence of the mesorectum from the 
majority of anatomy textbooks. Further, the lack of such a distinct fascial plane 
containing the local lymphovascular vessels may be the reason why tumours of other 
parts of the gastro-intestinal system (oesophagus and stomach) have less favourable 
prognosis.   
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Figure 3 – Schematic diagram of the mesorectum in two planes  
 
 
 
 
 
 
32 
 
1.2. Surgery for rectal cancer 
1.2.1. Principles of rectal cancer surgery 
Miles described the first ‘oncological’ operation for rectal cancer in 1908 (Miles, 1908). 
Whilst this improved the surgical treatment of rectal cancer from an almost one 
hundred percent mortality, it was still associated with a huge morbidity and mortality 
rate compared to modern treatment. The current-day “total mesorectal excision” (TME) 
operation proposed by Heald, is based on the embryological origin of the rectum and 
pathological spread of cancer (Heald et al., 1982, Heald and Ryall, 1982). Despite 
oncological therapies having done much to improve survival in recent years, it is good 
quality oncological surgery that remains the most important determinant of prognosis 
in rectal cancer. The acceptance and popularisation of TME has led to much improved 
survival demonstrated by the low local recurrence rates of less than 5%. Conversely, 
poor surgery yielding a sub-standard resection specimen invariably leads to local 
recurrence (Quirke et al., 1986). More recent evidence from the randomised Medical 
Research Council of United Kingdom CR07 and National Cancer Institute of Canada 
– CTG CO16 (CR07) trial (Sebag-Montefiore et al., 2009) has shown the primary 
importance of good quality surgery and how inadequate surgery can be only minimally 
compensated for by chemoradiotherapy (Quirke et al., 2009).  
As mentioned above, the fascia surrounding the mesorectum seems to act as an 
oncological barrier to the spread of tumour. This avascular plane can be developed by 
precise dissection to allow excision of the tumour with its fascial neurovascular 
envelope in one “monobloc” specimen. Gaining tumour clearance at the MRF that 
bounds the mesorectum is therefore hugely important - this boundary is referred to as 
the circumferential resection margin (CRM) by surgeons. The lines of excision are 
defined by the embryological legacy of the primitive gut. 
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1.3. Staging of rectal cancer 
In rectal cancer, a patient’s prognosis is determined by specific anatomical and 
tumour-related features. This information forms the basis of the various staging 
systems that have been developed and evolved over the years. Further, it influences 
treatment decisions and provides an estimate for the potential of local or distant 
recurrence, and ultimately long-term survival through risk-stratification models. These 
common prognostic factors include depth of tumour spread, the relationship of the 
tumour to the mesorectal fascia, the presence/absence of nodal disease, and 
presence/absence of tumour in the local veins – extramural venous invasion (EMVI).  
 
1.3.2. The history of rectal cancer staging 
1.3.2.1 Lockhart-Mummery staging 
Lockhart-Mummery proposed the first staging system for rectal cancer in the early 
1920s (Lockhart-Mummery, 1926). This classification was based on the identification 
of lymph nodes containing tumour and the depth of invasion. The study contained 200 
patients who had undergone perineal excision. Patients were grouped in to three 
categories (A-C) shown in table 1. The ‘five-year cure’ was significantly improved in 
patients in stage A compared to B and C.  
 
1.3.2.2. Dukes staging 
Dukes evolved the Lockhart-Mummery system and made it more specific with regards 
to the spread of tumour into the bowel wall (Gordon-Watson, 1930). A study in 1932 
of 215 patients classified patients into Stage A-C (Dukes, 1932). Stage A tumours 
were confined to the wall of the rectum compared with Stage B where tumour had 
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spread beyond the bowel wall into the surrounding tissues. Stage C consisted of any 
tumour in which there was evidence of tumour in regional lymph nodes. The more 
advanced the stage, the worse the prognosis. The Dukes system is still used today 
although modifications over the years have attempted to address the heterogeneity of 
tumours particularly in Stage B and C. This is shown in table 2. 
 
1.3.2.3. Kirklin and Astler Coller Staging 
Modifications of the Dukes system first gained popularity when first Kirklin (Kirklin et 
al., 1949), then Astler and Coller sought to address the heterogeneity within the 
original system.  
A further modification by Astler and Coller in 1954 took into account Kirklin’s 
modification but also included sub-staging of Dukes C tumours (Astler and Coller, 
1954). The five-year survival was adversely related to increasing depth of invasion 
and the presence of lymph nodes. Table 3 shows the staging system and associated 
survival rates.   
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Table 1 – Lockhart-Mummery Classification 
Stage Description 5-year cure rate 
A Favourable cases where tumour had not 
invaded the muscle layer; no lymph node 
involvement 
73.7% 
B Tumour spread to the muscle layer of the 
bowel but no appreciable lymph node 
involvement 
44.1% 
C Large and fixed tumours with lymph node 
involvement 
44.4% 
 
Table 2 – Dukes original classification of rectal cancer and prognosis 
  Dukes Stage Gross description of tumour spread Alive at 3 years (%) 
A Growth limited to rectal wall 80 
B Extension of tumour to extrarectal tissues 73 
C Metastases in regional lymph nodes 7 
 
Table 3 – Astler-Coller Staging system  
Stage Description 5-year survival (%) 
A Tumour invades submucosa 100 
B1 Tumour invades muscularis  
Propria 
66.6 
B2 Tumour invades subserosa 53.9 
C1 Regional lymph nodes; confined 
to muscularis 
42.8 
C2 Regional lymph nodes; beyond 
muscularis 
22.4 
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1.3.2.4. TNM Staging 
The original ‘TNM classification’ was developed by French surgeon Pierre Denoix 
(Denoix, 1946) and subsequently published by the Union International Contre le 
Cancer (UICC) ((UICC), 2010). There have been several revisions since its first 
proposal in the 1940s which relate to improved prognostic knowledge, resulting in 
further sub-divisions of the original three categories. Since 1959 these modifications 
have been guided by the American Joint Committee for Cancer (AJCC) where each 
category has been given an associated ‘stage’. Each revision has been published as 
an edition of the AJCC Cancer Staging Manual. The current 7th edition is shown in 
table 4. 
This system is based on three important staging sub-categories – tumour depth or 
penetration through the bowel wall (T); the presence and extent of nodal disease (N); 
and the presence of distant metastases (M). The increasing numerical value of the 
sub-stage indicates a worse prognosis, eg T4 is worse than T1. One or more of these 
combinations of TNM are associated with a stage or sub-stage.  
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Table 4 – 7th Edition of TNM classification of (colo)rectal cancer 
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The TNM system developed a way of categorising patients into a prognostic group 
which could standardise treatment and offer a survival estimate. However, the basis 
of the model is that patients can only be placed in one group – this is referred to as a 
‘bin model’. The first five editions of the AJCC Staging Manual changed very little, for 
example, the only major revision in the fifth edition compared to the first was that T2 
tumours were ‘downgraded’ from stage II to stage I. The sixth edition highlighted some 
of the difficulties with this system. For example, the basis of the TNM classification is 
that as one progresses through the stages the prognosis, and thus survival, become 
worse. However current evidence would suggest that patients staged as IIb according 
to the sixth edition have a worse survival than patients staged IIIa [O’Connell 2004]. 
This led to further modification and the publishing of the current 7th edition (UICC, 
2009). 
In some cases, tumour may be seen as isolated deposits – tumour deposits; which 
are not in continuity with the primary cancer. By definition these are classified as 
metastases although they are confined to the mesorectal fat and thus within the local 
field. In 5th edition, these deposits were classified on the basis of size. Those deposits 
which were less than 3mm were defined as tumour deposits and those greater than 
3mm as lymph nodes regardless of histological features (Sobin and Fleming, 1997). 
The 6th edition defined these deposits based on contour and categorised them as 
venous deposits if irregular in outline, and lymph nodes if smooth (Sobin, 2002). There 
remains confusion with regards to venous deposits with regards to their definition and 
implication. Pathologists have previously classified venous invasion based on the 
integrity of the vessel wall. Those which have an intact wall have been described as 
‘filling’ or ‘floating’ type and where there is disruption of the wall it is called ‘occlusive’ 
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or ‘infiltrating’ (Sternberg et al., 2006, Ouchi et al., 1996, Talbot et al., 1981, Jass et 
al., 1986). 
Whilst the TNM provides a universal language for the staging of tumours, there are 
difficulties associated with maintaining its accuracy with regards to prognosis, 
particularly as newer prognostic factors are identified. This also means that any 
evolution in the histopathological definitions must also be reflected in the staging 
system.  
An important distinction which must be made is that of differentiation within staging, 
i.e. clinical, radiological or pathological. Further, the original TNM stage does not 
account for the use of pre-operative or neoadjuvant treatment and has thus led to the 
use of prefixes so to alert clinicians as to which type of stage is being offered. For 
example, the prefix ‘p’ denotes the pathological stage whereas ‘y’ denotes the use of 
neo-adjuvant treatment. More recent modifications have included prefixes such as ‘mr’ 
to include magnetic resonance imaging (MRI) based staging. Prefixes may be 
combined, for example a patient who has had neo-adjuvant treatment that is being 
subsequently staged by MRI would have the prefix ‘ymr’. Equally, the same patient’s 
pathological staging would be ‘yp’. However, it is important to appreciate that these 
newer modifications and their use remain personal to individual units and have not 
been formally introduced into the nomenclature.   
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1.4. Assessment of rectal cancer 
1.4.1. Imaging assessment 
1.4.1.1. Overview of imaging in staging of rectal cancer 
In recent years, imaging has become a central part of the staging of rectal cancer. This 
involves assessing the local and distant spread of tumour. Choosing which imaging 
modality can optimally stage the extent of disease depends on the ability of the 
technique to identify the key prognostic features. These factors include a combination 
of traditional staging information such as tumour depth, nodal disease and metastatic 
spread – TNM classification; as well as more novel morphological characteristics such 
as extramural venous invasion (EMVI) and proximity of the tumour to the CRM.  
The two common modalities used for the local staging of disease (spread of tumour 
within the pelvis) are MRI and endo-anal ultrasound (EAUS). Computed tomography 
(CT) is the ‘gold standard’ investigation for staging distant disease. This is metastatic 
disease outside the pelvis such as liver or lung deposits. In some circumstances where 
there is uncertainty regarding the presence of metastatic disease, additional complex 
imaging in the form of positron emission tomography (PET) may be used to delineate 
lesions in more detail or identify minute areas of disease. Nevertheless, whichever 
imaging modalities are decided on, it is important to obtain as much information on 
tumour behaviour, spread and morphology in order to offer patients the most beneficial 
treatment and the best clinical outcomes. 
1.4.1.2. MRI 
MRI has revolutionised the pre-operative management of patients. The image 
resolution has improved in recent years due to advances in sophisticated multiple 
element coil arrays. Modern MRI machines use multiple surface coils which are 
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combined in an array and connected to amplifiers with multiple receiver channels – 
the result of this is a single image produced by information from each coil. This 
configuration has superseded endorectal coils as they produce high-resolution images 
with much wider coverage of the local anatomy.  
Its accuracy depends, however, on user expertise and correct technique during the 
procedure. For example, correct field alignment through the long axis of the rectum is 
an important determinant of accuracy. This can be seen in figure 4. Incorrect 
positioning and technique will lead to over- or under-staging of tumour depth and 
consequently influence treatment decisions – figure 5. Ideally, one should use T2-
weighted images for tumour detail. It may be necessary to use thin coronal sections 
for low tumours in addition to the sagittal images for planning and axial images through 
the field. MRI is able to provide detail on the structure of the rectal wall as well as 
regional information about the remainder of the pelvis and perineum. Other technical 
information can be seen on MRI such as the presacral fascia, sphincter complex and 
peritoneal reflection – figure 6. 
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Figure 4 – Imaging planes to stage tumours of the rectum accurately. The white lines 
represent the axis through which the images are taken. This is of key importance to 
stage tumours accurately. 
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Figure 5 – Incorrect plane alignment for MRI of the rectum resulting in under-staging 
and over-staging of tumour. Sagittal image showing low lying rectal tumour. Yellow 
dashed line corresponds to the alignment of the right upper image on which tumour 
seems to be infiltrating through the muscularis (over-staging). Right lower image was 
produced using the correct alignment (red dashed line on sagittal image), 
perpendicular to the tumour infiltrating border. On the latter one submucosal layer is 
preserved thus being staged as T1 (submucosal - sm2). 
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Figure 6 – Sagittal image (left) – red lines delineate peritoneal reflection, light green lines show presacral fascia.  
Axial image (right) - red dashed line delineate mesorectal fascia 
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1.4.1.3. MRI and detection of tumour depth of spread 
The pattern of spread in rectal cancer is circumferential and therefore progressive 
disease traverses outwards through the layers of the bowel wall. The micro-structure 
of the bowel wall can be identified on MRI as distinct layers. Spread of tumour through 
the bowel into the surrounding mesorectum and beyond is associated with worsening 
prognosis. Furthermore, the depth of penetration of a tumour through the bowel wall 
also determines operative strategy and determines how ‘radical’ one must be in order 
to completely excise the tumour with adequate ‘clearance’. For example, an ‘early 
tumour’ which has minimally spread into the bowel wall may be treated by local 
excision of the lesion without necessitating a more radical resection involving the 
rectum and mesorectum.  
Essentially, the risk of recurrence increases with tumour depth. However, there is a 
distinct cut-off in terms of prognosis relating to the depth of penetration. Tumours 
which only minimally extend into the mesorectum, and those which are confined to the 
bowel wall, are considered to be ‘good-prognosis’ or ‘low-risk’ cancers. This is 
discussed in detail below. In comparison, when tumours spread deep into the 
mesorectum the risk of disease recurrence is increased.   
MRI can readily identify the layers of mucosa and muscle through distinct signal 
characteristics. T2-weighted images are particularly useful for this. The mucosal layer 
is seen as a very fine line of low signal intensity overlying the much thicker and higher 
signal of the submucosa. Outside this the muscularis propria can be seen as a duel-
layer representing the inner circular and the outer longitudinal muscle layers. The latter 
has a typically irregular appearance due to vessels traversing the rectal wall. At this 
point, the muscle layer is not a uniformly regular radiological feature and this must be 
appreciated to be able to identify venous invasion with accuracy. The perirectal fat is 
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identified as a high signal with signal void areas surrounding the relatively low signal 
intensity of the muscularis. This is all enveloped by the fine layer of low signal intensity 
representing the mesorectal fascia. 
The results of initial studies which investigated the accuracy of MRI were limited by 
the technology relating to the coils (Hadfield et al., 1997). Furthermore, protocols 
which used greater than 3mm slices resulted in poor resolution and the over- or under-
staging of T2 and T3 tumours (Schnall et al., 1994). Although this continues to be a 
problem in some units, the clinical importance of distinguishing these tumours may not 
be as prognostically important as first thought, i.e. negligible difference in survival. It 
has been shown in the results of MERCURY study that tumours which penetrate more 
than 5mm into the mesorectum are associated with worse survival (Patel et al., 2012, 
Patel et al., 2011a, Taylor et al., 2011). Tumours which penetrate into the mesorectum 
minimally (less than 5mm) are considered ‘good prognosis’ tumours. Therefore, in 
terms of depth of penetration, a T2 tumour or early T3 tumour (less than 5mm 
penetration into the mesorectum) have similar survival. Both tumours at this level of 
tumour penetration would not be amenable to local resection.  
The depth of extramural spread into the mesorectum can be demonstrated on thin-
slice high resolution MRI. In one study of 28 patients undergoing staging MRI using a 
four-element surface coil showed good correlation with post-operative histology 
(Brown et al., 1999). 21 patients out of 24 (88%) who had tumours which extended 
5mm or more into the mesorectum were correctly identified on MRI. A further study of 
98 patients demonstrated a kappa agreement of 0.67 between MRI and pathology 
(Brown et al., 2003a). Others studies in the USA and Japan have confirmed correlation 
between MRI and pathology to be above 80% (Akasu et al., 2005).  
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In the MERCURY study which included 679 patients across Europe, there was 
agreement between MRI and histopathology in 295 cases out of 311 undergoing 
primary surgery for rectal cancer (2006). In the analysis, the accuracy was further 
quantified by demonstrating the mean difference between MRI and histopathology -
0.046mm (SD 3.85mm, 95% CI -0.487 to 0.395mm). This study formed the basis of 
the modern-day acceptance of the accuracy of MRI to predict tumour spread to within 
1mm.  
Cawthorn, Merkel and Willett were the first to report on this heterogeneity within T3 
tumours. Cawthorn reported 5-year survival to be 55% for those tumours with less 
than 4mm penetration into the mesorectum compared to 25% when more than 4mm 
(Cawthorn et al., 1990). Merkel studied patient’s survival characteristics with T3 
tumours and used a cut-off of 5mm. Those patients with extramural spread of more 
than 5mm had 5-year survival rate of 54% compared with 85% for those patients 
whose tumours had extramural spread of less than 5mm (Merkel et al., 2001). These 
results were independent of lymph node involvement. These early studies highlight 
the importance of accurate measurement of tumour penetration into the mesorectum 
and those tumours with a worse prognosis, namely T3c and T3d. Therefore, the 
distinction between T2 and T3 tumours with less than 5mm mesorectal spread – T3a 
and T3b; becomes irrelevant as these patients will have minimal benefit from CRT. 
This has led to the sub-staging of T3 tumours which has been adopted by the UICC 
TNM classification since 1993. This is shown in table 5. MRI can distinguish between 
sub-stage of T3 tumours. However, the importance is in recognising those tumours 
which penetrate more deeply into the mesorectum. Figure 8 shows T3 tumours of 
differing sub-stage on MRI. 
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Figure 7   - Series of MRI sections showing increasing T-stage in rectal cancer. From left to right: T1 semi annular tumour infiltrating 
submucosal layer at 5-10 o’clock; T2 semi annular tumour infiltrating rectal wall at 9-3 o’clock within the muscularis propria; T3 tumour 
extends through the muscularis at 1-5 o’clock; T4 tumour invades the mesorectal fascia and posterior vaginal wall at 1-2 o’clock 
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Table 5 – T3 sub-classification based on penetration into the mesorectum. T3a – T3d show increasing tumour spread. 
Sub-stage for T3 tumours Penetration into mesorectum 
A <1mm 
B 1-5mm 
C 5-15mm 
D >15mm  
 
 
Figure 8 – MRI sections showing T3 sub classification. From left to right: T3a; T3b; T3c; T3d.  
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1.4.1.4. MRI detection of the Circumferential Resection Margin (CRM) 
MRI is optimal modality for identifying the CRM and mesorectum. In addition to being 
able to detect the depth of tumour spread into the mesorectum it can also identify the 
tumour edge with similar detail. Pathologists recognise a clear margin for tumour 
excision to be 1mm. If tumour is seen within 1mm of the CRM it is said to be a ‘positive 
margin’ or ‘R1 resection’ – a clear margin is referred to as ‘R0’ and a macroscopically 
involved margin as ‘R2’. In the MERCURY Study, a total of 349 patients underwent 
pre-operative MRI assessment followed by TME surgery. All were predicted to have 
clear margins on MRI. 327 (94%) patients were subsequently found to have clear 
margins on histopathology (2006). This gave a specificity of 92%. Previously, a 
measured distance of 5mm on MRI had been shown to strongly correlate with a 
negative CRM on histology. This meant that patients were being offered CRT when 
tumours were within 5mm of the mesorectal fascia. However, this resulted in 
substantial overt-treatment of patients with safe margins. As described in later 
chapters, this has now changed and MRI can predict a safe margin at the 1mm level.
Figure 9 – MRI of CRM positive rectal cancer. Infiltration of the mesorectal fascia (at 
3-4 o’clock) and tumour spread into the left pelvic lateral compartment. 
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1.4.1.5. MRI detection of mesorectal lymph nodes 
The pre-operative detection of lymph nodes has been problematic however the 
evidence would suggest that MRI remains the most accurate. Pre-operative staging 
and subsequent treatment decisions are commonly made using MRI despite some 
reservations. In addition to detecting lymph nodes, the major challenge has been 
determining whether a node is malignant or not. Over the years, there has been a 
predilection for using size criteria to determine the nature of mesorectal nodes; that is, 
the larger the node, the more likely it will be malignant. There has been no robust trial 
evidence behind this or pathological correlation. A study which matched nodes from 
in-vivo and specimen MRIs with pathology specimens showed that there was no useful 
size cut-off for predicting nodal status (Brown et al., 2003c). Further, a histological 
survey of over 12,000 lymph nodes in rectal cancer showed considerable size overlap 
between normal or reactive nodes and those containing metastases (Dworak, 1991). 
A perceived limitation of MRI is the lack of accuracy and ability to detect nodes smaller 
than 3mm. Yet this may not be as clinically relevant as first appears as only 2% of 
nodes this size are malignant (Brown et al., 2003c). 
More important than size is nodal border and the tumour signal within the node. 
Tumour infiltration into lymph nodes leads to characteristics radiological features 
which can be readily identified on MRI (Brown et al., 2003c). Tumour leads to capsular 
disruption causing the nodal border to become irregular as opposed to the more 
rounded border of benign nodes.  This is shown in figure 10. 
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Figure 10 - Red lines show malignant mesorectal and right internal iliac nodes, which have irregular borders and heterogeneous 
signal. 
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A very small number of lymph nodes with a smooth bordered contour (<6%) has been 
shown to be malignant whilst those demonstrating irregular outline are malignant in 
over 90% of cases. Mixed signal intensity occurs due to the heterogeneity of the 
tumour and necrosis within the node. When using the signal characteristics and border 
outline together, the sensitivity is much improved. Using features of nodal border, 
contour and differing signal characteristics the sensitivity and specificity increases to 
85% and 97% (Brown et al., 2003c). 
Koh et al used ultra-small particles of iron oxide (USPIO) to attempt to detect small 
(>1mm) tumour foci in mesorectal nodes (Koh et al., 2004, Koh et al., 2010). In their 
study, mesorectal nodes were identified on T2-weighted high resolution MRI following 
administration of USPIO as they produced a characteristic radiological appearance. 
These nodes were correlated with histopathology for confirmation of malignant 
infiltration. The use of USPIO is not widespread and is still limited to experimental 
work. 
Lambregts et al investigated the accuracy of gadofosveset-enhanced MRI in nodal 
staging and restaging following pre-operative treatment (Lambregts et al., 2011a). 
They found that the use of gadofosveset increased accuracy and correlation compared 
to standard MRI protocols as well as being reproducible.  
These results suggest that even with MRI, N-staging is not sufficiently accurate for 
clinical use however imaging can help guide treatment decisions.   
1.4.1.6. MRI detection of EMVI 
To identify EMVI on MRI accurately, it is necessary to visualise the entire vasculature 
around the rectum, which can only be done effectively by tracing the vessels through 
a series of images along their length. This can help distinguish venous disease from 
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nodal deposits, a common mistake made even amongst experienced radiologists. 
Veins around the rectum are recognised on T2-weighted images as serpiginous or 
tortuous linear structures.  
Differentiating between larger and smaller vessels can be difficult and requires a 
combination of signal characteristics and morphology. The larger, named vessels such 
as the superior and middle rectal veins appear with anatomical consistency. Ideal 
assessment of MRI-detected EMVI (mrEMVI) must include the following: pattern of 
tumour margin (extension into small veins may produce a nodular border); location of 
tumour relative to major vessels; vessel calibre (tumour causes vessel expansion and 
increase in tumour signal in the lumen); and vessel border. Smaller venules can be 
seen perforating the normal outer rectal wall and produce a low to intermediate signal 
intensity in tubular structures on T2-weighted images. The importance of EMVI and its 
detection is discussed in further detail in section 1.7. 
1.4.1.8. Computed tomography 
Currently, the optimal imaging modality for assessing metastatic spread is CT of the 
chest, abdomen and pelvis. This technique is accurate in identifying lesions at the 
common sites of metastases and is widely available in most hospitals. Combination of 
CT with functional imaging techniques such as PET may be more useful if there are 
ambiguous areas on CT. Alternatively, MRI may be used to image specific organs 
such as the liver in more detail if the results of CT are equivocal. Figure 11 shows liver 
metastases on CT. 
1.4.1.5. PET 
Positron emission tomography (PET) has gained increasing popularity in the last few 
years. Although it has had limited uses for more than a decade, the combination of 
PET with CT has shown to be a particularly useful tool. The principle behind PET is 
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the use of radioisotopes with a half-life of around 100 minutes that through tracers 
quantify pathological biochemical processes which are thought to precede physical 
changes in the anatomy. The most common tracer is fluorine-18-labelled 
deoxyglucose (FDG). This radioisotope acts as an analogue to glucose and identifies 
cells which have an increased glucose metabolism such as cancer cells.  
PET/CT has been shown to have improved accuracy over CT and PET as individual 
examinations (Cohade et al., 2003). Yet there remain several questions about the use 
of PET/CT and where it fits into the repertoire of imaging modalities in the staging of 
rectal cancer. In the context of pre-operative staging, there is little evidence to support 
its routine use (Brush et al., 2011). No direct comparisons have been made in terms 
of accuracy of pre-operative local staging with MRI in large numbers and it is difficult 
to evaluate the sensitivity and specificity of this technique. However a recent study has 
shown that MRI and PET/CT may be used in combination for high risk patients (EMVI 
positive; extramural spread of >5mm; T4 disease or an involved CRM) as part of a 
more intensive staging process (Avallone et al., 2012). In this study, patients were 
stratified by MRI into whether they were at high or low risk of developing synchronous 
metastatic disease. Almost 21% of patients in the high risk group were confirmed to 
have metastatic disease on PET/CT compared to 4% in the low risk group. These 
patients may benefit from a further PET/CT (or liver MRI) in the initial staging process.    
Recent interest has been using PET/CT to assess treatment response to pre-operative 
treatment with CRT. Several small studies have been published within the last few 
years and have indicated positive results in terms of a predictive tool for tumour 
regression although one of the largest studies of this type has found no benefit in serial 
scans to assess response and prognosis (Martoni et al., 2011, Kalff et al., 2006). The 
general methodology of these studies has been to perform PET/CT before and varying 
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times after neo-adjuvant CRT and measured the response in terms of FDG uptake. 
Further work is necessary before this can be confidently used as a routine modality to 
assess tumour response. It may be too early to draw comparisons with an established 
technique like MRI, however the rationale behind using PET/CT as an imaging 
modality, which can not only demonstrate anatomical change but also functional 
change, is certainly complimentary at a minimum. Figure 12 shows a positive PET/CT 
scan confirming the presence of recurrent disease. 
 
Figure 11 – This shows a staging CT of abdomen with a liver metastasis. CT arterial 
and venous phases – a solitary metastasis is identified in the S7/S8 
 
 
Figure 12 – PET/CT confirming the recurrent disease from the common iliac lymph 
nodes on the right 
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1.4.2. Histopathological staging of rectal cancer  
1.4.2.1. Overview of pathological assessment 
Optimal pathological assessment of the resection specimen following surgery is 
essential for a number of reasons. First, the quality of reporting directly affects the risk-
stratification for patients by providing a final staging of the tumour. Secondly, there is 
direct influence on the treatment decisions regarding adjuvant therapy. Thirdly, it 
provides a reference for imaging modalities; comparison can be made between pre-
operative MRI and histopathology. 
Until relatively recently, the quality of pathology reporting in rectal cancer had been 
highly variable (Bull et al., 1997, Beattie et al., 2003) . This had been due to a 
combination of suboptimal preparation and dissection technique and a lack of 
standardisation regarding datasets. The use of proforma-based reporting has helped 
to encourage histopathologists to actively comment on specific factors thus leading to 
greater standardisation (Branston et al., 2002, Rigby et al., 1999). This has further 
been formalised in the UK with the Royal College of Pathologists’ minimum dataset 
for reporting (colo)rectal cancer (Williams, 2007b).  
The use of a universal staging system has helped in providing some consistency and 
rectal cancer should be reported by the TNM (UICC) and Dukes staging systems (see 
section 1.2). The two most important components of pathological reporting must relate 
to the important prognostic factors which will influence treatment decisions, in 
particular adjuvant chemotherapy; and the quality of surgery.  
Quality of surgery is known to affect the risk of local recurrence - the goal of oncological 
surgery of the rectum is to excise the tumour with the surrounding intact mesorectum. 
If the mesorectum, or worse still, the tumour is breached there is an association with 
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local recurrence (Quirke et al., 1986, Nagtegaal et al., 2002). The prognostic factors 
of relevance are discussed later in more detail. 
1.4.2.2. Technical considerations 
Photographs of the resection specimen should ideally be taken of the anterior and 
posterior surfaces. Opening up the bowel to a point just above the tumour means that 
the tumour surface can be evaluated in detail. Assessment of the relevant prognostic 
factors should be made following adequate fixation in formalin. Thin sections of 3-5mm 
is mandatory so not to miss crucial information. 
 
 
 
Figure 13 shows the macroscopic examination of the resected rectal cancer 
specimen. This image demonstrates the shiny surface of the mesorectum. 
The specimen should be graded according to the quality of the surgical resection. 
Ideally, the mesorectum and the levator canal should be graded separately which 
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means that for an anterior resection operation there will be one grading compared to 
two for an abdomino-perineal resection (APR). There are additional features which 
must be identified in the APR specimen including subtle variations in the CRM. An 
additional assessment is made of the levator and sphincter around the anal canal and 
below the mesorectum. As the specimen is taken as a cylinder there should be no 
defects into the sphincter muscles or levators. The specimen is graded as ‘levator’, 
‘sphincteric’ or ‘mucosal’ plane.  
Mesorectal grading is either complete, moderate or incomplete depending on the 
quality of the specimen and correlates with the mesorectal fascial plane, 
intramesorectal plane and muscularis plane, respectively. Table 6 shows the 
differences between the grades as given by the CR07 Trial (Sebag-Montefiore et al., 
2009). A ‘complete’ specimen has an intact mesorectum with only minor defects in the 
surface less than 5mm in depth. The specimen must display no coning. A ‘moderate’ 
specimen has moderate bulk to the mesorectum and with some degree of coning. The 
muscularis must not be exposed. An ‘incomplete’ specimen displays muscularis with 
deep defects to the mesorectum. The quality of the specimen reflects the plane of 
surgery encountered during the procedure.  
 
 
 
 
 
 
60 
 
Plane of surgery Description 
mesorectal fascial plane Smooth mesorectum with no defect 
more than superficial or 5mm in depth 
intramesorectal plane Moderate bulk to mesorectum but 
irregularity of the mesorectal surface. No 
muscularis propria visible 
muscularis propria plane Substantial loss of mesorectal tissue; 
deep cuts on to muscularis and irregular 
CRM 
 
Table 6 – CR07 definitions of specimen quality  
An incomplete excision is one where there is tumour at the margin of the specimen. In 
rectal cancer, this is rarely at the longitudinal margin occurring in less than 2% (Guillou 
et al., 2005). It is more common to find tumour at the CRM, which is strongly 
associated with local recurrence and reduced overall survival (Wibe et al., 2002). The 
most accurate studies have shown that tumour within 1mm of the resection margin is 
a poor prognostic factor (Quirke and Morris, 2007).  
1.4.2.3. Post neoadjuvant treatment assessment 
As most patients present with locally advanced tumours which require pre-operative 
or neo-adjuvant therapy prior to surgery, pathology must be equally accurate in the 
identification of prognostic factors following such treatment. The same factors must 
consistently be reported but in addition there can be assessment of the effect of any 
prior treatment on tumour regression (Goldberg et al., 1994). The most common forms 
of neoadjuvant treatment include short or long-course and whether radiotherapy is 
combined with chemotherapy. These produce changes associated with fibrosis, down-
staging and tumour regression depending on which regime is adopted (Wheeler et al., 
1999, Shia et al., 2004).  
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The prefix ‘yp’ is added to the traditional TNM stage to denote that this relates to the 
stage after neoadjuvant treatment assessment. The predominant feature suggesting 
a good response to treatment is fibrosis but this may also occur as a result of 
radiotherapy or cancer progression. Mandard et al, have described a tumour 
regression grade in oesophageal cancer following neoadjuvant therapy (Mandard et 
al., 1994) which has been adapted to the reporting in rectal cancer. This includes 
tumour type, grade, margin type, lymphovascular and perineural invasion, margin 
involvement and lymph node status. The scale is shown in Table 7 and relies on the 
degree of fibrosis seen and evidence of the presence of residual cancer cells. A 
pathological response is defined as TRG 1-3 and has been shown to be an 
independent prognostic factor for disease-free survival (Vecchio et al., 2005, 
Bouzourene et al., 2002). Furthermore, Martin et al in their meta-analysis of the 
outcome following pCR reported excellent survival (90.2% OS and 87% DFS) and low 
rates of disease recurrence (0.7% and 8.7% for local and distant failure, respectively) 
(Martin et al., 2012). 
 
Grade Description 
1 Complete regression of tumour; fibrosis only 
2 Fibrosis with scattered tumour cells 
3 Fibrosis and tumour cells; preponderance of fibrosis 
4 Fibrosis and tumour cells; preponderance of tumour cells 
5 Tumour without evidence of regression or fibrosis 
 
Table 7 – Mandard grading of pathological response following neoadjuvant treatment 
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There are three common systems used in rectal cancer which have been developed 
from the original Mandard scale. Dworak et al proposed a five-point scale based on 
inflammatory reaction and radiation-induced vasculopathy as well as fibrosis (Dworak 
et al., 1997). The Rectal Cancer Regression Grade (RCRG) offered a three-point scale 
based around the presence of tumour cells and the degree of fibrosis. The Royal 
College of Pathologists in the UK uses a similar grading system to the RCRG. All three 
of the grading systems described above have the potential for universal application 
and have been shown to have good intra-observer variability and are reproducible 
(Bateman et al., 2009).    
Although a survival benefit has been shown in patients who demonstrate a 
pathological complete response (pCR) following neoadjuvant therapy, the prognostic 
relevance of partial tumour regression is not as clear. There have been few studies 
which have shown an association with improved survival although a recent meta-
analysis has reported a response of 50% to be associated with improved DFS (Min et 
al., 2011, Lee et al., 2013). As there is a current lack of universal consensus, the 
methodology used in this thesis is explicitly described later. 
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1.5. Oncological treatment for rectal cancer 
There are two established curative approaches including: i) pre-operative or neo-
adjuvant treatment; and ii) postoperative or adjuvant treatment. The components of 
either strategy include radiotherapy (RT), chemotherapy or a combination of the two.  
The principles behind offering additional treatment to surgery is to help reduce the 
rates of local and distant recurrence. Further, locally advanced tumours may become 
more accessible following pre-operative treatment meaning there is a greater 
likelihood of complete excision. The decision to offer oncological treatment is based 
on the identification and recognition of adverse tumour features on presentation (in the 
case of neoadjuvant therapy) and following surgery (in the case of adjuvant therapy). 
Patients are accordingly risk-stratified depending on the type and number of adverse 
features identified. Accurate pre-operative imaging and post-operative pathology are 
critical to appropriately risk-stratify patients.  
1.5.1. Neoadjuvant chemoradiotherapy 
1.5.1.1 Important Radiotherapy Trials and Evidence 
 
Study of the optimal timing and dosage of radiotherapy dates back to the 1970s. The 
decision to give radiotherapy pre- or post-operatively has been a balance of the 
prognostic outcome and the accurate selection of patients. The important issues 
regarding RT include the concomitant use of chemotherapy as an induction agent and 
whether RT could lead to a greater number of sphincter-preserving operations being 
performed. The advent of high-resolution imaging and the recognition of the most 
important adverse features associated with rectal cancer has somewhat helped to 
standardising treatment and regimes somewhat.  
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The majority of initial studies using low-dose radiotherapy of between 5-25 Gray (Gy), 
did not demonstrate any survival benefit over surgery alone (Abulafi and Williams, 
1994). Although Goldberg et al did show with the use of 3x5Gy over 5 days followed 
by surgery reduced the local recurrence rate from 16% to 9% in their randomized trial 
of 468 patients (Goldberg et al., 1994).As the radiation dose increased to over 25 Gy 
however there was a concomitant improvement in local recurrence rates. The 
Stockholm Rectal Cancer Group showed a decrease in the local recurrence rates from 
20% to 8.5%, however there was no significant difference in five--year survival and 
there was an associated increase risk of post-operative wound infection (8% versus 
2%) (Cedermark et al., 1995). They randomised patients to receiving pre-operative 
radiotherapy over 5 to 7 days (25 Grays) followed by surgery or surgery alone. Longer-
term follow up from patients within the Swedish Cancer Registry (median follow-up of 
13 years) showed an improvement in both local recurrence (9% versus 26%) and 
overall survival (38% versus 30%) (Folkesson et al., 2005).  
Other European trials showed a range of reduction in local disease recurrence with 
pre-operative RT over surgery alone. Kapiteijn et al. as part of the Dutch Colorectal 
Cancer Group reported a prospective randomised trial also comparing pre-operative 
radiotherapy and surgery with surgery alone. They explicitly mentioned TME surgery 
in the title of the study thereby reflecting the importance attached to the quality of 
surgery issue. Patients underwent a similar regime of 25 Gy divided into five fractions 
over five days. At two years, there was no difference in overall survival although there 
was a significant difference in local recurrence rates (2.4% versus 8.2%) (Kapiteijn et 
al., 2001). This study further reinforced the reduction of local recurrence when good 
quality surgery was combined with pre-operative radiotherapy. One of the criticisms of 
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the Swedish trial was that the local recurrence rates (26%) in the surgery group were 
high.  
1.5.1.2. Combination chemotherapy and radiotherapy 
 
Post-operative radiotherapy trials did not initially show any significant improvement in 
survival. The MRC-CR07 trial which compared pre-operative short-course RT and 
post-operative RT with concomitant chemotherapy for selective patients undergoing 
surgery showed improvement in local control (5% versus 11%) and a marginal 
increase in survival (Sebag-Montefiore et al., 2009). There is now clear randomized 
evidence that RT with or without chemotherapy is best given pre-operatively in the 
neo-adjuvant setting. The benefits include improved local disease control, higher 
compliance and reduced toxicity (Frykholm et al., 1993, Sauer et al., 2004).       
It is common to offer patients with a ‘locally-advanced’ tumour RT with chemotherapy. 
There have been three randomized trials to date which have all shown an 
improvement in local disease control when RT is combined with chemotherapy but 
there is no definitive evidence indicating an overall survival benefit. Concerns have 
been raised about the additional toxicity of using combination chemotherapy in 
addition to RT and this is most likely due to the explanation of reserving such a regime 
for the most advanced of tumours. Bosset et al have also shown that in addition to 
improvement in local control by administering chemotherapy with RT, that the rate of 
compliance is significantly improved when chemotherapy is given pre-operatively 
(82% versus 42.9%) (Bosset et al., 2004). The most common chemotherapy agent 
used in this setting is 5-fluorouracil (5-FU) although there is some utility for oral 
Capecitabine (Hofheinz et al., 2012). The rationale behind using a combination of RT 
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and chemotherapy is that the latter has potentiating effects on RT and thus improves 
the response.  
Current regimes of neo-adjuvant treatment are based on risk-stratification of tumours 
as identified on initial imaging studies. If no adverse features indicating extensive 
locoregional spread are detected on MRI, surgery is the most appropriate course of 
action despite some studies  showing improvement of local recurrence for some 
patients if given pre-operative short-course RT (Sebag-Montefiore et al., 2009, 
Dahlberg et al., 1999, Kapiteijn et al., 2001, Valentini et al., 2009). Patients who exhibit 
poor tumour characteristics are most likely to benefit from neo-adjuvant treatment and 
are commonly offered RT and sensitizing chemotherapy before surgery between 6 
and 12 weeks later. 
1.5.1.3. Short-course versus long-course radiotherapy 
 
A typical short course regime would consist of 5Gy given over five days (25Gy total) 
compared with 1.8-2.0Gy given over 25 days to a total dose of 45-50 Gy. A major 
concern with using short-course regimes had been the long-term morbidity in these 
patients (Birgisson et al., 2007). A randomised trial was carried out comparing pre-
operative short-course radiotherapy with pre-operative long-course chemoradiation 
(Bujko et al., 2006). The study included 312 patients followed for a median follow up 
of 48 months. Patients were randomised to receive either 25 Gy in five fractions over 
five days or 50.4 Gy in 28 fractions in addition to sensitising chemotherapy (5-
Fluorouracil and Leucovorin). There were also no differences in overall survival at 4 
years (67.2% versus 66.2%). There were also no differences in disease-free survival 
or local recurrence rates although the chemoradiation group showed an increased 
early radiation toxicity. Despite these studies there is still no clear evidence on which 
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regime is optimal. National Institute of Clinical Excellence (NICE) in the UK has issued 
guidelines for the use of neoadjuvant therapy (Excellence, 2014). These are based on 
risk-stratification of patients depending on the MRI staging.  
1.5.2. Adjuvant chemotherapy 
Chemotherapy is most commonly used as a therapeutic rather than sensitizing agent 
in the postoperative or adjuvant setting. The Quick and Simple and Reliable 
(QUASAR) study investigated the effect of adjuvant chemotherapy in colorectal cancer 
patients but included a sub-analysis of rectal cancer (29% of the cohort). 5-FU and 
folic acid were the agents used. Some of these patients received pre-operative 
radiotherapy but this was only of the order of 20%. There was a statistically significant 
benefit seen in the rectal cancer subgroup (Gray et al., 2007).  
Several Japanese studies have reported on adjuvant chemotherapy in rectal cancer 
but the results may not be applicable to Western practise. There are differences in 
oncological regimes and surgical technique. A meta-analysis of these studies has 
shown an improvement in both disease-free and overall survival in patients who 
received adjuvant chemotherapy (Sakamoto et al., 2007). Fisher et al, also showed a 
significant improvement in overall survival in those patients receiving adjuvant 
chemotherapy (Fisher et al., 1988).  
With most locally advanced rectal cancers undergoing pre-operative long-course 
chemoradiotherapy or short-course radiotherapy, the role of adjuvant chemotherapy 
is less clear. A recent systematic review by Bujko et al examined four randomized 
trials in which patients were given neo-adjuvant radiotherapy with or without 
chemotherapy, and found no significant survival benefit (Bujko et al., 2010b). 
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Interestingly, of all the recent large-scale trials involving neoadjuvant CRT, there is no 
clear overall survival benefit seen despite improvement in local control.  
Despite the lack of strong evidence there is a recognition that adjuvant chemotherapy 
may provide a survival benefit in some patients. The National Comprehensive Cancer 
Network Guidelines recommended postoperative chemotherapy for all patients who 
had received neoadjuvant CRT regardless of stage. The European Society for Medical 
Oncology has suggested that patients with stage III and ‘high risk’ stage II should be 
offered adjuvant chemotherapy (Glimelius and Oliveira, 2009).     
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1.6. Biomarkers in rectal cancer 
1.6.1. Overview of biomarkers as a measure of disease activity 
A biomarker may be defined as a tumour characteristic that can be objectively 
measured and evaluated as an indicator of a normal biological process, or 
pharmacological response to a therapeutic intervention (2001). They can be 
prognostic by providing information about outcome or predictive by providing 
information about the outcome for specific treatments. Biomarkers may be used in a 
variety of situations and serve a number of purposes. They are not limited, as most 
commonly thought, to monitoring of treatment response. For example, they may be a 
diagnostic tool which can be used for risk-stratification (staging of disease), an 
estimator of prognosis, and in some cases for prediction of disease response (Tejpar, 
2007). Table 8 shows the categorisation of biomarkers. The study of such biomarkers 
can be broadly divided into imaging biomarkers; microRNA; metabolic markers; and 
EMT markers. 
 
Type Description 
Diagnostic Used to identify tumour type/ sub-type 
Monitor Monitors response to treatment or 
relapse in disease 
Prognostic – informative Correlates with survival 
Prognostic – treatment guiding Guides treatment decision making 
Predictive Guides use of specific treatment strategy 
according to phenotype or genotype 
 
 
Table 8 – Different types of biomarkers and their application in research 
70 
 
1.6.2. Imaging biomarkers 
The concept of an imaging biomarker is relatively new, but one which is becoming 
increasingly important for many phase II/III clinical trials as a surrogate end point. 
Imaging biomarkers provide a means to measure tumour response to a therapeutic 
intervention and/or detect early disease, in a non-invasive manner. Currently the 
imaging techniques which seek to quantify treatment response in rectal cancer can be 
broadly divided into those which measure tumour size and those which measure 
tumour activity. Whilst the former is commonly used to assess radiological response 
in clinical trials because of the association of size with survival functional imaging 
techniques may have the greater potential to uncover the underlying biological 
processes which lead to cancer.  
Reduction in tumour size after chemoradiotherapy has been shown to be a useful 
biomarker (Benjamin et al., 2007). This can be measured in one, two or three 
dimensions by routine imaging techniques such as CT and MRI (O'Connor et al., 
2008). The two commonly used criteria, World Health Organisation (WHO) 
(Organisation, 1979) and Response Evaluation Criteria in Solid Tumours (RECIST) 
(Therasse et al., 2000) have however, contrasting characteristics, in particular in the 
technique used to measure tumour size.  
Further limitations to using size measurements have been in deciding what degree of 
tumour bulk reduction constitutes a significant clinical response. An example of this is 
has been shown by Morgan et al who investigated the effect of a VEGF receptor 
inhibitor on colorectal metastases, whereby significant size reduction was not met with 
an equally significant overall response (<10%) (Morgan et al., 2003).  
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Novel MRI-based tumour regression grades (mrTRG) which stratify response on the 
degree of fibrosis visualised in the tumour following chemoradiotherapy have, 
however, recently been developed. The degree of fibrosis following CRT is graded on 
a scale analogous to histopathological tumour regression grade described earlier 
(Mandard et al., 1994).  
Another example is dynamic contrast-enhanced (DCE) CT/MRI which provides a 
detailed assessment of tumour blood flow through acquisition of data as specific 
contrast material passes through the vasculature. DCE-CT has the potential to identify 
angiogenesis and has been shown to be able to distinguish tumour from diverticular 
disease and detect early liver metastases (Leggett et al., 1997, Goh et al., 2007). 
Although reports have identified a correlation between tumour blood flow, the 
development of metastases and decreased survival (Goh et al., 2009, Hayano et al., 
2009), this has not been translated to widespread clinical application.  
Diffusion weighted imaging (DWI) assesses the Brownian movement of water 
molecules within cells using diffusion-weighted gradients to T2 sequences. 
Quantitative analysis is possible by calculation of the apparent diffusion coefficients 
(ADC) which are inversely correlated with tumour cellularity. DWI has been effective 
in detecting small liver metastases and differentiation from inflammatory lesion (Koh 
et al., 2008, Taouli et al., 2008, Ichikawa et al., 2006) as well as detecting lymph node 
metastases (Kim et al., 2008) but has been limited to mainly experimental work. 
Lambregts et al have shown that there may well be some utility in DWI to detect 
patients with a complete response following CRT (Lambregts et al., 2011d, Lambregts 
et al., 2011b, Lambregts et al., 2011c). In one study, they investigated the utility of 
DWI compared with standard MRI in 120 patients. 25 patients were found to have a 
complete response. The area under the ROC curve improved significantly with DWI. 
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Whilst DWI is currently not universally accepted as the optimal imaging modality to 
determine response to treatment, there is certainly some encouragement in these 
early small studies.  
Despite some promising beginnings and ongoing study into the use of detailed imaging 
biomarkers, size criteria with RECIST remains the only validated tool and one which 
has prognostic and clinical relevance. More recently, measuring the degree of fibrosis 
within the tumour complex and providing a radiological-based tumour regression grade 
such as mrTRG has shown good results and excellent correlation with histopathology-
based tumour regression grades.  
1.6.3. microRNA and response to treatment 
MicroRNAs are highly conserved 18-25 nucleotide non-coding RNA molecules which 
post-transcriptionally regulate gene expression. microRNA genes account for between 
2% and 5% of the human genome and are commonly clustered within the introns of 
protein coding genes.(Rodriguez et al., 2004) Bioinformatic studies estimate that each 
microRNA interacts with hundreds of mRNA targets and as a consequence the 
microRNAome may regulate more than 30% of all human genes(Garzon et al., 2006, 
Lewis et al., 2005). As well as regulating fundamental cellular processes including 
differentiation, proliferation and apoptosis, microRNAs have been implicated in the 
pathogenesis of numerous malignancies(Garzon et al., 2009).  
Growing numbers of oncogenes and tumour-suppressor genes are found to be under 
microRNA control and more than 50% of microRNA genes appear to be located at 
fragile sites or within cancer-associated genomic regions.(Iorio and Croce, 2009, Calin 
et al., 2004) In rectal cancer, aberrantly expressed microRNAs derail a number of 
cellular signal transduction and cell survival pathways including Wnt/β-catenin 
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pathway, EGFR pathway, and p53 function tying microRNA biology to known 
mutational events in the adenoma to carcinoma sequence of malignant transformation 
(Slaby et al., 2009). 
Accumulating evidence suggests that microRNAs may also have powerful clinical 
applications. microRNA expression profiles are capable of discriminating tumours of 
different developmental origin.(Lu et al., 2005) Furthermore, the expression of 
individual microRNAs may be used to predict patient survival, tumour stage, the 
presence of lymph node metastases and the response to therapy in rectal cancer 
(Slaby et al., 2009, Slaby et al., 2007, Schetter et al., 2008). 
Three studies have specifically examined the utility of microRNA expression 
signatures in predicting chemoradiotherapy response in rectal cancer (Della Vittoria 
Scarpati et al., 2012, Svoboda et al., 2012, Kheirelseid et al., 2013). Della Vittoria 
Scarpati et al, examined microRNA expression in fresh-frozen pre-treatment tumour 
specimens from 38 patients with locally advanced (T3/T4 Node +ve) rectal cancer and 
compared microRNA profiles in patients with complete (Mandard TRG 1; n=9) and 
incomplete (Mandard TRG >1; n=29) pathological responses to a standardised 
neoadjuvant chemoradiotherapy regime consisting of Capecitabine, Oxaliplatin and 
45 Gy of pelvic conformal radiotherapy. Thirteen significantly differentially expressed 
microRNAs were subsequently validated using high sensitivity TaqMan®qRT-PCR, of 
which two including miR-622 and miR-630 were found to predict chemoradiotherapy 
response with 100% sensitivity and specificity (Della Vittoria Scarpati et al., 2012). 
A similar analysis of 20 patients undergoing combined radiotherapy and 
Capecitabine/5-FU chemotherapy compared ‘responders’, namely those displaying a 
positive response to treatment (Mandard TRG 1 and 2), with ‘non-responders’ 
74 
 
(Mandard TRG 3-5). TaqMan Low Density Arrays identified a microRNA signature 
consisting of eight microRNAs capable of correctly classifying 90% (9/10) of 
responders and 90% (9/10) of non-responders (Svoboda et al., 2012). 
A third study, which used formalin fixed rather than fresh rectal cancer specimens 
identified a microRNA signature consisting of just three microRNAs (miR-153, miR-16 
and miR-590-5p), capable of distinguishing patients with complete and incomplete 
responses to therapy, however the value of this data is unclear as patient 
demographics, tumour characteristics, study end-points and the neo-adjuvant 
treatment strategy were not clearly described (Kheirelseid et al., 2013). 
As profiling methodology and the definition of tumour regression vary between these 
3 studies, inter-study comparisons are of limited value; however it is important to note 
that no overlap is observed between the microRNA signatures described. This 
suggests that a microRNA based ‘therapy-response’ prediction tool is some way from 
becoming a reality however although other studies have clearly established that 
microRNAs do play a role in regulating the tissue response to neoadjuvant therapy in 
CRC(Svoboda et al., 2008, Rossi et al., 2007, Nakajima et al., 2006). Perhaps by 
focusing on the contribution of microRNAs within the biological pathways that govern 
resistance and/or sensitivity to neo-adjuvant therapy in rectal cancer, more clinically 
pertinent data will emerge.    
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1.7. The importance of EMVI in locally advanced rectal cancer in the modern 
management of rectal cancer 
1.7.1. Background and history of EMVI 
Brown and Warren first documented the association between venous invasion and 
metastatic disease (Brown, 1938). They conducted a study examining the resection 
specimens of patients with rectal carcinoma. Patients who had evidence of venous 
invasion were more likely to develop visceral metastases. Although a few smaller 
studies confirmed this finding over the next two decades, it was not until Burns et al 
carried out an extensive analysis of patients with colorectal cancer that the role of 
venous invasion was further investigated in some detail. They carried out a 
retrospective analysis of 338 patients with colorectal cancer of which 198 were rectal 
or rectosigmoid tumours. 93 (46.9%) were found to have venous invasion on 
histopathological examination. Further analysis of the results revealed that 74% 
patients with venous disease subsequently developed metastasis. With limited follow 
up data, they reported 119 deaths concluding that 57% of the patients died as a results 
of metastatic disease. This study was one of the first to highlight the difficulty for 
histopathologists in accurately detecting venous invasion in the resection specimen. 
Earlier smaller studies had not found venous invasion to be as prevalent in rectal 
cancer but, Burns et al utilised specialised stains of Masson Trichrome and Weigert 
elastic tissue stain in addition to routine Haematoxylin and Eosin (H&E) preparation in 
difficult cases. The histopathological criteria that pathologists adopted included the 
presence of intraluminal blood following an endothelial contour; communication with 
an identifiable vessel; and the number of endothelial cells present (a greater number 
indicated more likely to be a vein than a lymphatic vessel).  
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In 1963, Carroll et al published the largest study on venous invasion in rectal cancer 
expanding on Dukes and Bussey’s work from St Mark’s Hospital (Carroll, 1963). At the 
time there was an extensive follow-up programme in place at St Mark’s and a large 
database of patients. Dukes and colleagues had already meticulously described the 
techniques used to identify venous invasion in resected specimens. Carroll used this 
series of patients who comprised a cohort between 1928 and 1952, to carry out a 
comparative study between a ‘general’ group of patients including some with evidence 
of venous invasion where venous invasion was not specifically sought and a ‘venous’ 
group, where pathologists had specifically sought to identify venous invasion if 
present. The prevalence of venous invasion was approximately 12%, which was less 
than most existing series at that time. In the most detailed analysis up to that time, 
they found that venous invasion was also associated with other adverse features such 
as lymph node metastases and extent of perirectal spread (penetration into the 
mesorectum). Using adjusted five-year overall survival as an endpoint, they also 
showed that venous invasion led to a significantly decreased survival (36% versus 
57.4%) in the ‘general’ group. Metastatic disease was preferentially to the liver and 
associated with invasion of the superior haemorrhoidal (rectal) vein.  
It was not until the seminal paper by Talbot et al in 1980 entitled  The Clinical 
Significance of Invasion of Veins by Rectal Cancer (Talbot et al., 1980) that such a 
detailed analysis was performed since that undertaken by Carroll. Again with the aid 
of Bussey and specimens from St Mark’s Hospital, 706 specimens from patients 
presenting with rectal carcinoma between 1960 and 1966 were retrospectively 
reviewed in detail. This was the first study to detail the pattern of invasion and whether 
invasion was within or outside of the muscle wall and the size and thickness of the 
vein involved. Interestingly they found the use of elastin stains unhelpful but in cases 
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of ambiguity opted to discount the presence of venous invasion. In their study venous 
invasion was demonstrated in 51.9% with 36.1% (of the total number of cases) being 
classified as ‘extramural’. This was the first study to state explicitly whether venous 
invasion was intra- or extramural. They also found an increased risk of liver 
metastases in patients who had venous invasion than those without (35% versus 14%) 
and this was more apparent in thick-walled and extramural veins. Survival was only 
affected when venous invasion affected the extramural veins (33% versus 73%). 
There was no significant difference in survival if venous invasion of intramural veins 
was found.  
Several subsequent studies following this found similar results and researchers now 
began to make a distinction between intra- and extramural venous invasion. 
Inconsistency in techniques and definitions made the comparison of different studies 
problematic, however, hence the lack of a meaningful meta-analysis or systematic 
review on the subject.    
Table 9 shows a selection of important studies which investigated the prognostic role 
of venous invasion and the definitions and pathological techniques used. The most 
common finding was that a definition of venous invasion was rare.  
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Table 9 – Historical studies investigating the prognostic effect of vascular/venous invasion/ EMVI 
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Venous invasion, and subsequently EMVI have traditionally been identified on the 
routine histopathological analysis of resection specimens. Yet there remains 
unacceptable variability in reporting between pathologists. More recently, the 
increasing accuracy of high resolution magnetic resonance imaging (MRI) has meant 
that many prognostic factors can now be confidently identified on imaging and this 
includes venous invasion. 
1.7.2. Histopathology definitions  
Venous invasion is recognized when tumour is seen in an endothelium-lined space, 
either surrounded by a rim of muscle or containing red blood cells. Histological staining 
with standard H&E is used as routine.  Pathologists classify venous invasion into three 
types: (i) tumour cells are found to fill the vascular lumen, with or without recanalization 
of the lumen (ii) tumour cells are located in the centre of the vascular lumen, distant 
from the vein wall (iii) tumour cells are seen to be infiltrating or occluding the wall of 
the vessel, showing marked thickening and inflammatory reaction. The extent of 
venous invasion is often described as minimal, (1-2 involved veins), intermediate (3-4 
involved veins) or massive (5 or more involved veins). Note is also made of anatomical 
sites of invasion and whether the veins are intramural (within the bowel wall), 
extramural (outside the bowel wall in the peri-colonic fat or adventitia) or both.  
The use of elastic stains in addition to H&E to improve EMVI detection remains 
contentious. Talbot et al did not find such stains helpful in detecting venous invasion 
and relied on meticulous specimen handling and cut-up due to the large amount of 
background fibrous tissue within the rectal wall itself whereas other studies by Carroll 
and Freedman et al have advocated the use of specialised stains (Freedman et al., 
1984, Carroll, 1963). Elastic fibres are present in the adventitia of vessels, but not 
lymphatics, and therefore elastin stains can be used to highlight the presence of veins 
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and their adjacent arteries. Sternberg et al showed elastin staining to increase the 
probability of identifying vessel involvement by 38.5% (Sternberg et al., 2006). Vass 
et al demonstrated that the use of an elastin stain was more crucial in increasing the 
sensitivity of detection of EMVI than having the specimen examined by a moderately 
experienced pathologist (Vass et al., 2004).  
Recently Roxburgh et al have found significant improvement in reporting of EMVI 
using elastin-based stains. Indeed they demonstrated that by using a specialised stain 
over and above the routine staining with H&E, the detection rates improved from 19% 
to 58% (Roxburgh et al., 2010). This study further showed that patients found to be 
EMVI positive on staining had a worse prognosis compared to EMVI negative patients.  
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Figure 14 – Hematoxylin and eosin stain (H&E stain or HE stain) of EMVI in rectal cancer. The black arrow shows tumour extension 
into the vein. 
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Littleford et al investigated the effects of inter-observer variability on EMVI reporting 
(Littleford et al., 2009). Comparison of four subspecialist gastrointestinal pathologists 
with a specific interest in colorectal cancer found there was only “poor-to-moderate 
agreement.” The Medical Research Council conventional versus laparoscopic 
assisted surgery in patients with colorectal cancer (CLASICC) trial found a 20% 
difference in EMVI detection when comparing specialist GI pathologists with non-GI 
pathologists. Central review of the histopathology slides increased the EMVI rate from 
approximately 10% to 30%.   
Whilst there is now active detection of EMVI and guidelines offered by the Royal 
College of Pathologists (Williams GT, 2007), there is still some variation on the 
definitions and most suitable sampling technique. And although the use of special 
stains undoubtedly improves the detection rate of EMVI, there is still no consensus on 
technique and no robust evidence that has led it to be universally accepted.    
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1.7.3. Radiological detection of EMVI 
1.7.3.1. Incidence   
 
In 2003, a prospective study of 98 patients with biopsy-proven rectal cancer 
undergoing TME surgery was carried out to determine the accuracy of MRI in 
identifying a number of prognostic factors including EMVI. EMVI was considered 
present if certain morphological features were seen on 3mm slices as defined by a 
serpiginous extension of tumour signal within a vascular structure (defined as a tubular 
structure containing signal void on T2-weighted images shown in continuity on 
adjacent slices) (Brown et al., 2003b). The rate of detection of EMVI on MRI (mrEMVI) 
was compared with histopathological assessment of resection specimens. EMVI was 
documented on histology if tumour was present in an extramural endothelium lined 
space that was either surrounded by a rim of muscle or contained blood cells. Eighteen 
patients had large vessel EMVI visible on H&E stain. 15 of these 18 cases found 
mrEMVI although more subtle involvement of tumour within smaller vessels was not 
demonstrated by MRI. 
1.7.3.2. Radiological features 
 
Brown et al first described in detail the MRI characteristics of EMVI. Veins around the 
rectum were recognised on T2-weighted images as serpiginous or tortuous linear 
structures. Differentiating between larger and smaller vessels was difficult and 
required a combination of signal characteristics and morphology. There was a signal 
void in the tubular structures thought to be vessels in addition to changes in contour. 
The larger, named vessels such as the superior and middle rectal veins appeared with 
anatomical consistency which helped in confident identification. Ideal assessment of 
mrEMVI must include the following: the pattern of tumour margin (extension into small 
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veins may produce a nodular border); the location of tumour relative to major vessels; 
the vessel calibre (tumour causes vessel expansion and increase in tumour signal in 
the lumen); and vessel border. Smaller venules can be seen perforating the normal 
outer rectal wall and produce a low to intermediate signal intensity in tubular structures 
on T2-weighted images. Venous invasion into these smaller venules can be 
recognised by their expansion and irregularity adjacent to the tumour due to 
contiguous tumour extension.  
The prognostic significance of mrEMVI has been documented in a study by Smith et 
al (Smith et al., 2008a). They offered a scoring system based on previous experience 
which identified particular morphological and signal characteristics. This was validated 
against histopathology although in modern use it has been abbreviated to mrEMVI 
positive or negative. One hundred and forty two patients were included in the study 
undergoing either primary TME-surgery (n=94) or neo-adjuvant therapy followed by 
TME surgery (n=48). In the group in which patients underwent CRT then surgery, the 
incidence of mrEMVI on the initial baseline staging scans was 39.4% but fell to 24.1% 
following restaging. For patients with evidence of EMVI, recurrence-free survival at 
three years was compared between MR- and histopathlogy-detected EMVI. This was 
reported as 35% and 34%, respectively. Recurrence-free survival when EMVI was not 
present was 73.8% and 74.1% for the MRI and histopathology groups, respectively.  
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EMVI grade EMVI status Description 
0 Negative Pattern of tumour extension through 
muscle coat is not nodular; no 
adjacent vessels 
1 Negative Minimal extramural stranding; not in 
region of vessels 
2 Negative Stranding demonstrated in vicinity of 
extramural vessels; normal calibre 
vessels; no tumour in vessels 
3 Positive Intermediate signal intensity on 
vessels; only slight expansion of 
vessels 
4 Positive Nodular expansion of vessel with 
obvious tumour signal 
 
 
Table 10 – Grading of EMVI as it is seen on MRI 
 
Using similar grading criteria mrEMVI was reported in 42% of patients undergoing 
primary surgery for rectal cancer. 26.8% had histology proven EMVI of which 8.9% 
demonstrated venous invasion into vessels less than 3mm in calibre. mrEMVI with a 
score of more than two had 100% sensitivity and 89% specificity in identifying EMVI 
involving veins greater than 3mm diameter. 
Sensitivity and specificity for the MRI-detection of EMVI has been reported to be 
between 62%-100% and 88-89% (2006, Koh et al., 2008b, Smith et al., 2008a) but 
this may still be an underestimate of newer, better high resolution MRI scanners. MRI-
criteria for the identification of EMVI are, however, arguably more rigid. Specific 
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radiological features are sought which can be objectively noted to determine the 
presence or absence of EMVI.  
1.7.4. The current limitations of EMVI being used as a factor for treatment  
The lack of firm evidence has led to unacceptable variability in the treatment offered 
to patients who show evidence of EMVI. It is important that patients are offered an 
accurate estimate of the risk of disease recurrence and any survival benefit offered by 
oncological therapy. To attempt to resolve the actual prognostic effect of EMVI, there 
must be agreement on a universally accepted definition for detecting it. This will allow 
future studies to compare the effect of EMVI on rectal cancer in a reproducible manner. 
The current ‘gold standard’ for detection relies on histopathology but there is no 
consensus on methodology. As there is variation in histopathological processing 
techniques, the prevalence of EMVI has not been estimated accurately. Consequently, 
there is a risk that patients with a potentially poor prognosis are being denied optimal 
treatment.  
MRI has been shown to be accurate in identifying EMVI on baseline imaging but there 
has been no evaluation of its accuracy in tumours after CRT. Many patients present 
with locally-advanced disease and the current practice is to offer them neoadjuvant 
chemoradiotherapy as described above. These patients are further staged following 
this treatment but the accuracy of MRI in this context has not been investigated fully. 
For MRI to remain an important part of decision making following CRT, it must be 
shown to be able to identify features such as EMVI with the same accuracy as on initial 
staging.  
EMVI is an important consideration in stage II rectal cancers. Currently, stage II 
tumours are not routinely offered adjuvant chemotherapy as historical studies have 
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suggested that they pose little risk of disease recurrence. As more adverse features 
are being identified, however, it is clear that stage II cancers comprise a wide ranging 
group of tumours. They can be risk-stratified into groups depending on which features 
are present. If EMVI is shown to be a high-risk feature, adjuvant chemotherapy may 
improve survival and should be offered in such circumstances. Furthermore, the role 
of adjuvant treatment in patients who have already undergone CRT is certainly not 
clear. Evaluating the survival benefit in patients with persistent EMVI will aid future 
guidelines and form the basis of prospective randomized trials. 
Tumour biology and biomarkers are being increasingly used to guide treatment. 
Biomarkers can be biochemical or radiological and therefore treatment response seen 
in adverse features like EMVI following CRT have the potential to be used as imaging 
biomarkers. Such imaging biomarkers like mrTRG have been investigated recently but 
not validated in large numbers. Using similar MRI-based TRG scores specific to 
individual tumour characteristics such as EMVI may further detail the survival benefit 
of patients who show improvement. For example, if EMVI is shown to improve in 
radiological terms and in survival, it may be possible to target therapies at improving 
this feature. Furthermore, if there is an underlying biology which explains the presence 
of features such as EMVI which changes in correlation with radiological characteristics 
following treatment and this too can be linked to survival then there may be molecular 
targets which can be exploited for developing new therapies. To date there is no 
specific profile related to recognised adverse features.  
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1.7.5. The future of EMVI-related trials 
The recognition of EMVI as an important prognostic factor is now seen by its 
inclusion in data analyses for the many current trials in rectal cancer. This will allow 
detailed sub-analyses to be performed with respect to EMVI in the context of 
modern-day surgery and oncological therapies. Such analyses on the background of 
well-designed trials will help minimise the inconsistencies of some of the historical 
trials on venous invasion which meant that the results were difficult to compare.  
The most detailed and accurate way of determining the true predictive and 
prognostic value of EMVI in relation to the outcome and management of rectal 
cancer is to conduct a robust, well-designed clinical trial. Most of the work in this 
thesis has been used to design such a trial.  
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Chapter 2 
Hypotheses 
 
The overall aim of this thesis was to investigate the radiological and pathological 
changes which occur in EMVI following neoadjuvant chemoradiotherapy in rectal 
cancer and to relate this to survival. 
 
2.1. Hypotheses 
 
i. Extramural venous invasion is a poor prognostic factor in rectal cancer. 
ii. EMVI produces characteristic radiological changes which can be identified 
and described on MRI following CRT. 
iii. EMVI increases the risk of disease recurrence in stage II rectal cancer 
following CRT. 
iv. Adjuvant chemotherapy reduces the risk of disease recurrence in patients 
who demonstrate persistent EMVI following CRT. 
v. ymrEMVI is a poor prognostic indicator following CRT. 
vi. ymrEMVI is equally accurate as ypEMVI in determining prognosis in rectal 
cancer following CRT. 
vii. yEMVI is associated with other adverse characteristics in rectal cancer. 
viii. mrEMVI can be used as an imaging biomarker to predict poor survival. 
ix. Locally advanced rectal cancer with evidence of EMVI show distinct tumour 
profiles. 
x. CRT causes a change in the rectal cancer tumour profile. 
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2.2. Investigations 
 
The following investigations were undertaken to test the hypotheses in section 2.1. 
i. Systematic review of the clinical relevance of EMVI in rectal cancer. 
ii. A pictorial description of ymrEMVI following CRT and optimal detection 
strategies. 
iii. The association of mrEMVI with other adverse features in rectal cancer. 
iv. A survey of surgeons and oncologists in their attitudes to EMVI. 
v. The clinical outcome of stage II rectal cancer with ypEMVI. 
vi. The prognostic relevance of mrEMVI following CRT. 
vii. The effect of adjuvant chemotherapy on persistent EMVI following CRT. 
viii. mrEMVI as an imaging biomarker in rectal cancer. 
ix. Differences in tumour profiles between EMVI positive and EMVI negative 
tumours following CRT. 
x. The development of the Molecular, pathologic and MRI investigation of the 
prognostic and predictive importance of extramural venous invasion in rectal 
cancer (MARVEL) trial. 
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Chapter 3 
Methods 
3.1. Study population and design  
The sub-studies within this thesis used patients’ data retrieved from a prospectively 
maintained computer database. This is an internal database kept on a secure NHS 
server. It is updated in real-time and includes every ‘transaction’ involving the patient 
– consultations, tests, results, etc. This allows for accurate and detailed data collection 
and follow-up. From this database, a separate ‘research database’ was created also 
on the secure NHS server. These data were specific to this thesis and allowed for 
statistical analysis. The hospital database is continuously updated in real-time by the 
administrative staff within the hospital. The research database was maintained by 
myself and updated on a monthly basis to include any changes in follow up. This would 
include updated imaging, clinical follow up and treatment changes. 
All original data were re-reviewed as part of the methodology. This included re-
examining imaging studies, pathologic samples (where necessary) and performing 
further laboratory work on existing specimens as in the case of the molecular biology. 
The follow up data, however, used in each study was retrospective and the limitations 
of this are discussed in the relevant sections.  
All patient data included in the analyses were obtained from the Royal Marsden 
Hospital (RMH) network of hospitals. Patient data were collected using the central 
RMH database following ethical approval. The study was classified as ‘Service 
Evaluation’ by the local ethics committee. Ethical approval was granted by the local 
ethics committee following the completion of a specific Service Evaluation application 
form. Ethical approval was granted by The Royal Marsden Hospital Research and 
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Development committee following submission of project protocols – Study reference 
SE82. 
Patient inclusion criteria were dependent on the particular hypothesis being 
investigated however all patients were required to have primary rectal cancer with no 
evidence of metastatic disease on presentation (further details of the inclusion and 
exclusion criteria are described below in the individual study chapters). The study 
period encompassed January 2006 to December 2012. There was no sample size 
calculation for the retrospective studies as the ‘timeframe’ was used to include all 
consecutive patients. The limitations of this approach and the potential for type II 
statistical error is discussed in the relevant sections.  
The RMH network included the following hospitals: The Royal Marsden Hospital; 
Croydon University Hospital (formerly Mayday Hospital); Epson and St Helier’s 
Hospital Trust; St Georges Hospital; Basingstoke Hospital; Southampton University 
Hospital.  
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3.2. MRI technique 
3.2.1. Imaging protocol 
 
The importance of technique with particular reference to field alignment and image 
acquisition has been explained in section 1.5. It is equally important not only to use 
thin slices but also small field of view (FOV) for accurate identification. Many MRI 
scanners and resultant images are produced with adequate slices of 3mm but with a 
FOV of 22cm by 22cm and a low matrix resolution. Using correct FOV also affects the 
voxel size. If the voxel size is increased, resolution is lost and morphological 
characteristics become less obvious.   
The imaging protocol employed a thin, 3-mm section turbo spin-echo T2-weighted 
technique with a surface pelvic phased array coil and a small ﬁeld of view (160mm x 
160mm, 256 x 256 matrix) with a minimum of four signal averages to ensure a 0.6 x 
0.6 x 3 mm high resolution image (1mm3 voxel size). A 1.5-T MRI scanner and four 
sequences were used: sagittal, coronal and at least two acquisitions in the oblique 
axial planes. We ensured that oblique axial scans were always perpendicular to the 
long axis of the rectal wall. 
This high-resolution technique is recommended for optimal visualization of rectal and 
mesorectal anatomy (Brown et al., 2003b) and for characterization of mesorectal 
lymph nodes (Brown et al., 2003c). The same technique was previously used for post-
treatment assessment in the MERCURY Study (2006). 
Comparison of post-treatment MR images with pre-treatment MR images is conducted 
by ensuring that both sets of images are acquired using the same angles. Pre-
treatment images are used to help locate the treated tumour, which may be difficult to 
visualize in patients who have had a good response to CRT. Our centre does not use 
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purgative bowel preparation or enemas. After initial localization imaging, large-FOV 
sagittal and axial images are acquired. These first two sequences allow an overview 
of the treated tumour, potentially involved lymph nodes, and direction of the rectal wall. 
This overview enables the planning of the following three high-spatial-resolution 
sequences that are vital for visualization of the tumour and post-treatment fibrosis. The 
first sequence planned is axial to the plane of the tumour and rectal wall. Thin section 
(maximum, 3 mm) axial T2-weighted images through the treated rectal cancer are 
planned using the sagittal T2-weighted images. These images are obtained 
perpendicular to the long axis of the rectum using a 16-cm FOV. The second sequence 
is oblique axial imaging for evaluation of the lymph node drainage territory. Further 
oblique axial imaging to ensure coverage of the draining nodes and tumour deposits, 
which can extend above the superior edge of tumour should be performed. The third 
sequence is in the coronal plane for low rectal cancers. Relying on oblique axial 
imaging alone can be limiting at the level of the anorectal junction. At that level, the 
rectal wall changes in diameter and the distance to the neighbouring tissues is smaller. 
The images may not show the rectal wall in its entirety and over-staging may result 
from partial volume averaging. 
Therefore, high-resolution coronal imaging, which will show the relationship between 
the rectal wall and the levator muscles and between the anal sphincter complex and 
the intersphincteric plane, is useful for tumours in the lower one third of the rectum. 
3.2.2. MRI assessment of T-staging, nodal disease and CRM involvement 
 
MRI-assessed T staging of tumour post treatment (ymrT) was based on interpretation 
of local extent of persistent tumour signal intensity relative to the layers of bowel wall 
on T2-weighted images. T-sub-staging for both MRI (ymrT stage, after preoperative 
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treatment but before surgery) and pathology (ypT stage assessed after surgery) were 
standardized. Nodal stage post treatment was based on interpretation of lymph node 
border characteristics and signal intensity. A node was regarded as positive if either 
an irregular border or mixed signal intensity was demonstrated. Post-treatment MRI 
scans were evaluated for predicted circumferential resection margin status (mrCRM). 
A clear mrCRM was defined if the distance of tumour to the mesorectal fascia was 
greater than or equal to 1mm on MRI. 
3.2.3. MRI assessment of height of tumour 
 
For lower-third rectal tumours, the definition of predicted mrCRM involvement was 
tumour within 1mm of the levator muscle. If the tumour was present at or below the 
level of the puborectalis sling, the mrCRM was predicted as involved if there was 
invasion into the intersphincteric plane or beyond.  
3.2.4. MRI assessment of EMVI  
 
A description of the MRI characteristics of EMVI are described explicitly in the section 
below. Appendix A shows the reporting proforma used for data collection. 
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3.3. Histopathological analysis 
All specimens included in the study were assessed using the TNM 7th edition staging 
criteria. Tumours were further classified using the T3 sub-stage as described above in 
Section 1 and shown in Table 5 (Hermanek et al., 1989).  
Each specimen went through the exact same preparation and handling prior to a 
macroscopic examination leading to a grading of specimen quality including 
photographing (section 1.4). The surgical specimen was opened anteriorly by scissors 
avoiding the actual tumour. It was then pinned to a cork board under slight tension.  
The anterior and posterior surfaces of the mesorectum were painted with ink. The 
specimen was then immersed in 10% formalin for 48 hours. The position of the 
peritoneal reflection was noted. The fixed specimens were sliced in 3-5mm thin 
sections above and below the tumour with further photographs taken.  If the CRM was 
suspected to be involved or threatened it was noted whether this was due to the 
primary tumour, nodal spread, dis-continuous tumour spread or EMVI. Foci of tumour 
in the mesorectum which measured less than 3mm were considered to be micro-
satellite deposits in contrast to those larger than 3mm which were considered to be 
nodal deposits. The number of nodes and those containing tumour were recorded.    
The distance of spread into the mesorectum and beyond the muscularis propria was 
recorded. In addition, the presence of EMVI, lymphatic invasion, lymphocytic infiltrate 
and perineural invasion are recorded. EMVI was considered to be present if the 
following criteria were fulfilled. The microscopic identification of EMVI relies upon of 
the identification of tumour cells within an endothelial or smooth muscle-lined space 
containing red blood cells outside the muscularis propria of the bowel wall as defined 
in the UK Royal College of Pathologists (RCPath) guidelines for reporting colorectal 
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cancer (Williams GT, 2007). Appendix B shows the reporting proforma used for data 
collection. 
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3.4. Molecular profiling and tissue microarray (TMA) analysis  
Formalin-fixed paraffin embedded (FFPE) rectal tumour resection blocks were 
selected for further processing. Tissue specimens of four separate stage tumours were 
collected including EMVI-positive tumours subdivided into lymph node positive or 
lymph node negative and EMVI-negative subdivided into lymph node positive or lymph 
node negative.  
3.4.1. Laser Microdissection 
Paraffin embedded rectal tumours representing all four subtypes listed above were 
used for laser capture microdissection (LCM). LCM was used to successfully isolate 
epithelial cells within the rectal tumour. Tissue sections 10 micromillimetres thick were 
mounted on to polyethylene naphthalate (PEN) membrane glass slides and stained 
with Cresyl Violet. The staining procedure was as follows: 
 1 min Xylene; 30 seconds in 70% Ethanol 
 1 min in 1% Cresyl Violet acetate (in Ethanol) 
 1-2 min in 100% Ethanol.  
Stained slides were allowed to dry in a fume hood and then stored for up to two weeks 
at room temperature with dessicant. Epithelium was microdissected using the Leica 
LMD microdissection platform (Leica Microsystems, UK) and collected in 50µl 
Digestion buffer (Recoverall Kit, Ambion) per slide. Microdissected cells were collected 
from 5-10 sections prior to ribonucleic acid (RNA) extraction.  
LCM uses an ultraviolet (UV) laser beam to cut around selected cells, which are then 
lifted off the slide and collected directly into an eppendorf tube below prepared for RNA 
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extraction. Some samples did not contain such large amounts of RNA and therefore 
required more cells to be cut and collected using LCM.  
3.4.2. RNA Extraction  
RNA was extracted using the RecoverAll Total Nucleic Acid isolation kit (Ambion) 
according to the manufacturer’s instructions. The nucleic acid quantity in each 
collected epithelium sample was determined by spectrophotometry. A minimum of 
100ng of RNA was required to generate expression data on the human, rat and mouse 
miRCURY microRNA array allowing extra RNA for subsequent validation. 
3.4.3. RNA labelling  
For each sample 100ng of total RNA were labelled using a mixture of calf-intestinal 
alkaline phosphatase (CIP) buffer, spike-in microRNA (positive control) and CIP 
enzyme and was then incubated at 37°C in a polymerase chain reaction (PCR) cycler 
for 30 min. This was followed by a five minute incubation period at 95°C, which stops 
the enzymatic reaction and denatures the RNA and is then snap cooled on ice. A 
‘master mix’ comprising labelling enzyme, dimethyl sulphoxide (DMSO), fluorescent 
label Hy3 and labelling buffer was added to the CIP reaction. The labelling reaction 
was incubated in the PCR cycler at 16°C for two hours followed by 15 min at 65°C.    
3.4.3. Array Hybridization and washing 
 
The labelling reaction was made up to 200µl with nuclease-free water and 200µl 
hybridisation buffer was added. Labelled RNA was denatured at 95 °C for two minutes 
and then placed on ice. 400 µl hybridisation mixture were pipetted into the 
hybridisation chamber (Corning) and the Exiqon miRCURY LNA microRNA array was 
gently inverted over the solution ensuring that no bubbles were trapped beneath it. 
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The chamber was sealed, wrapped in foil and placed in a hybridisation oven overnight 
at 56 °C. 
After sixteen hours the chambers were dismantled and the arrays were washed in low 
to high stringency wash buffers (A, B and C each for two minutes) (Exiqon miRCURY 
array kit), followed by a few seconds in 99% ethanol. Arrays were dried briefly in a 
chemical hood and stored in the dark to await imaging. 
3.4.4. Array scanning and data acquisition  
Slides were placed face down and scanned using the GenePixPro 3.0.5 software. 
Scanner settings used were as follows: 532 laser wavelength to detect the Hy3 label 
and a Pixel size of 5 micron/pixel and ‘lines to average’ set at 2. A low-resolution 
preview scan of the whole slide allowed the positioning of a box defining the scan area. 
Following high resolution scanning the brightness and contrast was adjusted 
automatically or manually to obtain the best view. Once the image was saved as a 
TIFF file, the miRbase file containing the grid can was loaded and aligned with the 
blocks. Once all the features were aligned, the data were analysed. The results were 
saved and exported into an Excel spreadsheet. The mean fluorescence minus the 
background fluorescence could then be normalised. The panel of normalising genes 
on the array as well as positive and negative controls were used when determining 
whether the hybridisations were successful and samples were of sufficient quality to 
be included in the overall analysis. 
3.4.5. Real-time reverse transcription-PCR 
Singleplex TaqMan® microRNA assay reactions were performed for validation of 
profiling results. For each quantitative PCR assay, 50 ng of total RNA was converted 
into complementary deoxyribonucleic acid (cDNA) using a microRNA-specific reverse 
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transcription step and the TaqMan® MicroRNA Reverse Transcription system 
according to the manufacturer’s instructions (Applied Biosystems, Foster City, USA). 
Reactions were performed in triplicate and the ABI-HT7500 qPCR instrument (Applied 
Biosystems, Foster City, USA) were used with the following cycling parameters:  
 95 ºC for 10 minutes  
 40 cycles of 95 ºC for 15 seconds  
 60 ºC for 60 seconds   
Expression levels were normalised and calculated using cycle threshold (CT1) value 
technique with a reference value of 1 for a specific specimen. 
3.4.6. PCR Amplification 
PCR amplification was performed under recommendations by Applied Biosystems. A 
total volume of 20µl reaction mixture included 1.0µl TaqMan Small RNA Assay, 1.0µl 
of product from RT reaction, 10µl TaqMan 2X Universal Master Mix and 7.67µl 
Nuclease-free water and was placed into each well. The plate was sealed with an 
optical adhesive cover, and then centrifuged to spin down the contents and eliminate 
any bubbles. U6 housekeeping gene was used as an endogenous control. Each 
microRNA expression level was calculated using CT1 value. 
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3.5. Statistical analysis 
Average values where calculated using mean or median where appropriate and 
standard deviation or interquartile range, respectively. For continuous data the mean 
was used and for categorical data the median value was used. Differences between 
groups were assessed using the Chi-squared test or Fisher’s Exact test as appropriate 
for categorical data and student’s t-test for continuous data. Survival estimates for 
disease-free survival (DFS) and overall survival (OS) were obtained using the Kaplan-
Meier product limit method. Life tables were used to give DFS or OS at specific time-
points, eg 3 years or 5 years. Patients were censored at the last point of known contact 
or if they died during follow-up without experiencing the outcomes of interest.  
Cox’s proportional hazard models were built to test the impact of confounding 
variables on survival (age, gender, neoadjuvant therapy, etc). These models allow the 
effect of predictive factors on outcome to be assessed, accounting for censored 
outcome, differing time of follow-up, and the interval between surgery and the adverse 
event of interest. Hazard ratios (HR) and 95% confidence intervals (CI) were 
generated. Firstly, univariate analysis was performed of individual data variables to 
test for significance. This was followed by multivariate analysis of all variables. In order 
to provide clinically and meaningful risk adjustment, several strategies were used to 
create multivariable models: 
1. Fully adjusted model – all predictive risk factors that were judged to be clinically 
relevant (irrespective of statistical significance) were entered into a fixed model.  
2. Parsimonious bidirectional stepwise model based on Akaike information 
criterion (AIC) – AIC measures the relative quality of a statistical model, trading off 
goodness of fit for complexity. It thus provides an accurate means for model selection, 
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and is not driven by significant p-values alone, which can lead to poorly fitted models. 
A smaller AIC indicates a better model.  
3. Parsimonious forward stepwise model– a final model was built using selection 
based on p-values alone in order to compare to previous models. Variables significant 
at p<0.1 at univariable level were entered, and remained if p<0.05.   
Data were analysed using SPSS 19, 20 or 21 (SPSS Inc, Chicago, Illinois) and R 3.0.0 
(R Foundation for Statistical Computing). 
The statistical plan for each project was reviewed and discussed with two statisticians. 
Approval of the statistical plan was part of the formal local ethics procedure but where 
there were further analyses required this was reviewed with the Royal Marsden 
statisticians.  
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Chapter 4 
Systematic review on prognostic effect of EMVI in rectal cancer 
4.1. Introduction 
Venous invasion has been considered a significant prognostic factor in rectal cancer 
for well over half a century. It is well documented that tumour spread to the veins 
outside the muscularis propria of the bowel wall is an independent poor prognostic 
factor (Freedman et al., 1984, Jass et al., 1986, Talbot et al., 1981) but to what extent 
this confers a survival risk is still largely unknown. Improved oncological therapies and 
the potential for more intensive post-operative surveillance means that understanding 
the clinical importance of venous invasion is paramount if we are to offer patients 
optimal treatment. 
The modern term used to describe venous invasion of tumour cells, which bears the 
strongest prognostic relevance in rectal cancer, specifically describes the involvement 
of the veins beyond the muscularis propria of the rectal wall - EMVI is defined by the 
presence of tumour cells within the veins beyond the outer limits of the muscularis 
propria and within the vicinity of the tumour. This definition is key to appreciating the 
limits of the historical literature and therefore how applicable it is in current day 
management. 
The importance of EMVI as an adverse feature has been recognised by the Royal 
College of Pathologists (RCPath) in the UK and is therefore now included in the 
minimum dataset for reporting colorectal cancers (Williams, 2007b). There is a 
recommendation that detection rates should be at least 25%. RCPath recommends 
regular audit to examine the quality of reporting of features such as EMVI. The College 
of American Pathologists (CAP) also recognise the importance of venous invasion 
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although they have included it in the reporting protocol as part of ‘lymphovascular 
invasion’, which may have different prognostic implications (Liang et al., 2007).  
This systematic review critically reviews the historical evidence for the prognostic 
importance of venous invasion on survival specific to rectal cancer.  
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4.2. Methods 
4.2.1. Identification of studies 
An electronic search was carried out using MEDLINE (1965-2013), EMBASE (1980-
2010), CINAHL (1982-2010) and the Cochrane library databases. In addition, Google 
scholar and Pubmed were used to search additional articles prior to 1965. The 
following medical subject heading (MeSH) terms and keywords were used: ‘rectal 
cancer’; ‘venous invasion’; ‘vascular invasion’; ‘extramural’; and ‘EMVI’. The “related 
articles” function was used to broaden the search and all abstracts, studies, and 
citations retrieved were scanned for subject relevance. The latest date of this search 
was 1st August 2013. All potentially relevant manuscripts were retrieved and 
evaluated for inclusion. Additional references from the collective libraries of the senior 
authors were identified. Reference lists of all relevant publications were hand-
searched for additional studies missed by this search strategy, and cross referencing 
continued until no further relevant publications were identified.  Figure 15 shows the 
search strategy. 
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Figure 15 – PRISMA flowchart of methodology for systematic review  
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4.2.2. Study inclusion criteria and data extraction 
Study methodology was carried out in accordance with the “Preferred Reporting for 
Systematic Reviews and Meta-Analyses” (PRISMA) recommendations for improving 
the standard of systematic reviews. Studies that met the following pre-defined criteria 
were included in the review process:  English language publications were included, 
studies had to report the outcome of venous invasion or EMVI in curative rectal cancer.  
Where multiple studies describing the same patient population were identified, the 
most recent publication was used unless additional information was imparted by earlier 
work. Case reports were excluded. Studies of colorectal cancer were included where 
there was specific analysis of rectal cancer within the study population.  
Outcome measures: Studies were only included if they reported outcome information 
including disease recurrence and overall survival. An assessment of the quality of all 
eligible studies was carried out by two independent reviewers. 
4.2.3. Data Synthesis 
Forest plots were used to display the prevalence of EMVI positive patients and the 
total overall prevalence reported in the literature. We also used forest plots to illustrate 
the 5 year survival rate.  
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4.3. Results 
4.3.1. Literature search and description of studies 
Two reviewers performed an independent search of the literature which were cross-
referenced. The outlined search strategy identified 364 publications of potential 
relevance. Following screening of titles and abstracts, 253 studies were excluded of 
which 142 articles did not report the outcome for venous invasion specifically, 32 which 
included patients who did not undergo surgery, 30 which described techniques only 
but did not report on the outcomes, 25 case reports, 24 articles described venous 
invasion outside the context of cancer.  
This left 111 articles which were retrieved in full text. A further 28 articles were 
identified from the references contained in these articles, providing a total of 139 
articles for evaluation. Of these 125 did not meet the detailed inclusion criteria, and 
were withdrawn from evaluation, leaving 14 studies published between 1935 and 2013 
that were entered into the review process. For ease of description the results are 
presented according to prevalence, method of detection, survival; local and metastatic 
disease and association with other factors. 
4.3.2. Study Characteristics 
A total of 7262 patients in the 14 studies were included in the review. The studies were 
spread over seven decades (1938-2006) and six involved were retrospective. Only 6 
studies commented on number of pathologists and blinding status (Harrison et al., 
1994, Talbot et al., 1980, Dukes and Bussey, 1958, Seefeld and Bargen, 1943, 
Madison et al., 1954, Khankhanian et al., 1977). There was variation in the histological 
stains used, the commonest being H+E, Gieson’s, elastin and Brominol.  
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All the included studies dealt with rectal tumours but two also incorporated 
rectosigmoid tumours (Seefeld and Bargen, 1943, Madison et al., 1954). 
4.3.3. Prevalence 
The overall prevalence of EMVI histopathologically positive patients was 26% 
[Random effects: Event rate 0.26 (0.18, 0.36), z=-4.3, Q=787, I2=98%]. The results 
for each study are graphically portrayed in figure 16. 
4.3.4. Survival in the presence of venous invasion 
5 year overall survival rates for patients with EMVI were reported in seven studies (4, 
6, 17, 18, 20-22) and the overall survival was 39.5% [Random effects: Event rate 0.395 
(0.29, 0.51), z=-1.9, Q=58.06, I2=90%]. (Figure 17) 
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Author Year 
No.  
Patient
s 
Study Design Stain 
Tumour  
Site 
Elastin 
stain 
No. EMVI +ve 
pts 
Prev VI +ve 
EMVI +ve 
5yr survival 
Brown & Warren  1938 170 Retrospective H+E Rectum Yes 104 61% No 5yr data 
Dukes & Bussey (Dukes and 
Bussey, 1941) 
1941 689 Prospective No stain Rectum No 107 17% No 5yr data 
Seefeld & Bargen (Seefeld and 
Bargen, 1943) 
1943 100 Prospective 
H+E, 
Gieson’s 
Rectum Yes 20 20% 5% 
Madison et al (Madison et al., 
1954) 
1954 42 Prospective 
Brominol, 
H+E, 
Gieson’s 
Rectum Yes 19 43% No 5yr data 
Carroll (Carroll, 1963) 1963 1996 Retrospective H+E Rectum No 240 11.8% 36% 
Khankhanian et al 
(Khankhanian et al., 1977) 
1977 143 Retrospective Not stated Rectum No 70 19% (BVI + LVI) Data not usable 
Talbot et al (Talbot et al., 
1980) 
1980 706 Prospective 
H+E, 
elastin 
Rectum Yes 366 52% 33% EMVI+ve 
Rich et al (Rich et al., 1983) 1983 142 Prospective H+E Rectum No 23 17% No 5yr data 
Freedman et al (Freedman et 
al., 1984) 
1984 494 Retrospective 
No 
comment 
Rectum Yes 89 36% 31% EMVI+ve 
Jass et al (Jass et al., 1986) 1986 447 Prospective H+E Rectum No 116 
26% 
(extramural 
only) 
41% EMVI+ve 
Sasaki et al (Sasaki et al., 
1987) 
1987 774 Retrospective H+E Rectum No 163 
21% 
(extramural 
only) 
No 5yr data 
Minsky et al (Minsky et al., 
1988) 
1988 168 Retrospective 
H+E, 
elastin 
RS/Rectum Yes 81 48% 33% EMVI+ve 
Harrison et al (Harrison et al., 
1994) 
1994 348 Retrospective 
H+E, 
elastin 
Rectum Yes 74 21.2% 21% EMVI+ve 
Ptok et al (Ptok et al., 2007) 2006 1043 Retrospective Not state Rectum No 75 9% 80.7% LVI +ve 
 
Figure 16 – Prevalence of EMVI in studies included
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Figure 17 – Survival of patients with histopathologically confirmed EMVI 
Carroll  analysed the survival characteristics of 2447 patients (Carroll, 1963). Venous 
invasion was identified by gross dissection of the resected specimen. The corrected 
5-year survival rate was compared between those patients whose resection specimen 
demonstrated venous invasion on histopathological analysis and patients with no 
evidence of venous invasion. Five year survival rates of Dukes’ B tumours with venous 
invasion were 67.5% compared with 77.6% without and of Dukes’ C with venous 
invasion was 23.1% compared with 32%. A further comparison using histopathological 
tumour grade showed a significantly lower five year survival rate in tumours of low and 
average histological grade when venous invasion was present (34.8% and 44.8% 
versus 77.3% and 60.6%).   
Talbot et al examined 706 patients who were operated on with a view to cure, between 
1960 and 1966 at St Marks’ Hospital (Talbot et al., 1980). The tumour sections were 
reviewed with the help of additional stains for elastic tissue where necessary. Venous 
invasion was found in 51.9% of patients and of these 36.1% had extramural venous 
invasion. This incidence increased with Dukes stage as follows: 20%, 47%, and 64% 
in Dukes A, B and C. Of the 706 patients, 684 were included for survival analysis. The 
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5-year survival rate where venous invasion was evident was 57% compared with 73%. 
The survival rates according to Dukes’ stage showed that when venous invasion was 
not present the 5-year survival rate was 86% and 46% for Dukes B and C tumours.  
Freedman et al reviewed the outcomes of 769 patients with rectal cancer who 
underwent potentially “curative surgery” (Freedman et al., 1984). Of these only 494 
were considered to have undergone “curative surgery” (the excluded cases were those 
where the surgeon believed there to be residual tumour) and only 21% had evidence 
of venous invasion. The patients with venous invasion were subdivided into 
submucosal, extramural or unknown with respective five year survival rates of 42%, 
31% and 32%. Venous invasion was shown to be an independent factor on survival 
on statistical analysis.     
Minsky et al found a prevalence of 48% of what was termed ‘blood vessel invasion’, 
48% in a pathology review of 336 patients (Minsky et al., 1988). Most (71%) were 
classified as intramural only, and there were only 19% of patients who had extramural 
venous invasion. The survival analysis revealed a significant decrease when 
extramural venous invasion was present compared with intramural venous invasion or 
no evidence of blood vessel invasion at all (33% versus 72% versus 72%)They did 
not, however, find venous invasion to be an independent prognostic factor for 5-year 
survival following a proportional hazards analysis. Jass et al studied the survival 
characteristics of patients from St Mark’s Hospital (Jass et al., 1986). All 447 patients 
were reported to have “extramural” venous invasion and the five year survival of 
patients with EMVI was 41% compared with 67% in those without. 
Only one study has not demonstrated a decreased survival risk  but this did not stratify 
between colon and rectum (Khankhanian et al., 1977). This study reviewed 143 cases 
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of Dukes’ B colorectal cancer. Vascular invasion was found in only 18.8%. Disease-
free interval and overall survival were not significantly different in these patients but 
interestingly, relapse was seen in 41.3% of patients without vascular invasion 
compared with 29.6% in those which exhibited vascular invasion implying that vascular 
invasion is a protective factor on survival. The details of the histopathological analysis 
were not given in this study. 
4.3.5. Local and metastatic disease in venous invasion  
Brown and Warren first showed the association between venous invasion and disease 
recurrence. In their study, 71% of patients with venous invasion developed recurrent 
disease with the vast majority of these being distant metastases. In comparison none 
of the 70 patients who showed no evidence of venous invasion developed metastases. 
Rich et al studied patterns of disease recurrence in 142 cases of rectal and 
rectosigmoid tumours undergoing curative surgery (Rich et al., 1983). Venous invasion 
was found to be an independent prognostic factor for an increased risk of local and 
distant disease recurrence which was independent of nodal status. In patients who 
had node positive disease, local recurrence was seen in 100% of patients compared 
with 41% when there was no venous invasion. In node negative disease this was 59% 
compared with 33%.  
In the study of Talbot et al, patients with evidence of venous invasion had a greater 
incidence of liver metastases (35% compared with 14% in those patients with no 
evidence of venous invasion). A further comparison between the types of venous 
invasion showed that those patients with extramural venous invasion had liver 
metastases in 40% of patients compared with 23% of patients who had evidence of 
intramural venous invasion. The overall rate of liver metastases in all patients was 
25%. When venous invasion was not seen, this was 14% and in those patients where 
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it was present this increased to 35%. Knudsen et al demonstrated venous invasion in 
265 patients of whom 136 had metastatic disease in the liver at the time of death. This 
compared with liver metastases in 45 patients of the remaining 417 patients where 
there was no evidence of venous invasion (Knudsen et al., 1983).  
A study by Horn et al reported venous invasion in 22% (28/128) patients undergoing 
primary “curative” surgery (Horn et al., 1991). Five year distant recurrence-free 
survival was 84.3% when EMVI was not present and 32.9% when present. Distant 
metastases occurred in 46.4% of patients with venous invasion compared with 10% 
without.  For local recurrence this was 21.4% when venous invasion was present 
compared with 23% in the absence of venous invasion. The 5-year local recurrence-
free survival was 75.4% and 80%, respectively but this did not reach statistical 
significance.      
Willett et al analysed the survival of patients with node negative, T3 rectal cancer 
(Willett et al., 1999). None of the 117 patients included in the study were given 
neoadjuvant or adjuvant chemo- or radiotherapy. Survival was measured in 10-year 
actuarial rates for local disease control, distant disease free recurrence and recurrence 
free survival with rates of 76%, 68% and 62%, respectively. Multivariate analysis 
showed vessel involvement as well as depth of invasion and tumour grade to be 
independent factors for freedom from distant metastases and local recurrence.    
A more recent study examined the prognostic factors which led to recurrence in 256 
Dukes’ B and 74 Dukes’ C cancers after curative surgery. Univariate analysis showed 
that vascular invasion was significantly associated with a higher rate of disease 
recurrence. In the Dukes’ B group, patients with vascular invasion had 3.13 times 
higher risk of developing recurrence. This correlated to the same risk as Dukes’ C 
116 
 
patients who did not have vascular invasion. These results were also borne out in the 
survival analysis where Dukes’ B patients with vascular invasion had a 2.61 times 
higher risk of death. This was also similar to patients in the Dukes’ C group. Vascular 
invasion remained a significant risk factor on multivariate analysis. 
Dresen et al analysed a subgroup of patients from the Dutch TME trial (Dresen et al., 
2009). Various prognostic factors were analysed between a group of patients who 
developed local recurrence with a group who were disease-free at two years. Using a 
logistic regression model, they found EMVI associated with an increased risk of 
developing local recurrence (odds ratio 4.54 and 4.51 in CRM positive and negative 
patients). EMVI was found in 41.3% of the patients in the recurrent group compared 
with 13% where EMVI was not present. Similar results were reported by Takahashi et 
al who showed a hazard ratio of 1.90 in patients with vascular invasion (Takahashi et 
al., 1996). 
4.3.7. Association with other prognostic factors 
Recent studies have suggested an association between known prognostic factors and 
venous invasion implying the multifactorial nature of certain poor prognosis tumours. 
For example, EMVI is almost exclusively seen in T3 and T4 tumours, which gives it a 
positive correlation with the depth of tumour penetration of the bowel wall. But other 
important prognostic factors such circumferential resection margin (CRM) involvement 
and nodal disease, have also been shown to be associated with venous invasion.  
An association with the CRM has been previously reported by Chapuis (Chapuis et 
al., 2006). He studied the risk factors which were associated with tumours that had a 
positive resection margin following surgery. The aim was to identify features which 
would lead to a positive resection margin. Several factors were identified on initial 
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analysis but using a multiple logistic regression model, nine factors proved to be 
significant including venous invasion (Odds Ratio 1.7). A similar study of 418 patients 
by Ueno et al also demonstrated that vascular invasion was a predictor of CRM 
involvement (Odds Ratio 2.7) (Ueno et al., 2002).   
Venous invasion has also been reported to be a predictive factor for lymph node 
metastasis. This has been mainly studied in early rectal cancers, that is, those which 
are confined to the bowel wall (T1 and T2). These tumours may be treated by less 
radical, local excision procedures however this is dependent on the absence of nodal 
disease. A study of 59 patients with early rectal cancer (54 submucosal carcinoma 
and 5 carcinoma in-situ) reported a lymph node involvement of 9.2% (Kodaira et al., 
1981). The odds of nodal disease increased 18-fold for those who had venous 
invasion. Venous invasion was seen in 11.8% of patients. 60% of patients with lymph 
node involvement had venous invasion but only 7% where there was no nodal disease. 
These findings were also shown by both Blumberg et al and Goldstein et al in T1 and 
T2 cancers (Blumberg et al., 1999, Goldstein and Hart, 1999). Goldstein studied the 
resection specimens of 73 abdominoperineal (APR) specimens; 11 of which had nodal 
disease. Amongst the associated risk factors was small vessel invasion. This 
association may not only be restricted to early cancers. A study by Saclarides et al of 
all stages of rectal cancer reported venous invasion to be strongly associated with 
nodal metastases (Saclarides et al., 1994). 
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4.4. Discussion 
Historically, there has been a tendency to categorise all invasion of the vasculature 
including venous, arterial, lymphatic and perhaps even perineural under one 
pathological category. This has led to difficulty in accurately understanding which of 
these, if not all, are actually prognostically relevant. In recent years, there has been 
an increasing realisation that it is the veins that are most likely to be implicated in the 
development of metastatic disease and survival.  
The association between venous invasion and poor prognosis has been shown in the 
present review to date back to the mid-20th century but the most striking finding is the 
huge variability in detection rates on histopathology. This ranges from 9-61% and 
reflects the inconsistent nature of recognition and detection. It is worth remembering 
that historically many pathologists were not aware of the importance of venous 
invasion as a prognostic factor and therefore may not have been actively seeking it. 
Also, the historical definitions of venous invasion did not make it clear whether 
detection was intramural, extramural or both. The more consistent detection rates 
which are found in most recent reports almost exclusively use the terminology of 
‘extramural venous invasion’.  
Furthermore, the specialisation which exists amongst today’s pathologists is another 
factor which would limit variability in the diagnosis of venous invasion. But the most 
reasonable explanation for the variation must be the lack of standardisation in 
detection technique and definition of morphology. This means that relying on non-
standardised pathology may lead to under-reporting and thus inaccurate risk 
stratification of patients. Consideration should be given to the use of elastin stains to 
identify cases of venous invasion where there is uncertainty, in addition to reference 
to imaging studies such as MRI.   
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MRI has been shown to be accurate in identifying EMVI with reproducible results. It is 
also accurate in identifying EMVI following CRT using the same identification 
technique. CRT can destroy the morphological architecture which pathologists use to 
detect EMVI and thus make it difficult to identify. Such difficulty appears to be less of 
a problem when using MRI. A further advantage of MRI over histopathology is that 
pelvic imaging is able to visualise the entire rectum in-situ whereas the analysis of a 
small sample of the tumour is dependent on macroscopic assessment by the 
pathologist in the first instance, to ensure a representative area has been evaluated.  
It is notable that despite being shown to be an independent adverse feature in multiple 
studies, it is not seen to be mandatory in many centres to offer patients oncological 
treatment based on its finding. This may be due to the inconsistent detection rates 
shown above or it may be that it is rare to find EMVI without the association with more 
traditional adverse features such as nodal disease or increased T-stage.  
The evolution of rectal cancer management may, however, lead to a change in attitude 
towards EMVI if a more selective approach is taken to neoadjuvant treatment. The 
universal policy of irradiating all T3 tumours or any tumour that has local nodal disease 
may be over-treating some patients. There is accumulating evidence that not all T3 
tumours behave the same and that it is depth of penetration through the mesorectum 
(T3 sub-stage) that is prognostic – this is discussed in detail in Chapter 1. Further, in 
the presence of optimal TME surgery nodal disease may not be prognostic for local 
recurrence. In these situations early T3 tumours, or those with N1 disease, may not 
benefit from neoadjuvant CRT and it may be EMVI which tips the balance.  
The major limitation in the present study is the inconsistency of terminology for venous 
invasion. The articles which specifically refer to EMVI are more helpful as there is a 
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specific definition. Furthermore, many studies which have reported on venous invasion 
have not separated colon from rectal cancer. In addition, many of the earlier reports 
have not mention demographic data or tumour characteristics in much detail. The 
more historical studies have also been reported in an era where both surgery and 
oncology have evolved, which introduces an element of bias in the results.  
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Chapter 5  
Optimal methods of detection of EMVI following CRT in rectal cancer  
Aim  
This chapter describes the optimal technique for imaging the rectum post-CRT and 
explicitly describes the process of detecting mrEMVI. There is also a description of 
optimal histopathological technique. 
5.1. Introduction 
MRI has become central to pre-operative risk-stratification of rectal cancer. The 
significant tumour characteristics that influence treatment decisions can be accurately 
and confidently identified on early MRI staging, which is now considered a mandatory 
investigation for rectal cancer in the UK. Each of these factors produces specific 
radiological characteristics which help radiologists identify their presence with 
reproducibility. These include tumour depth, locoregional nodal disease, involvement 
of the CRM and EMVI. The importance and accuracy of MRI in pre-CRT staging has 
been explicitly described in Chapter 1.  
Locally advanced tumours which exhibit high-risk features are commonly offered CRT 
to reduce the risk of locoregional disease recurrence and improve survival. The 
prognostic relevance of the same tumour characteristics following treatment with CRT 
is not clear, yet some clinicians base their management plans on the initial staging 
regardless of the response which may have occurred. For example, if a patient 
demonstrates malignant mesorectal lymph nodes on initial staging (pre-treatment 
MRI), which are subsequently not seen on post-CRT imaging or in the resected 
specimen, they may still be offered adjuvant chemotherapy as ‘high-risk’ stage II 
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disease (based on the initial imaging). Such decisions are commonly made as part of 
local policy rather than national, continental or universal guidelines. 
There is still no universal agreement on the best imaging modality to gauge treatment 
response following CRT but of the current modalities, MRI is the most accurate 
although may be limited by availability. The importance of MRI in its ability to measure 
treatment response is seen by its inclusion in many current national and international 
trials in rectal cancer. Furthermore, the clinical relevance in relation to survival and risk 
of recurrence is currently being investigated and validated prospectively against 
pathology for several of the traditional adverse features described in Chapter 1 – T-
stage, nodal involvement and relationship of the tumour margin to the CRM. These 
features are given the prefix ‘y’ to denote that patients have undergone CRT. 
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5.2. MRI technique 
The accurate assessment of mrEMVI relies on the availability of high-resolution and 
high-quality MRI. The technique to identify tumour characteristics optimally using MRI 
has been described in detail in Chapter 3. Crucially this not only requires high-
resolution small ‘field of view’ images of the mesorectum but also higher resolution 
sagittal images for the appropriate planning of axial and coronal sequences. Briefly, 
the protocol employs a thin 3-mm section turbo spin-echo T2-weighted technique with 
a surface pelvic phased array coil. No bowel preparation, air insufﬂation or intravenous 
contrast agents are used. The sagittal T2 weighted images are used to plan T2-
weighted small field of view axial and coronal images through the rectal cancer. These 
images are performed perpendicular to the long axis of the rectum and obtained using 
a 16-cm ﬁeld of view and a 3mm section thickness resulting in a voxel size of 1.1mm3. 
Low-resolution images (voxel size greater than 1.1mm3), images degraded by patient 
motion artefact or those which are not performed perpendicular to the rectum lead to 
ambiguous staging and inability to determine ymrEMVI.    
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5.3. Pre-treatment baseline mrEMVI  
EMVI displays specific radiological characteristics on MRI T2-weighted images as 
previously described by Brown at el and Smith et al (Smith et al., 2008b, Brown et al., 
2003a). Veins around the rectum are recognised on T2-weighted images as 
serpiginous or tortuous linear structures. There is a signal void seen in the tubular 
structures thought to be vessels in addition to changes in contour. Smaller venules 
can be seen perforating the normal outer rectal wall and produce a low to intermediate 
signal intensity in tubular structures on T2-weighted images. Venous invasion into 
these smaller venules can be recognised by their expansion and irregularity adjacent 
to the tumour due to contiguous tumour extension.  
 These radiological features reflect the degree of venous invasion although the clinical 
relevance of increasing ‘radiological’ severity remains unknown.  The prognostic 
importance of mrEMVI ‘positive’ status has, however, been documented and shown 
to correlate with pathology and outcomes (Smith et al., 2008a). Since this validation 
against histopathology, which is described in Section 1.7.3.2 by Smith et al in 2008, it 
has become routine practice in our institution to report on mrEMVI status. Reporting 
of EMVI has simultaneously become a mandatory requirement for histopathologists in 
the UK as part of the minimum dataset in (colo)rectal cancer (Williams, 2007a).  
 
Briefly, ideal assessment of mrEMVI must include the following: the pattern of tumour 
margin (extension into small veins may produce a nodular border); the location of 
tumour relative to major vessels; the vessel calibre (tumour causes vessel expansion 
and increase in tumour signal in the lumen); and vessel border. 
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Figure 18 – Pre-treatment MRI sections showing EMVI. Large vessel invasion (superior rectal veins), medium and large venous 
invasion (branches of superior rectal veins and medial rectal veins), Small vein invasion – middle and lower rectal veins 
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5.4. Post-treatment ymrEMVI 
Post-treatment EMVI can also be readily detected on MRI (ymrEMVI) using the 
sequences described above. CRT produces characteristic morphological change 
within the tumour that can be graded radiologically to reflect response. It can cause 
similar changes in the radiological characteristics of the extramural veins eg extension 
into small veins may produce a nodular border, cause vessel expansion and increase 
in tumour signal in the lumen. Much like the grading system proposed by Smith et al 
for pre-treatment mrEMVI, the MRI features of ymrEMVI can be scored according to 
the degree of venous invasion. We have developed a novel scale to reflect response 
which is similar to the tumour regression grade (TRG) used by pathologists to measure 
tumour response. This has been termed the mrvTRG scale and grades the response 
from 1-5. This scale is yet to be validated prospectively against histopathology but has 
been tested retrospectively and is also the subject of analysis for the prospective study 
described in chapter 13. The mrvTRG system is described in Table 11.   
 
MrvTRG Score Post-treatment mrEMVI features 
1 Tumour signal replaced by vessel fibrosis 
2 Less than 25% tumour; 75% fibrosis 
3 25-49% tumour signal 
4 50-75% tumour signal 
5 Minimal fibrosis of tumour signal 
 
Table 11 –mrvTRG grading system following CRT 
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The mrvTRG score reflects the degree of fibrosis seen in relation to tumour signal in 
the vessel.  Fibrosis is seen as low signal on high-resolution T2 weighted images and 
the fibrosis of EMVI classically distorts the extramural vasculature. The radiologist 
should initially decide whether tumour signal or fibrosis is seen within the vein. 
Thereafter determining the exact mrvTRG depends on the relative degree of fibrosis 
and tumour signal within the veins. The radiological characteristics for a mrvTRG 
grade 2 is shown in Figure 19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
128 
 
 
Figure 19 – mrvTRG Post CRT MRI shows fibrotic component only at the site of previously infiltrated vessels, mrvTRG2. Arrows depict the areas of fibrosis 
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5.5. Implications of ymrEMVI and mrvTRG 
The ability to assess the treatment response after neoadjuvant CRT has exciting 
implications although this is yet to be prospectively validated against histopathology. 
If one is to continue to hold histopathology as the Gold Standard despite limitations 
which are discussed in further chapters, radiologists and pathologists must work 
together to optimise detection rates.  
Using post-CRT imaging to progressively risk-stratify patients as they pass through 
phases of their treatment means that patients are offered optimal management 
strategies which are flexible. The regression grading and association with clinical 
outcomes means that mrEMVI has the potential to be used as an imaging biomarker 
in the future (this is shown and discussed in Chapter 11). If ymrEMVI can be used to 
predict disease progression and identify those patients are the highest risk of 
recurrence, it would allow clinicians to tailor surveillance and oncological treatment 
accordingly and ultimately improve outcomes. Ultimately, those that would most 
benefit from consolidation therapy would be offered such treatment without burdening 
lower risk patients with unnecessary morbidity. 
The use of MRI in detecting a known prognostic marker of metastatic disease can also 
help pathologists with both techniques working hand-in-hand rather than competing. 
Pathological detection of EMVI following CRT (ypEMVI) is difficult as the 
morphological changes cause destruction in the vessel architecture and associated 
microanatomy which pathologists use to confirm the presence of EMVI. If there 
remains a singular reliance on pathology to detect EMVI then we are at risk of missing 
patients who would benefit from adjuvant chemotherapy. If pathologists are able to 
confer with their radiologist colleagues, cases where there may be suspicion of EMVI 
but no obvious evidence can be re-examined using MRI as a reference.  
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There are also adjuvant treatment implications. As the results of current trials become 
available, we will be able to more confidently understand the role of specific tumour 
characteristics on long-term survival following CRT. This will allow clinicians to offer 
chemotherapy to the most appropriate patients, that is, those who will benefit from 
such therapy without using a ‘blanket’ policy for all.   
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5.6. Histology-based detection 
Histopathological examination is the current gold standard method by which EMVI is 
identified; the significance of the finding has been appreciated, at least conceptually, 
for over eighty years (Willis, 1930). The accurate identification of EMVI relies on 
meticulous examination and sampling at both the macroscopic and microscopic level; 
ancillary staining methods may also help to highlight the architecture of vascular 
structures and increase the identification rate.   
 
5.6.1. Macroscopic examination   
The macroscopic examination of rectal cancer specimens has been described in 
Section 3.3 in detail. Briefly, resection specimens must be appropriately opened, 
pinned out and fixed in formalin solution for at least 48 hours before dissection. Once 
adequately fixed, the specimen should be cross-sectionally sliced transversely at a 
thickness of three to four millimetres; these thin slices allow identification of the depth 
of tumour invasion and status of the circumferential resection margin.  
 
5.6.2. Microscopic examination 
The microscopic identification of EMVI relies upon of the identification of tumour cells 
within an endothelial or smooth muscle-lined space containing red blood cells outside 
the muscularis propria of the bowel wall as defined in the UK Royal College of 
Pathologists (RCPath) guidelines for reporting colorectal cancer (Williams GT, 2007). 
Due to the difficulties associated with tissue sectioning and architectural distortion by 
tumour or fibrosis following CRT, vascular spaces may become difficult to identify on 
routine haematoxylin and eosin (H & E) staining.  As a result, the rate of EMVI with H 
& E staining has been documented to be as low as 8% (West et al., 2010), yet the 
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RCPath guidelines suggest that EMVI should be detected in at least 25% of cases of 
colorectal cancer. There is no guidance as to the expected rate in rectal cancers alone 
or those treated with neoadjuvant CRT. In situations where uncertainty or 
disagreement exists as to the nature of subserosal tumour deposits, the RCPath 
guidelines recommend that deeper sections through the tissue block should be 
performed to attempt to clarify the nature of a lesion; alternatively histochemical and 
immunohistochemical stains can be invaluable tools.   
 
 
Figure 20 – EMVI in rectal cancer on H&E stain. The thick walled artery is shown next 
to the thinner walled vein.  
 
EMVI was introduced into the 6th version of TNM staging when the classification of 
extramural tumour deposits was based on contour with irregular deposits being 
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classified as vascular invasion and smooth deposits lymph nodes. This classification 
did not make sense as vessels are generally smooth structures leading to 
unacceptable variation in reporting rates. For this reason, the guidance was removed 
from the more recent 7th addition of TNM. 
 
5.6.3. Special Stains: histochemical staining 
The elastic lamina within medium-to-large vessels provides a landmark, which can be 
highlighted by special stains such as orcien and elastin Van Gieson (EVG); the 
application of these stains has been shown to increase the detection of EMVI from 
19.6 to 58% (Roxburgh et al., 2010). The major drawbacks of these methods are that 
they are non-specific and interpretation maybe hampered by background staining.  
 
5.6.4. Special stains: immunohistochemistry 
Immunohistochemical stains using antibodies directed towards endothelial (CD31 and 
CD34) or smooth muscle (smooth muscle actin) antigens within vessel walls also 
increase the sensitivity of histopathology-detected EMVI. The potential advantage of 
these methods is an increased specificity over histochemical staining, although the 
endothelium may become lost or obscured when a tumour embolus occupies a vessel. 
Kingston et al examined the rate of detection when using H & E, EVG and 
immunohistochemistry for CD31 and CD34 in fifty cases of colorectal cancer in which 
vascular invasion had previously not been identified; with the use of special stains they 
identified vascular invasion in 48% of cases (Kingston et al., 2007a). Although this 
study did not differentiate between intramural and extramural vascular invasion, it 
showed that EVG was the most sensitive method, however, in a minority of cases 
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immunohistochemical staining was still required. An example of these histochemical 
and immunohistochemical stains in practice is shown in Figure 21.   
 
5.7. Limitations in detection of ymr- and ypEMVI 
The perceived difficulty in interpreting post-treatment images on MRI with respect to 
EMVI is two-fold. Firstly, the operator must be sufficiently confident to be able to 
identify mrEMVI at baseline and have some indication of the severity and vessel 
involvement. However, following appropriate training and subsequent proforma-based 
reporting, it has been shown that mrEMVI can be identified with accuracy and 
reproducibility. Secondly, there is a perception that post-treatment MRI features can 
be difficult to differentiate with regards to tumour signal and fibrosis.  
In histopathological detection, the success in identification relies on rigorous technique 
with appropriate sampling and sectioning. This is accompanied by the use of strict 
criteria to define whether pEMVI is present or absent. The use of CRT prior to surgery 
makes this all the more challenging but adherence to the detection criteria means that 
EMVI can be identified confidently, even in these situations. The use of elastin-based 
stains certainly have a role and there is current work being done to investigate the 
optimal staining technique when using these stains. 
The increasing use of neoadjuvant therapy has meant that many of the traditional 
concepts regarding risk-stratification have been made less clear. The prognostic 
importance of known adverse tumour features is being re-examined in the context of 
pre-operative treatment. This gives us an opportunity to investigate and validate 
radiological factors along with pathology. EMVI has been shown to be an independent 
marker of poor prognosis and accurately identifiable on MRI. We have shown that 
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EMVI can also be seen on MRI following CRT. Further, the response to CRT can be 
quantified and scored against a novel regression grade and related to clinical 
outcomes. This MRI-based tool provides clinicians with a method of risk-stratification 
which can be universally applied.   
136 
 
Figure 21 – Special stains: elastin Van Gieson (A), and antibodies against smooth 
muscle actin (B), CD34 (C) and CD31 (D). The position of tumour within the vessel is 
highlighted by an arrow. 
A 
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Chapter 6  
Patterns of disease recurrence in ypEMVI-positive rectal cancer  
 
Aim  
The aim of this study was to determine whether there was an association between 
mrEMVI and known adverse tumour characteristics such as pT stage, pN stage and 
pCRM status following pre-operative treatment with long-course CRT and curative 
surgery. Furthermore, by comparing the patterns of recurrence between these tumour 
sub-types, this may provide suggestions for surveillance in these high-risk patients. 
 
6.1. Introduction  
Risk-stratification of patients diagnosed with rectal cancer is undertaken using staging 
systems which rely primarily on three tumour characteristics – tumour penetration or 
spread through the bowel wall (T-stage); presence of nodal disease (N-stage); and the 
presence of metastatic disease (M-stage). This TNM staging system was primarily 
based on the histopathological findings of the resection specimen following surgery 
(Chapter 1.4). However in recent years, patients can be staged using similar criteria 
through imaging in the form of CT and MRI. The presence or absence of these features 
influences both neoadjuvant (if staged by imaging) and adjuvant treatment strategies 
(if staged by histopathology); and further estimates the risk of disease recurrence - 
histopathological staging following surgery is the primary determinant of adjuvant 
treatment decisions despite their being a lack of firm evidence regarding their 
prognostic value following CRT. MRI staging is more commonly used in neoadjuvant 
treatment decision making. 
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EMVI does not form part of the current staging systems but is recognised as a poor 
prognostic feature as described in earlier chapters. By definition, it is only found in 
locally advanced tumours as it is the presence of tumour cells in the veins beyond the 
bowel wall thus requiring tumour penetration to at least T3 stage. Therefore the 
majority of these tumours are often offered neoadjuvant treatment on the basis of 
increased tumour penetration regardless of the presence of other adverse features.  
It is common for locally advanced tumours to exhibit more than one adverse feature 
but there may be a proportion of patients who will present with mrEMVI on initial 
staging without additional adverse features – these patients may, in fact, benefit from 
pre-operative treatment which is currently not the routine standard. Further and more 
importantly, there may be a similar proportion of patients who are also not being 
offered adjuvant treatment on the basis of pEMVI alone. This may be a relevant issue 
as distant progression of disease is commonly thought to be mitigated by systemic 
treatment with chemotherapy rather than local radiotherapy given pre-operatively. 
EMVI has been shown to be associated with distant disease recurrence in Chapter 4. 
Tumour cells spreading through the surrounding venous channels may be part of the 
process and a precursor which leads to distant metastases. Presence of tumour cells 
in these veins as indicated by evidence of EMVI may place these patients at a higher 
risk of recurrence and thus be an indication for more intensive surveillance strategies 
or oncological treatment.   
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6.2. Methods 
6.2.1. Patient selection 
The patient selection and data collection is described in Chapter 3. This included 
staging characteristics, pathology staging and follow-up. Patients were grouped into 
‘positive’ or ‘negative’ based on the initial mrEMVI status. Post-CRT histopathology 
data were compared between the groups. 
6.2.2. Staging  
The staging process is described in Chapter 3.  
6.2.3. Primary outcome measure 
The rate of recurrence was the primary endpoint and was compared between the two 
groups. In addition, the sites and timing of recurrence and association with ypT-stage, 
ypN-stage and ypCRM status were secondary measures. 
6.2.4. Statistical analysis 
Survival analysis was compared between the two groups. Differences between groups 
were assessed using the Chi-squared test or Fisher’s Exact test as appropriate. 
Survival estimates for DFS were obtained using the Kaplan-Meier product limit 
method. Patients were censored at the last point of known contact or if they died during 
follow-up without experiencing the outcomes of interest. 
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6.3. Results 
 
A total of 442 patients were included in the study. 370 patients were mrEMVI positive 
compared with 72 who were designated mrEMVI negative based on the initial 
baseline MRI scans.  
6.3.1. Tumour characteristics on pathology 
 
There was a statistically significant difference in the stage of presentation between 
mrEMVI positive and negative tumours. The majority of tumours which were initially 
mrEMVI positive were found to be ypT3 on pathology. This compared with the 
mrEMVI negative group where the tumours were more commonly ypT2. However 
there was no significant difference in those tumours which presented very late as 
ypT4 cancers. Less than 25% of patients in the mrEMVI positive group were given a 
final staging of ypT2 or less.  
The final pathology nodal stage of both groups was not significantly different. The 
majority of patients in both groups were node-negative (stage II). This may be a 
reflection of success with regards the neo-adjuvant treatment. There was no 
difference in margin positivity between the groups or in evidence of lymphatic or 
perineural invasion. There were more mucinous tumours in the mrEMVI positive 
group and more tumour which showed evidence of lymphocytic infiltrate – p<0.05. 
6.3.1. Timing and patterns of recurrence 
 
The rate of recurrence was not significantly different between the two groups (25% 
versus 30%). However the timing of the recurrences were different. The vast majority 
(70%) occurred within the first two years in the mrEMVI positive group compared 
with less than 50% in the mrEMVI negative group. For mrEMVI negative tumours, 
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the majority of recurrences occurred beyond three years. In the mrEMVI positive 
group, recurrences were evenly spread between one, two and three years. This is 
shown in table 12. 
 
 Recurrence  Year 1 Year 2 Year 3+ 
 
mrEMVI 
negative 
 
18  3 (16.7%) 5 (27.8%) 10 (55.5%) 
mrEMVI 
positive 
 
110  35 (31.2%) 42 (38.2%) 33 (30.6%) 
 
Table 12 – Timing of recurrence in mrEMVI positive and negative tumours 
 
6.3.2. Site of recurrence 
 
More than half of recurrences in the mrEMVI negative group were locoregional 
compared to less than1:6 in the EMVI positive group in which most were distant to 
the lung and liver with the latter accounting for more than 40% of disease relapse. 
This is shown in table 13. 
Site of 
recurrence 
 
mrEMVI negative mrEMVI positive 
Liver 
 
3 (16.7%) 46 (41.8%) 
Lung 
 
5 (27.8%) 32 (29.1%) 
Local 
 
10 (55.5%) 18 (16.3%) 
Other 
 
0 14 (12.8%) 
 
Table 13 – Patterns of recurrence in mrEMVI positive and negative tumours 
143 
 
Pathological characteristic EMVI-positive (n=370) EMVI-negative  (n=72) p-value 
ypT-stage 0 33 (8.9%) 8 (11.1%)  
1 11 (3.0%) 7 (9.7%)  
2 53 (14.3%) 30 (41.7%)  
3 234 (63.2%) 22 (31.4%)  
4 22 (5.9%) 5 (6.9%) p<0.001 
ypN-stage 0 226 (61.1%) 52 (74.2%)  
1 100 (2.7%) 13 (18.1%)  
2 44 (11.9%) 7 (9.7%) p<0.19 
ypEMVI Negative 280 62  
Positive 90 10 0.07 
ypCRM Negative 348 66  
 Positive 22 6 0.62 
Mucinous No 330 39  
 Yes 40 33 <0.001 
Lymphatic invasion No  330 62  
Yes 40 10 0.58 
Perineural invasion No 345 66  
Yes 25 6 0.82 
Lymphocytic infiltrate No  266 42  
Yes 104 31 0.02 
 
 
Table 14 - Differences in the histopathological characteristics of mrEMVI positive and negative tumours
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6.4. Discussion 
The main finding of this study is that locally advanced rectal cancers that are staged 
as mrEMVI positive and subsequently undergo neoadjuvant CRT show earlier 
recurrence compared to mrEMVI negative tumours. Further, there is a preponderance 
to liver metastases when compared with mrEMVI negative tumours. They are also 
associated with a higher ypT-stage on final pathology. The difference in relapse 
patterns is most marked in the first year following surgery with the majority of 
recurrences for mrEMVI positive tumours occurring within 24 months. Consequently, 
3-year DFS is significantly different between the two tumour sub-types indicating that 
mrEMVI positivity places patients in a high-risk category for disease recurrence.  
The complex process which leads to disease recurrence is not yet understood. It is 
unlikely that one tumour characteristic will singularly influence metastatic spread but 
that the presence of specific prognostic factors will give an estimation of risk. A 
combination of factors and thus high-risk features may speed up the process by acting 
synergistically or it may be that one feature predominates over others. Regardless of 
this, it is not surprising to find locally advanced tumours exhibiting a number of high-
risk features. That is, a tumour which has penetrated into the mesorectum is more 
likely to have EMVI as demonstrated in the results of this study. Interestingly, there 
were a number of patients who were found to be ypT2 or less in the mrEMVI positive 
group. By definition, EMVI should only be present in tumours which have breached 
the bowel wall (T3 and above). This shows that tumour regression may have taken 
place that has resulted in an initially T3 tumour being down-staged to T2 or less or that 
EMVI can exist in an irradiated T2 tumour. Either way, this is a new finding which 
needs further investigation in terms of prognostic relevance.  
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Whilst the post-operative treatment of high-risk tumours remains broadly similar for 
most patients, the results of this study can determine different approaches to 
chemotherapy in terms of timing (pre-operative versus post-operative) and duration of 
treatment. Furthermore, understanding the patterns of recurrence can influence 
surveillance timing and strategy. For example, if one particular feature has a specific 
target organ for metastases then it is possible to tailor surveillance accordingly to 
detect any disease at an early stage. 
In this study, mrEMVI positive tumours have been shown to have a preponderance for 
liver metastases. These findings have been shown in earlier reports on EMVI which 
are summarised in Chapter 4. Veins are a known route of cancer spread. These 
provide a conduit to other organ systems and due to the anatomical venous drainage 
of the most of the rectum, the liver is often seen as a site of metastasis. Whilst the 
evidence for amending treatment strategies for EMVI is still being evaluated, there is 
an opportunity to tailor follow-up. The majority of recurrences occurred in the first two 
years which may mean that there are micro-metastases present at the time of initial 
treatment that just simply are not apparent on current imaging modalities. These 
patients have a significant risk of liver disease and it may be sensible to offer them 
increased surveillance with more frequent imaging of the liver. Early detection of liver 
metastases and subsequent prompt treatment is associated with good survival. A 
more standardised and consistent approach to follow-up is necessary to improve the 
outcome for metastases.  
The most useful application of these findings is to predict prognosis before treatment 
and to determine treatment following CRT. There will be a proportion of patients who 
will have only EMVI as an adverse feature (early T3, node-negative tumours with a 
clear CRM). These tumours are still at risk of disease progression and should be 
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considered for adjuvant treatment. There appears to be variability in practise amongst 
clinicians with regard to adjuvant treatment and EMVI, particularly in node-negative or 
stage II disease (Bujko et al., 2010a). This point is addressed in subsequent chapters. 
It may be that patients with EMVI are only being treated with chemotherapy post-
operatively because they display other high-risk features such as nodal disease or 
increased tumour depth. Whilst it is encouraging that these patients are being offered 
more intensive treatment, there still remains a proportion of patients who may be 
missing out on additional treatment.   
The current 7th edition of the TNM staging system which is universally used in rectal 
cancer does not have a separate sub-stage for vascular invasion or EMVI (Table 4). 
The standard reporting proforma for pathologists in the UK and USA both have 
sections for EMVI although the USA guidelines combine vascular invasion with 
lymphatic invasion. Future versions of the TNM staging system may involve more 
tumour features such as EMVI but at present it is up to local units or national guidelines 
to remind clinicians of the increased risk of disease recurrence associated with EMVI. 
A further interesting point from the results is that it appears that EMVI and lymph node 
status are independent. There is a current thinking amongst some pathologists that 
EMVI is a surrogate marker for lymph node status. These results do not agree with 
that premise. There is also the finding that mucinous tumours are more prevalent in 
the EMVI positive group. There is no clear explanation for this except for the fact that 
most EMVI positive tumours are more advanced. Mucinous tumours are aggressive 
and present with more advanced disease. However whether it is the more aggressive 
mucinous sub-type which leads to EMVI or vice versa is not known.  
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One major limitation of this study is the small number of patients in the mrEMVI 
negative group. With only 18 patients, there is the potential for a type II statistical error. 
Ideally, greater numbers of mrEMVI negative patients are needed to accurately 
describe the sites and timing of recurrences. The study is also retrospective which 
introduces further bias although the robust maintenance in updating the database 
does mitigate this bias somewhat. Follow up data is dependent on contact between 
the hospital and patient which means that patients may be lost to follow up in some 
cases. 
In summary, mrEMVI positive tumours exhibit other high-risk features such as 
increased tumour penetration, nodal disease and CRM positive status following CRT 
and surgery. But there remains a proportion of patients who may have isolated 
mrEMVI with no other adverse features. These patients may benefit from intensive 
treatment as they are at risk of disease recurrence predominantly in the liver. Tailored 
surveillance regimes may be appropriate for the early detection of metastases. 
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Chapter 7  
The importance of EMVI in the multidisciplinary management of rectal 
cancer – a survey amongst surgeons and oncologists 
 
Aim 
The aim of this study was to explore the variability between clinicians in treating 
patients with EMVI-positive, stage II rectal cancer.  In addition, it attempted to 
determine to what extent the use of MRI and the per-operative identification of EMVI 
influences treatment decision-making.  
7.1. Introduction 
Treatment decisions for rectal cancer in the UK are made in the multidisciplinary team 
(MDT) meeting where clinicians from complementary specialities are able to discuss 
the optimal management strategies for individual patients. This affords clinicians the 
opportunity to put forward their case on treatment strategy and a decision is made 
through consensus. On the whole, decisions are made using the best available 
evidence from each discipline. Contentious issues which can lead to disagreement 
include the importance of specific tumour characteristics when deciding on more 
intensive treatment and secondly, which patients are most likely to benefit from 
additional treatment.  
Adjuvant chemotherapy improves survival in patients with stage III rectal cancer 
(Fisher et al., 1988, Wolmark, 1988).  Nodal disease, which distinguishes stage II from 
stage III disease, is known to be associated with worse survival and disease 
recurrence and is an independent marker of poor prognosis (Dukes and Bussey, 1958, 
Grinnell, 1942, Grinnell, 1950, Gilbertsen, 1960, Moossa et al., 1975). The evidence 
for the use of adjuvant chemotherapy in patients with stage II disease (node-negative) 
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is not so robust and current guidelines leave a lot of room for interpretation (Bujko et 
al., 2010a). In practice, the decisions patients make are often influenced by their 
clinicians’ interpretations of the guidelines. There is currently no robust randomized 
trial evidence with regard to novel prognostic factors such as EMVI and the outcome 
of stage II rectal cancer, it is therefore not surprising that there is such variability in 
practise.  
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7.2. Methods 
An electronic questionnaire was sent to a group of colorectal surgeons and 
oncologists. The cohort of surgeons comprised a limited membership of the 
Association of Coloproctology of Great Britain and Ireland (ACPGBI) who had 
previously given their consent to participate in such surveys. Their primary practise 
consisted of university and district general hospitals.  
265 consultant surgeons were sent the questionnaire along with a covering letter 
explaining the aims of the survey and how these results may help in designing future 
studies. The same survey and letter were also electronically sent to a group of 
oncologists through the Pelican Cancer Research Foundation database - this is a 
national database of oncologists with a diverse practise of university and district 
general hospitals. A total of 99 oncologists were sent the survey. Two reminder emails 
were sent at 4 weeks and 12 weeks. 
The survey featured nine questions including four specifically on clinical scenarios and 
treatment efficacy. Participants were asked to comment on the importance and 
detection of EMVI in their respective MDTs, their personal approach to patients with 
EMVI and clinical scenarios.  
Responses were recorded for surgeons and oncologists as absolute numbers and 
percentages. These were compared using Fisher’s exact test and Chi-squared where 
appropriate.  
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7.3. Results 
A total of 263 surgeons were sent the electronic questionnaire of which 142 (54%) 
responded.  This compared with 68 (69%) out of 99 oncologists who were also sent 
the survey. Less than 2% in each group did not answer all the questions on the survey. 
7.3.1. EMVI as a treatment consideration 
 
1.  Is extramural venous invasion routinely commented upon in 
your MDT? 
2.  Do you consider EMVI an important consideration when 
deciding whether your patients should have adjuvant 
chemotherapy? 
3.  Should adverse features on staging MRI be considered 
when deciding on giving adjuvant chemotherapy? 
4.  Would you be prepared to treat patients on MR detection of 
EMVI? 
 
Table 15 – Survey questions for EMVI 
 
EMVI was commented on in the MDTs of all respondents either by pathology or 
radiology. 68.5% of surgeons would always consider EMVI when deciding treatment 
options whereas 30.1% would only do so in selected patients. There was a significant 
difference in the responses between surgeons and oncologists with surgeons being 
more likely to react to the presence of EMVI than oncologists - 52.9% were in favour 
of treating EMVI (p<0.05). 
84.6% of surgeons and 76.5% of oncologists believed that MRI is an important 
consideration when deciding on treatment. When asked if mrEMVI could be used 
alone in treatment decision making, 35.6% of surgeons said they would and 54.8% 
would consider it in selected cases and 9.6% would not rely on mrEMVI alone. This 
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compared with the oncologists where only 13.7% prepared to treat patients on the 
basis of mrEMVI with a further 56.9% in selected circumstances. 29.4% would not 
treat patients on the basis of mrEMVI alone (p>0.05). 
7.3.2. Clinical scenarios questions 
 
5.  A patient is given long-course chemoradiotherapy for 
malignant nodes seen on staging MRI. The final 
pathology shows R0 resection with a clear CRM/ node 
negative/ EMVI positive. Would you give adjuvant 
chemotherapy? 
6.  Using the last example, what do you think the survival 
benefit is: 
7.  A patient is given neo-adjuvant chemoradiotherapy for 
a T3c rectal cancer. There are no suspicious nodes or 
EMVI on staging MRI. The final pathology is T3N0M0, 
EMVI negative, CRM clear by 5mm. Would you give 
adjuvant chemotherapy? 
8.  Using the last example, what do you think the survival 
benefit is? 
 
Table 16 – Survey questions 
 
The majority of surgeons and oncologists were prepared to treat the patient in 
Question 5 with adjuvant chemotherapy (71.2% of surgeons versus 68.6% of 
oncologists).   
In Question 7, more than 88% of surgeons would not offer adjuvant chemotherapy to 
the patient described. 50% thought there was some benefit albeit less than 5% 
compared to 47.1% who thought there was no benefit whatsoever. There was a 
difference in the responses to the use of adjuvant chemotherapy compared to the 
oncologists who were more likely to offer adjuvant treatment in this case compared to 
the surgeons (p<0.05). For a patient with Stage II disease and no adverse features, 
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21.6% would still offer adjuvant therapy but the majority thought there was either less 
than 5% (54%) or no benefit at all (42%). 
 
9.  In the absence of an evidence base for a significant survival benefit in 
EMVI positive, node negative tumours would you be prepared to 
randomise such patients to adjuvant chemotherapy versus 
observation? 
 
Table 17 – Survey question 
 
77.5% of surgeons would support their patients being involved in such a trial and a 
further 5.6% would support this in patients over 70 years old. However, a significant 
percentage 16.9% would not be prepared to take part in such a trial. Interestingly, 68% 
of the oncologists would consider a randomized trial for Stage II patients with EMVI 
and only 14% would not. 18% would be prepared to involve patients over 70 years of 
age in the trial. 
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Figure 22a-h – Pie charts showing responses between surgeons and oncologists 
Q1 - Is extramural venous invasion routinely commented upon in your MDT? 
 Surgeons       Oncologists 
  
 
 
 
 
Yes - Pathology
Yes - Pathology and
Radiology
Yes - Pathology only
 Yes - Radiology only
 Yes - Pathology and
Radiology
 Did not answer
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Q2 - Do you consider EMVI an important consideration when deciding whether your patients should have adjuvant chemotherapy? 
 
 
 
 
 
Yes always
In selected patients
Never
Yes - Always
 In selected patients
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Q3 - Should adverse features on staging MRI be considered when deciding on giving adjuvant chemotherapy? 
 
 
 
 
 
 
Yes No
Yes
 No
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Q4 - Would you be prepared to treat patients on MR detection of EMVI? 
 
 
 
 
Yes
Maybe
No
Yes
Maybe
No
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Q5 - A patient is given long-course chemoradiotherapy for malignant nodes seen on staging MRI. The final pathology shows R0 resection with a clear CRM/ 
node negative/ EMVI positive. Would you give adjuvant chemotherapy? 
 
 
 
Yes
No
Yes
No
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Q6 - Using the last example, do you think the survival benefit is: 
   
 
 
Below 5%
More than 5%
 No survival benefit
Below 5%
More than 5%
No benefit
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Q7 - A patient is given neo-adjuvant chemoradiotherapy for a T3c rectal cancer. There are no suspicious nodes or EMVI on staging MRI. The final pathology 
is T3N0M0, EMVI negative, CRM clear by 5mm. Would you give adjuvant chemotherapy? 
  
 
 
Yes No
Yes No
161 
 
Q8 - Using the last example, what do you think the survival benefit is? 
  
 
 
 
Less than 5%
More than 5%
No survival benefit
Less than 5%
More than 5%
No benefit
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Q9 - In the absence of an evidence base for a significant survival benefit in EMVI positive, node negative tumours, would you be prepared to randomise such 
patients to adjuvant chemotherapy versus observation? 
  
Yes to all patients
Only over 70s
No
Yes to all patients
 Only in over-70
No
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7.4. Discussion 
The results of the survey show that EMVI is recognised by both surgeons and 
oncologists as a prognostic factor and discussed in almost all MDTs. Further, whether 
it was detected on pathology and/or radiology, it is a consideration in treatment 
decisions. However, oncologists seemed to be more selective in their approach to 
EMVI. Although this survey did not explore the relative importance of EMVI compared 
with other prognostic factors, it is notable that it is considered in overall management 
strategy. A further point highlighted is that most clinicians are now prepared to treat 
patients on the basis of MRI findings pre-operatively. This signals a significant shift in 
attitude towards risk-stratification in the last decade where MRI can now be confidently 
used to be more selective in which patients should be offered pre-operative treatment.  
The standard of care for locally advanced high-risk rectal cancer without metastatic 
disease is neoadjuvant CRT (Sauer et al., 2004), this is described in detail in Chapter 
1. Although there has been some recent debate surrounding the benefit of adjuvant 
chemotherapy in patients who have already undergone neo-adjuvant chemoradiation 
(Bujko et al., 2010b), it still forms the mainstay of treatment for systemic disease and 
the risk of metastases.  
The QUASAR trial is the most frequently quoted with regard to adjuvant chemotherapy 
decisions for stage II tumours and the perceived survival benefit for patients is 
approximately 3.6% (Gray et al., 2007). Histopathological staging remains the basis 
for decision-making and it is important that stage II tumours which may potentially 
benefit from adjuvant therapy are identified through high-quality pathology reporting. 
The emphasis is very much on the pathologist diligently examining the specimen with 
appropriate sections to reveal as much information as possible. Quirke and colleagues 
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have extensively reported on the importance of this (Quirke and Morris, 2007, 
Maughan et al., 2007, Morris et al., 2007).  
EMVI is arguably the most debated of these additional risk factors in deciding on 
oncological treatment. Yet there is little doubt that venous invasion has a prognostic 
influence but lack of consistent reporting in both pathology and radiology has made it 
difficult for clinicians to understand its exact clinical relevance. This lack of confidence 
in accurate detection of EMVI may be one of the reasons why it is not considered as 
a mandatory treatment factor.  
In the present study, surgeons were more likely to rely on MRI than oncologists for 
decision-making (84.5% versus 76.5%) and specific to EMVI, oncologists were less 
likely to base treatment on mrEMVI. Despite this, the responses to the clinical 
scenarios of offering adjuvant chemotherapy to a patient with stage II rectal cancer 
with evidence of EMVI but no other adverse features and one with no adverse features 
whatsoever were similar (71.2% versus 68.6%). However whilst the surgeons were 
equally divided between the perceived survival benefit as to whether it was more or 
less than 5%, 54.9% of the oncologists thought there was < 5% benefit compared to 
33.3% that thought it may be > 5%. The interesting point is that QUASAR states the 
benefit for patients in receiving adjuvant chemotherapy is 3.6%, but more than a third 
of surgeons and oncologists believe the benefit to be more than 5%. In the second 
scenario where there were no adverse features in Stage II disease, the surgeons were 
less likely to offer adjuvant chemotherapy (11.3%) which is consistent with the current 
literature compared with 21.6% of the oncologists who would offer adjuvant treatment 
with no obvious evidence base.   
 
165 
 
The limitations of this survey are that it did not include detailed explanations from the 
respondents in the rationale behind decision-making. As the results include a degree 
of subjectivity and not entirely based on trial evidence, it would have been interesting 
to understand the rationale behind some of the decision-making. It should also be 
noted that this questionnaire was sent to predominantly UK-based clinicians. The 
importance and understanding of EMVI as a prognostic factor is more apparent in the 
UK than other countries such as the US. Further, the central role of MRI and using it 
to guide treatment through risk-stratification is again more common in the UK where a 
more selective approach is taken in the use of pre-operative therapy. Furthermore, 
there is the possibility of selection bias in the present study. The database of surgeons 
and oncologists who were available to the survey and those who respond are more 
likely to do so if they are progressive in their treatment. Survey studies of all types 
suffer from an element of selection bias as the respondents represent a self-selected 
group. Lastly, the questionnaire itself was not validated in any formal manner and thus 
simply represents the important issues as thought by the authors of the study.    
This survey reinforces the evolution in thinking with regards to adjuvant therapy in 
stage II disease. Factors such as EMVI should be given due consideration and the 
information we offer patients must be more accurate. We cannot continue to rely on 
historical studies which may, by no fault of design, have missed the importance of 
surgical technique and the emergence of novel prognostic factors which do not rely 
solely on pathology for identification. There appears to be an acknowledgement for a 
randomised controlled trial with regards to EMVI although it will be important to get the 
inclusion criteria and trial design correct. The effect of adjuvant chemotherapy in 
patients that have undergone neoadjuvant CRT and have also been down-staged 
must also be accounted for in any future trial design.     
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Chapter 8 
The survival of patients with stage II rectal cancer and evidence of 
pEMVI following neoadjuvant chemoradiotherapy 
 
Aim 
The aim of this study was to investigate the survival of patients with stage II rectal 
cancer and to determine whether pEMVI status had an effect on disease recurrence. 
8.1. Introduction 
The complex process of treatment decision making and some of the difficult issues 
surrounding rectal cancer were described in the previous chapter. Staging, either pre-
operatively or post-operatively (MRI versus pathology) provides a risk-stratification 
based on known prognostic factors, which influences the extent of any oncological 
treatment in addition to curative surgery. Patients with stage II disease comprise a 
heterogenous group with variable survival depending on the presence or absence of 
specific tumour features (Newland et al., 1994). Examples of these adverse features 
include penetration of more than 5mm into the mesorectum, peritoneal perforation, 
and the presence of EMVI. The influence of these prognostic factors following pre-
operative therapy also remains unclear in the context of disease recurrence and the 
role of subsequent adjuvant chemotherapy (Bujko et al., 2010b). 
Unlike patients with stage III, or lymph node positive disease, the survival benefits 
following the use of adjuvant chemotherapy remain unclear in patients with stage II 
rectal cancer. There is no specific randomized trial evidence for the benefit of adjuvant 
chemotherapy per stage in rectal cancer, particularly when additional adverse features 
are also present. Much of the guidance for the use of adjuvant chemotherapy in rectal 
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cancer is extrapolated from trials of colon cancer due to limited data. Furthermore, 
with the increasing use of neoadjuvant RT or CRT the benefits of adjuvant 
chemotherapy for all stages of rectal cancer is uncertain (Bujko et al., 2010b). 
Although there are no specific guidelines regarding the presence of EMVI, many 
clinicians consider EMVI when deciding on oncological treatment as seen in previous 
chapters. The heterogeneity in the existing trial data precludes any meaningful meta-
analysis which would help resolve this issue and furthermore, prognostic factors such 
as EMVI have not been consistently documented in many of the historical trials.  
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8.2. Methods 
 
8.2.1. Patients 
 
Patients were identified from the prospectively maintained Royal Marsden Hospital 
Rectal Cancer database. Data were extracted on consecutive patients undergoing 
potentially curative resectional surgery for rectal cancer. Patients with synchronous 
tumours, undergoing local excision and those treated with palliative surgery were 
excluded. There was central review of all pathology and radiology by specialised GI 
pathologists and radiologists. 
8.2.2. Staging  
 
The staging process is described in Chapter 3.  
8.2.3. Outcome measures 
 
The primary outcome was 3-year disease-free survival from the date of surgery. The 
main secondary outcome was the rate of CRM positivity.  
8.2.4. Definitions 
 
Stages II disease was classified as T1-4, N0, M0 and stage III as T1-4, N1-2, M0. A 
positive resection margin was defined as tumour within 1mm of the circumferential 
resection margin. Adjuvant chemotherapy was offered to patients if they had 
pathologically positive nodal disease (i.e. stage III). DFS was the time from the date 
of surgery to the date of pelvic recurrence and/or distant disease or death due to pelvic 
recurrence and/or distant disease.  
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8.2.6. Statistical analysis  
 
In order to assess the interaction of EMVI and nodal status, the following variables 
were defined which combined their positive and negative status respectively, resulting 
in four categories including EMVI-/N-, EMVI+/N-, EMVI-/N+, EMVI+/N+. The statistical 
analysis is described in Section 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
170 
 
8.3. Results 
8.3.1. Demographics and treatment  
A total of 478 patients were included in the study of which 168 were female (35.1%) 
and 310 were male (64.9%). The median age was 63.9 years (interquartile range 54.4-
73.0 years). 331 (69.2%) patients had undergone neoadjuvant chemoradiotherapy 
with 373 (78.0%) having had sphincter-sparing surgery.  
8.3.2. Histopathology staging characteristics 
Only 41 (8.6%) patients had T0-2 disease compared with 437 patients (91.4%) who 
had either T3 or T4 tumours. 331 (69.2%) tumours were well or moderately 
differentiated and 147 (30.8%) were either poorly differentiated or had evidence of 
mucinous change or signet cells. CRM was negative in 437 (91.4%) tumours. 
Grouping the patients by stage, 233 (48.7%) patients had stage II disease and 245 
(51.3%) had stage III.  
8.3.3. Comparison of nodal and EMVI status 
The prevalence of EMVI in the entire cohort was 34.9%; 57/233 stage II patients 
(24.5%) and 110/245 stage III patients (44.9%). Positive EMVI status was associated 
with neoadjuvant chemoradiotherapy, T-stage 3/4, positive CRM and nodal disease. 
When splitting EMVI status by presence of nodal disease (stage II or stage III), the 
significant differences included gender, the use of neoadjuvant chemoradiotherapy, T-
stage and positive CRM. These can be seen in tables 18 and 19.  
8.3.4. Survival analysis 
At a median follow-up of 25 months (95% CI 1.5-36) there were 114 recurrences of 
which 30 (26.3%) were local recurrences. The 3 year DFS for stage II tumours was 
76% and stage III tumours 62%. On univariate analysis CRM involvement was a 
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significant factor for reduced 3 year DFS (HR 1.92 95% CI 1.11-3.31) and was also 
found to be of borderline significance on multivariate analysis (HR 1.75 95% CI 1.00-
3.06) – p-value 0.051. For the purposes of analysis, stage II tumours with no evidence 
of EMVI (EMVI-/N-) were used as reference to test the significance of EMVI and nodal 
status on disease recurrence. EMVI status was found to be significant on both 
univariate and multivariate analysis for node-negative and node-positive tumours. In 
the node-negative (stage II) tumours the HR was 1.95 (95% CI 1.04-3.65) on 
univariate and HR 2.08 (95% CI 1.10-3.95) on multivariate analysis. For node-positive 
(stage III) tumours HR was 2.65 (95% CI 1.63-4.30) on univariate and HR 2.74 (95% 
CI 1.66-4.52) on multivariate analysis. Nodal status was also found to be significant 
on both univariate and multivariate analysis – HR 1.71 (95% CI 1.03-2.85) and HR 
1.79 (95% CI 1.04-3.07), respectively. These results are seen in table 20. The 3-year 
DFS EMVI and nodal status were EMVI-/N- 79% (72-86%); EMVI+/N- 59% (44-75%); 
EMVI-/N+ 63% (53-74%); EMVI+/N+ 50% (39-64%) (Figure 23).  
172 
 
Table 18 - Cohort demographics by the absence and presence of extra-mural venous invasion 
 
  EMVI absent  EMVI present    
  n=311 % n-167 % Total P-value 
Age (years) 18-64 171 66.8 85 33.2 256  
 65-74 72 61.5 45 38.5 117  
 75+ 68 64.8 37 35.2 105 0.612 
Gender Female 117 69.6 51 30.4 168  
 Male 194 62.6 116 37.4 310 0.122 
Year of surgery 1999-2006 103 65.2 55 34.8 158  
 2007-2013 208 65.0 112 35.0 320 0.967 
Neoadjuvant therapy No 85 57.8 62 42.2 147  
 Yes 226 68.3 105 31.7 331 0.027 
Sphincter preserving 
surgery Yes 238 63.8 135 36.2 373  
 No 73 69.5 32 30.5 105 0.278 
Pathological T-stage T0-2 37 90.2 4 9.8 41  
 T3-4 274 62.7 163 37.3 437 <0.001 
Differentiation Well/moderate 217 65.6 114 34.4 331  
 Poor/signet/mucin 94 63.9 53 36.1 147 0.733 
CRM Negative 292 66.8 145 33.2 437  
 Positive 19 46.3 22 53.7 41 0.009 
Nodal status Negative 176 75.5 57 24.5 233  
 Positive 135 55.1 110 44.9 245 <0.001 
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Table 19 - Cohort demographics by the absence and presence of extra-mural venous invasion, split by lymph node status 
 
  EMVI-/N-  EMVI+/N-  EMVI-/N+  EMVI+/N+   
  n=176 % n=57 % n=135 % n=110 % P-value 
Age (years) 18-64 87 34.0 25 9.8 84 32.8 60 23.4  
 65-74 42 35.9 19 16.2 30 25.6 26 22.2  
 75+ 47 44.8 13 12.4 21 20.0 24 22.9 0.091 
Gender Female 70 41.7 21 12.5 47 28.0 30 17.9  
 Male 106 34.2 36 11.6 88 28.4 80 25.8 0.033 
Year of surgery 1999-2006 61 38.6 15 9.5 42 26.6 40 25.3  
 2007-2013 115 35.9 42 13.1 93 29.1 70 21.9 0.876 
Neoadjuvant 
therapy No 45 30.6 19 12.9 40 27.2 43 29.3  
 Yes 131 39.6 38 11.5 95 28.7 67 20.2 0.029 
Sphincter 
preserving surgery Yes 131 35.1 43 11.5 107 28.7 92 24.7  
 No 45 42.9 14 13.3 28 26.7 18 17.1 0.055 
Pathological T-
stage T0-2 0 0.0 0 0.0 37 90.2 4 9.8  
 T3-4 176 40.3 57 13.0 98 22.4 106 24.3 <0.001 
Differentiation Well/moderate 127 38.4 41 12.4 90 27.2 73 22.1  
 Poor/signet/mucin 49 33.3 16 10.9 45 30.6 37 25.2 0.221 
CRM Negative 166 38.0 50 11.4 126 28.8 95 21.7  
 Positive 10 24.4 7 17.1 9 22.0 15 36.6 0.062 
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Table 20 - Univariable and fully adjusted multivariable Cox’s proportional hazard models for 3 year disease free survival  
 
  Univariable    Multivariable    
  HR 
95% CI 
lower 
95% CI 
upper P value HR 
95% CI 
lower 
95% CI 
upper P value 
Age (years) 18-64 Ref    Ref    
 65-74 0.97 0.62 1.50 0.873 0.92 0.58 1.44 0.701 
 75+ 0.83 0.51 1.35 0.452 0.91 0.55 1.51 0.716 
Gender Female Ref    Ref    
 Male 1.45 0.96 2.19 0.076 1.37 0.90 2.08 0.145 
Year of surgery 1999-2006 Ref    Ref    
 2007-2013 1.22 0.83 1.77 0.312 1.25 0.85 1.85 0.258 
Neoadjuvant therapy No Ref    Ref    
 Yes 1.26 0.82 1.93 0.286 1.37 0.87 2.13 0.171 
Sphincter preserving 
surgery Yes Ref    Ref    
 No 1.28 0.84 1.95 0.255 1.29 0.83 1.99 0.259 
Pathological T-stage T0-2 Ref    Ref    
 T3-4 1.00 0.51 1.98 0.996 1.13 0.54 2.36 0.748 
Differentiation Well/moderate Ref    Ref    
 Poor/signet/mucin 1.09 0.74 1.60 0.677 1.09 0.73 1.63 0.661 
CRM Negative Ref    Ref    
 Positive 1.92 1.11 3.31 0.019 1.75 1.00 3.06 0.051 
EMVI/N EMVI-/N- Ref    Ref    
 EMVI+/N- 1.95 1.04 3.65 0.037 2.08 1.10 3.95 0.024 
 EMVI-/N+ 1.71 1.03 2.85 0.037 1.79 1.04 3.07 0.035 
 EMVI+/N+ 2.65 1.63 4.30 <0.001 2.74 1.66 4.52 <0.001 
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Figure 23 - Kaplan-Meier survival curve for 3-year disease free survival, stratified by 
EMVI and lymph node status 
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8.4. Discussion 
The main finding of the present study is that patients with histopathological evidence of 
extramural venous invasion (ypEMVI) following CRT had worse 3-year disease-free 
survival (DFS) whether they had stage II or stage III rectal cancer. The prevalence of 
ypEMVI was 34.9%; stage II (24.5%) and stage III (44.9%), indicating a significant 
number of patients are at risk of developing metastatic disease within 3 years. The HR 
for ypEMVI, either alone or in combination with nodal involvement, was 2.08 and 2.74, 
respectively. There was an increased rate and risk of disease recurrence in ypEMVI 
positive patients independent of tumour stage. Notably, the 3-year DFS for patients with 
stage II disease and evidence of ypEMVI was similar to those who had stage III disease. 
It is important to note that the use of neoadjuvant treatment did not affect disease free 
survival which is consistent with previous reports (Sauer et al., 2004, Bosset et al., 2004). 
This highlights that pre-operative chemotherapy given as a sensitizer is not an adequate 
substitute for full-dose systemic chemotherapy.   
As discussed in earlier chapters, the effect of neoadjuvant CRT leading to fibrosis and 
destruction of the vessel architecture can make accurate identification of EMVI even more 
difficult. Additional elastin stains have been recommended where there may be doubt 
however this practise was not undertaken in the present study. The prevalence of ypEMVI 
was 34.9% and specific to stage II tumours approximately 25% of cases. In our institution, 
EMVI is detected using guidelines offered by the Royal College of Pathologists which 
suggest EMVI prevalence to be a minimum of 25% (Williams, 2007a). In equivocal cases 
where there is suspicion of EMVI, a patient’s MRI scans can perhaps be referred to as a 
guide prior to reviewing the tumour blocks.  
The current policies for offering adjuvant chemotherapy following neoadjuvant CRT rely 
on histopathological identification of specific tumour characteristics known to be 
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associated with disease recurrence. Such policies are based on the large scale 
randomised trials showing a definite benefit for patients with Stage III colorectal cancer 
and a questionable benefit for Stage II disease (Gray et al., 2007, Bujko et al., 
2010b),(James et al., 2003).  
Further, the current guidance for rectal cancer is mostly derived from trials predominantly 
comprising colon cancers due to absence of high-quality data specific to rectal cancer 
trials. The observations from colon cancer trials are not necessarily translated to rectal 
cancer. The European Rectal Cancer Conference stated there is no evidence to support 
the use of adjuvant chemotherapy after preoperative chemoradiation (Valentini et al., 
2009). In the QUASAR trial evaluating Stage II patients undergoing primary surgery, 
venous invasion was recorded in only 13% of patients – this is well below the detection 
rates reported currently and those recommended by the Royal College of Pathologists 
(Gray et al., 2007, Williams, 2007a). The trial showed that since patients in the Stage II 
category had DFS in excess of 80% at 3 years and chemotherapy benefit was only 3.6%, 
therefore adjuvant therapy should be recommended for stage II cancers with caution. Our 
findings and more recently published work, suggests that the true prevalence of EMVI if 
carefully sought using either MRI or pathology may be in the order of 25-50% (Petersen 
et al., 2002, Smith et al., 2008a, Roxburgh et al., 2010) and significantly greater than 
rates reported in the QUASAR trial. Furthermore disease free survival for EMVI positive 
stage II disease of 59% with a HR of 2.08 (95% CI 1.10-2.95) is substantially worse than 
the quoted rates and is equivalent to Stage III risk. This would suggest that the patient 
population evaluated in the QUASAR trial is dissimilar and therefore the proposed 
survival benefit of only 3.6% is unlikely to apply to patients with high-risk features such 
as EMVI. Further, that stage III patients have a worse outcome in terms of disease 
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recurrence if there is evidence of EMVI (HR 2.74 95% CI 1.66-4.52) may mean that those 
patients could also undergo more intensive follow-up.  
The main limitation of this study is that adjuvant chemotherapy was excluded from the 
Cox regression analysis. It is our institution’s policy to routinely offer all stage III patients 
combination chemotherapy with Capecitabine and Oxaliplatin. Stage II patients enter a 
discussion with the oncologist as to the pros and cons of further treatment based on 
existing published evidence. Another limitation is that this is a retrospective study. This 
introduces difficulty with accurate follow up and bias however the maintenance of the 
database described in earlier sections does well in trying to mitigate this as much as 
possible. Further investigation of these findings in the context of a prospective 
observational study would help to validate these results. Furthermore, this unit is a tertiary 
referral centre where the most complex and advanced cases of rectal cancer are dealt 
with. Thus one would expect the case mix to include more advanced disease and not 
necessarily represent the wider population. This may introduce further difficulty when 
trying to apply these findings more generally.  
Currently, patients are informed that stage II disease confers a much lower risk of disease 
recurrence than stage III and further, that the benefit of adjuvant chemotherapy is less 
than 4%. This study has shown that ypEMVI status is an important independent 
prognostic factor for disease recurrence in both stage II and stage III disease affecting 
over a third of patients in these groups. The risk of disease recurrence in stage II disease 
is significantly increased if there is evidence of ypEMVI equivalent to node-positive (stage 
III) disease. Whilst the survival benefit of adjuvant chemotherapy is yet to be quantified 
in this context, when counselling patients following surgery for rectal cancer it is important 
to describe the greater than two-fold hazard ratio for developing distant or local failure 
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compared with negative ypEMVI status so they can make an informed decision with 
regards to the potential gains from systemic chemotherapy.  
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Chapter 9 
A comparison of the prognostic effect of ypEMVI and ymrEMVI in rectal 
cancer 
 
Aim 
This study aimed to compare the survival between ymrEMVI and ypEMVI to determine 
whether they can be complimentary in prognosis based treatment decisions.  
9.1. Introduction 
EMVI status following pre-operative treatment is denoted ymrEMVI for MRI and ypEMVI 
forhistopathology. Whilst it has been accepted that pathology is the ‘gold standard’ for 
the final staging of rectal cancer – this concept was borne out of the study of patients 
undergoing primary surgery. The prognostic importance of EMVI following pre-operative 
CRT on imaging (ymrEMVI) or histopathology (ypEMVI) is not fully known. Further, the 
optimal technique in detecting EMVI following CRT is also not known and whether MRI 
and pathology can complement each other.  
CRT results in specific morphological changes in the tumour complex which is most 
readily seen as fibrosis. This can be detected both on MRI and pathology. This change 
also leads, however, to architectural damage making it more difficult to identify staging 
characteristics, in particular EMVI. As there is no universal technique to guide 
pathologists when searching for EMVI in post-CRT specimens, detection may not always 
be optimal. The criteria for identifying EMVI on MRI is consistent whether it is sought 
before or after CRT.  
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9.2. Methods 
9.2.1. Patients 
The patient selection has been described in section 3. Briefly, patients were identified 
from the prospectively maintained Royal Marsden Hospital Rectal Cancer database. Data 
were extracted on consecutive patients undergoing potentially curative resectional 
surgery for rectal cancer with evidence of EMVI on baseline MRI. The term “EMVI” was 
sought from routine post-treatment radiology and pathology reports for rectal cancers.  
Inclusion criteria were all adult patients that had undergone long-course 
chemoradiotherapy (LCRT) for locally advanced rectal cancer with no evidence of 
metastatic disease. Patients must have had evidence of mrEMVI on baseline staging MRI 
scan to be included. All patients must have undergone total mesorectal excision (TME) 
surgery. Exclusion criteria were patients with synchronous tumours; incomplete neo-
adjuvant treatment; non-curative surgery and emergency presentation. There was central 
review of all pathology and radiology. 
9.2.2. Pre-operative Staging  
Patients underwent a minimum of two scans (before and after neo-adjuvant treatment) 
which were made available for review. If a patient had undergone more than one post-
treatment MRI then the most recent MRI to subsequent surgery was used for the 
purposes of assessment. The MRI scans were reviewed independently blinded to the 
pathology reports. 
9.2.3. MRI technique and image acquisition 
This has been described in section 3.  
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9.2.4. Histopathology technique 
The standard datasets for reporting colorectal cancers as issued by the Royal College of 
Pathologists (UK) were used for all examinations at our institution (Quirke and Morris, 
2007). This is described in detail in section 3. All slides had been initially assessed by the 
local hospital before undergoing further review by our institution, blinded to the results of 
the pre- or post-treatment MRI.  
9.2.5. Data collection 
Data were collected on patient demographics, pre-operative staging (tumour depth – 
mrT-stage, nodal disease – mrN-stage, proximity to the circumferential resection margin 
(mrCRM) and mrEMVI status) and survival. Final tumour stage was documented from the 
pathology reports which included ypT-stage, ypN-stage, ypCRM involvement and 
ypEMVI status. 
9.2.6. Outcome measure and statistical analysis 
The primary outcome measure was three-year disease-free survival. Secondary 
endpoints included recurrence rates, final yT-stage, yN-stage and yCRM status.  
Statistical analysis of differences between the groups was performed using Chi-squared 
or Fisher’s exact test where appropriate. Survival analysis was undertaken between 
ymrEMVI and ypEMVI including rate of recurrence, time to recurrence and three year 
disease-free survival, which was obtained using the Kaplan-Meier product-limit and 
compared using the Mantel-Cox log-rank test. A p value of <0.05 was considered 
significant. A positive event was histology-proven recurrence (local, distant or both) or 
death from any cause.  
Cox’s proportional hazard models were built to test the impact of confounding variables 
on survival. This allows the effect of predictive factors on outcome to be assessed, 
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accounting for censored outcome, differing time of follow-up, and the interval between 
surgery and the adverse event of interest. Hazard ratios (HR) and 95% confidence 
intervals (CI) were generated.  
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9.3. Results 
 
A database search revealed 188 patients who met the inclusion/exclusion criteria detailed 
above from a total of 580. Therefore the prevalence of EMVI at baseline MRI stage was 
32.4%. Of the total number of patients, 121 were male and 67 were female. The median 
age was 74 +/-13 years (range 30-87 years).  
9.3.1. Baseline staging 
137/188 (73%) patients were staged as ‘mrT-poor’ (>mrT3c); 123/188 (65%) had MR 
nodal disease; and 81/188 (43%) were defined as potentially positive mrCRM. Therefore, 
the majority of the patients included in the analysis had locally advanced tumours. There 
were 69 low-rectal (37%); 62 mid-rectal (33%) and 57 upper-rectal (30%). 
9.3.2. Post-treatment staging 
At the end of treatment 5.3% of cases were pathologically CRM positive compared with 
43% with threatened CRM on MRI prior to treatment. Patients were categorised into 
pathology and MRI detected EMVI negative or positive – ypEMVI and ymrEMVI. For each 
group, the final pT and pN staging was recorded from histopathological analysis of the 
surgical resection specimen. There were more advanced pT-stage and pN-stage cases 
when comparing pEMVI negative and positive patients – p<0.05. There was no statistical 
difference in CRM status between the patients with and without pEMVI but the overall 
prevalence of CRM involvement in the study was low. Comparison of the post-treatment 
staging characteristics showed similar results between mrEMVI negative and positive; 
there were more locally advanced pT-stage and pN-stage tumours – p<0.05.    
 
185 
 
9.3.3. Concordance between MRI and histopathology EMVI status 
There were 99 patients (52.7%) that had evidence of persistent ymrEMVI following 
neoadjuvant CRT and 89 patients (47.3%) had become mrEMVI negative following 
treatment.  Histopathology detected 36 cases (19.1%) of ypEMVI following CRT. 
Therefore, there may have been under-detection by histopathology or over-detection by 
MRI as there was a significant difference in detection rates of EMVI between the two 
techniques.  
9.3.4. Recurrence rates    
When comparing the recurrence rates of EMVI negative and positive patients whether by 
MRI or pathology, there was a statistically significant difference. Furthermore, the 
recurrence rates for ypEMVI and ymrEMVI negative patients of 23.9% and 25.8% 
respectively, were similar as was the case comparing ypEMVI and ymrEMVI positive 
groups 41.7% and 40.4%, respectively. Of the discrepant cases between MRI and 
histopathology, the sub-group in which patients were ymrEMVI positive but ypEMVI 
negative the recurrence rate was 39.4%. Patients who were mrEMVI negative on 
baseline staging had a recurrence rate of 22.2%. This is shown in table 22. 
9.3.5. Survival analysis 
 
The DFS for ymrEMVI positive patients was significantly worse than ymrEMVI negative 
patients - 42.7% (95% CI 16.8-68.6%) versus 79.2% (95% CI 70.0-88.4%); Mantel Cox 
log-rank test p<0.05. For those patients with ypEMVI there was also worsened DFS of 
36.9% (95% CI 15.7-48.1%) compared with 65.9% (95% CI 56.1-75.7%) for ypEMVI 
negative; Mantel Cox log-rank test p<0.05. A comparison of MRI detected or pathology 
detected EMVI showed no significant difference between the groups. This was also 
shown to be the case comparing ymrEMVI and ypEMVI negative patients. In the sub-
group of discrepant cases where patients were ymrEMVI positive but ypEMVI negative 
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DFS was 46.7% (95% CI 33.5-54.5%). A total of 27 patients were mrEMVI negative on 
baseline imaging and remained EMVI negative on MRI and histopathology after CRT. 
The DFS of this group of patients was 72.5% (95% CI 69.3%-77.1%), which was similar 
to those patients which became ymrEMVI negative from initially being mrEMVI positive 
(p>0.05). Survival curves are shown in figures 24 and 25.    
Factors found to be significant on univariate analysis were tested further in multivariate 
regression – Table 23. Using the Cox proportional hazard regression model, mrEMVI +ve 
and pEMVI +ve were independently significant for predicting disease recurrence with 
hazard ratios of 1.97 (95% CI 1.01-3.90) and 2.39 (95% CI 1.11-5.14), respectively.  
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Staging characteristic 
 
Post CRT Sub-groups 
ypEMVI 
negative 
n=142 
ypEMVI 
positive 
n=46 
ymrEMVI 
negative 
n=89 
ymrEMVI positive 
 
n=99 
 
 
ypT-stage  
PCR (T0N0) 12 0 11 3 
T1 7 1 6 1 
T2 31 2 20 13 
T3 83 36 48 72 
T4 7 9 4 10 
ypN-stage 0 101 15 70 48 
1 37 20 17 39 
2 4 11 2 12 
ypCRM 
status 
Negative 136 42 87 91 
Positive 6 4 2 8 
ypEMVI 
status 
Negative 142 0 79 63 
Positive 0 46 10 36 
 
Table 21 – Final staging characteristics following CRT and surgery  
  
Group Recurrences p-value 
Local 
n=20 
Distant 
n=104 
Total 
n=124 
ypEMVI - 3 31 34/142 (23.9%)  
<0.05 ypEMVI + 6 14 20/46 (43.5%) 
ymrEMVI - 3 21 23/89 (25.8%)  
<0.05 ymrEMVI + 5 35 40/99 (40.4%) 
mrEMVI - 3 3 6/27 (22.2%)  
 
Table 22 – Recurrence rates of EMVI negative and positive tumours following CRT
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Variables Group Patient 
numbers     
Univariate analysis Multivariate analysis 
HR 95% CI p-value HR 95% CI p-value 
Patient characteristics Sex Female                67 Ref                   
0.625-1.912 
         0.756 Ref 
0.93 
 
0.53-1.68 
 
0.832 Male 121 1.093 
Height Upper/mid 119 Ref        
0.815-2.298 
 
0.235 
Ref 
1.46 
 
0.80-2.68 
 
0.223 
Low 69 1.369 
Baseline MR staging mrT stage Good 51 Ref  
0.638-2.206 
 
0.588 
Ref 
1.12 
 
0.51-2.43 
 
0.782 
Poor 137 1.187 
mrN stage Negative 65 Ref 
1.196 
 
0.691-2.071 
 
0.523 
Ref 
1.72 
 
0.90-3.28 
 
0.199 
Positive 123 
mrEMVI Negative 0 Ref 
0.902 
 
0.527-1.544 
 
0.706 
Ref 
0.89 
 
0.42-1.89 
 
0.078 
Positive 188 
mrCRM Negative 107 Ref 
0.846 
 
0.497-1.441 
 
0.539 
Ref 
0.85 
 
0.44-1.62 
 
0.617 
Positive 81 
Post-CRT   preoperative 
MR staging 
ymrT stage Good 
Poor 
116 
72 
Ref 
1.218 
 
0.723-2.052 
 
0.459 
Ref 
1.01 
 
0.54-1.89 
 
0.984 
ymrN stage Negative 
Positive 
104 
84 
Ref 
1.179 
 
0.701-1.982 
 
0.534 
Ref 
0.431 
 
 
0.21-0.91 
 
0.206 
ymrEMVI Negative 
Positive 
89 
99 
Ref 
1.987 
 
1.237-4.323 
 
0.004 
Ref 
1.97 
 
1.01-3.90 
 
0.044 
ymrCRM Clear 
Involved/threatened 
148 
40 
Ref 
1.26 
 
0.674-2.354 
 
0.469 
Ref 
1.16 
 
0.50-2.67 
 
0.729 
Final pathology staging ypT  Good 
Poor 
54 
134 
Ref 
1.125 
 
0.695-1.279 
 
0.534 
Ref 
0.99 
 
0.11-8.62 
 
0.994 
ypN Negative 
Positive 
118 
70 
Ref 
2.912 
 
1.724-4.878 
 
<0.001 
Ref 
3.41 
 
0.91-12.82 
 
0.069 
ypEMVI Negative 
Positive 
142 
46 
Ref 
3.889 
 
2.088-6.281 
 
<0.001 
Ref 
2.39 
 
1.11-5.14 
 
0.026 
ypCRM Negative  
Positive 
178 
10 
Ref 
3.352 
 
1.421-7.907 
 
0.006 
Ref 
1.32 
 
1.24-2.38 
 
0.032 
Table 23 – Univariate and multivariate analysis (Cox proportional Hazards for disease free survival) by clinical, preoperative MRI and 
postoperative histopathology characteristics
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Figure 24 – Comparison of 3-year Disease-free Survival    Figure 25 – Comparison of survival outcome of 3-year DFS 
between ypEMVI -ve and ypEMVI +ve     between ymrEMVI -ve and ymrEMVI +ve patients 
  
                       
ymrEMVI negative DFS 79.2%  
(95% CI 70.0-88.4%) 
n=89 
ymrEMVI positive DFS 42.7%  
(95% CI 16.8-68.6%) 
n=99 
ypEMVI negative DFS 65.9%  
(95% CI 56.1-75.7%) 
n=142 
ypEMVI positive DFS 36.9%  
(95% CI 15.7-48.1%) 
n=46 
  Recurrences 
ypEMVI - 34/142 23.9% 
ypEMVI + 20/46 43.5% 
  Recurrences 
ymrEMVI - 23/89 25.8% 
ymrEMVI + 40/99 40.4% 
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9.4. Discussion 
This is the first study to examine the independent clinical relevance of post CRT yEMVI 
status. The main finding of the present study was that disease-free survival was 
significantly reduced for patients who had either MRI or histopathological evidence of 
EMVI following pre-operative CRT, and that this was independent of yT and yN stage. 
DFS for ymrEMVI-positive patients was significantly worse than for ymrEMVI-negative 
patients. Equally, patients with ypEMVI had a DFS of 36.9% compared with 65.9% for 
ypEMVI-negative. The difference in survival between patients whohave converted 
from EMVI positive to negative on MRI or histopathology, versus those who showed 
persistent EMVI implies that this is of predictive as well as of prognostic relevance.  
Pre-treatment EMVI status has been previously shown to be a prognostic factor (Smith 
et al., 2008a). In that study mrEMVI status was not shown to be an independent 
variable, only the initial T-stage was significant. The present study differs as we have 
only evaluated locally advanced tumours undergoing preoperative CRT. These were 
almost exclusively T3 and above hence EMVI status was independent of T stage in 
our series. The overall prevalence of EMVI in the present study at baseline was similar 
but following CRT, ymrEMVI was shown to be an independent variable for disease 
recurrence.  
The importance of possible post-CRT prognostic factors and their role in disease 
recurrence is still not well understood and there is still no randomized trial evidence 
confirming the benefit of adjuvant chemotherapy after preoperative therapy (Bujko et 
al., 2010b). We have shown that disease relapse rates for persistent mrEMVI at three 
years are 40.4% with a HR of 1.97 compared with mrEMVI negative patients in whom 
relapse rates are 25.8%. This information may be of relevance when counselling 
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patients of the ongoing risks and potential gains of adjuvant chemotherapy after CRT 
in the absence of randomised trials that have specifically addressed this question. The 
present study suggests that patients could be risk-stratified before and after CRT 
based on their mrEMVI status and advised accordingly.  
Examining the results of ymrEMVI and ypEMVI detection reveals a striking difference 
in detection. Of the initial 188 mrEMVI positive patients, 99 remained EMVI positive 
on MRI with only 36 (36.4%) being detected on histopathology. Significantly the 
prognosis for mrEMVI positive tumours that were pathologically ypEMVI negative was 
as poor and significantly worse than patients with no ymrEMVI or ypEMVI involvement. 
Furthermore both the survival and recurrence rates of patients with no evidence of 
mrEMVI on baseline staging prior to CRT were similar to those patients who had 
become EMVI negative following CRT.  This finding would suggest that MRI is a better 
modality for detection of EMVI in patients who have undergone CRT than “routine” 
histopathology. Perhaps if these discrepant cases were re-examined with specialised 
stains specifically looking for EMVI, histopathology detection rates may be increased 
and similar to that of MRI.  
CRT leads to fibrosis which can distort the normal micro-architecture which guides 
pathologists to identify venous invasion leading to a known false-negative rate during 
histopathology analysis (Liang et al., 2007, Ouchi et al., 1996). Whereas a post-CRT 
MRI clearly shows massive tumour extension into the extramural veins which can be 
followed anatomically along the line of the vessel, the cross sections taken for 
examination do not permit the pathologist to follow the vessels in the coronal or sagittal 
plane explaining difficulty pathologists have in detecting EMVI. CRT often destroys the 
features that must be present for histopathological detection yet the vascular anatomy 
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remains obvious on MRI. This is the most likely explanation of low detection rates by 
histopathology in the present study.  
There may be some gain in histopathological examination by taking additional sections 
at deeper levels using specialised stains if necessary in cases where mrEMVI is 
suspected but not confirmed on pathology. Recent studies have reported the improved 
detection of EMVI when using an elastin stain (Kingston et al., 2007b, Inoue et al., 
1992, Vass et al., 2004, Roxburgh et al., 2010). Furthermore, the actual processing 
and sectioning technique influences detection rates (Howlett et al., 2009). The Royal 
College of Pathologists has recommended that a minimum of four blocks from the 
tumour specimen should be evaluated to identify certain prognostic factors including 
EMVI. One study examined the potential to “miss” EMVI when too few blocks were 
examined and found that 41.3% of EMVI-positive tumours would be missed if only two 
blocks were examined. This compares with only 4% of cases being missed If five 
blocks are examined (Talbot et al., 1981). It should be borne in mind that pathologists 
only section a relatively small sample of the specimen (5x5 micron sections) whereas 
MRI has the ability to visualise the entire rectum with tumour in-situ. 
There are several limitations of this study. Firstly, it is not universal practice for rectal 
cancers to be re-staged with MRI following CRT and thus there is a reluctance to rely 
on consequent MRI findings to guide treatment strategies. Secondly, the MRI scans 
were reviewed by a specialist GI radiologist and it may be argued that general 
radiologists may not have the same accuracy for detection of mrEMVI or ymrEMVI 
without specialised training. Assessment for MRI staging factors after treatment has, 
however, been shown to be reliable if a high resolution protocol and consistency in the 
use of reporting criteria are followed (2006). A further limitation is that this is a 
retrospective study but, the MRI scans were prospectively reviewed through a blinded 
193 
 
process and the data used was analysed from a prospectively kept computer 
database.  
In summary, the pre and post CRT evaluation of EMVI is of prognostic and predictive 
relevance. The finding of persistent EMVI is more likely to be detected using high 
resolution MRI than conventional pathology and this has independent prognostic 
significance for disease free survival. Where MRI is used to restage patients after 
chemoradiotherapy, ymrEMVI information may be used to counsel patients regarding 
the ongoing risk of metastatic disease and potential effectiveness of adjuvant 
chemotherapy.  
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Chapter 10 
The survival benefit of adjuvant chemotherapy of patients with 
persistent mrEMVI following neoadjuvant chemoradiotherapy for 
rectal cancer  
 
Aim 
 
The aim of this study was to determine if a survival advantage from adjuvant 
chemotherapy is observed in patients with persistent mrEMVI following CRT. 
10.1. Introduction 
The role of adjuvant chemotherapy in rectal cancer remains contentious as discussed 
in previous chapters. The evidence-base is simply lacking when compared to colon 
cancer. Furthermore, the survival benefit of adjuvant chemotherapy in patients who 
have already undergone CRT is even less clear. Briefly, although CRT leads to 
decreased local recurrence, no large-scale studies have shown an improvement in 
overall survival. Therefore, there is still be a role for adjuvant chemotherapy to 
continue to improve long-term survival but this may involve a change in strategy from 
clinicians in terms of timing and duration. 
EMVI can be considered a ‘high-risk’ feature in rectal cancer and stage II tumours 
which demonstrate EMVI have been shown to have similar survival as stage III 
tumours following CRT (Chapter 8). Perhaps it may be prudent to consider less 
traditional tumour characteristics such as EMVI to guide treatment in the context of 
pre-operative chemoradiotherapy. That is, for patients who have undergone surgery 
after CRT, using the MRI scans as evidence of mrEMVI may be a novel method of 
deciding on whether to offer adjuvant chemotherapy.  
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10.2 Methods    
10.2.1. Patients 
Patients were identified from the Royal Marsden Hospital Rectal Cancer. Data were 
extracted on consecutive patients undergoing curative treatment for locally advanced 
rectal cancer. Treatment included long-course neoadjuvant CRT followed by surgery.  
Adjuvant chemotherapy was given to selected patients based on the presence or 
absence of specific adverse or ‘high-risk’ features (nodal disease, increasing tumour 
penetration into the mesorectum, threat of the circumferential resection margin and in 
selected cases for EMVI). Patients with synchronous tumours, undergoing local 
excision and those treated with palliative surgery were excluded. There was central 
review of all pathology and radiology by specialised GI pathologists and radiologists, 
respectively. 
10.2.2. Staging  
The staging of patients is described in Chapter 3.  
10.2.3. Outcome measures 
The primary outcome was 3-year disease-free survival from the date of surgery. The 
main secondary outcome was recurrence rate. 
10.2.4. Definitions 
Performance status was defined according to the Eastern Cooperative Oncology 
Group (ECOG) classification and shown in table 24.  
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Classification Description 
0 Asymptomatic – fully able  
1 Symptomatic but fully ambulatory; restricted in strenuous 
physical activity 
2 Symptomatic; <50% time in bed  
3 Symptomatic; >50% time in bed 
4 Bedbound 
5 Death 
 
Table 24 – (ECOG) Classification of performance status 
10.2.6. Statistical analysis  
Analysis has been described in section 3. Briefly, differences between groups were 
assessed using the Chi-squared test or Fisher’s Exact test as appropriate (if there 
were fewer than five patients in any one group, Fisher’s test was used instead of Chi-
squared). Survival estimates for DFS were obtained using the Kaplan-Meier product 
limit method. Patients were censored at the last point of known contact or if they died 
during follow-up without experiencing the outcomes of interest.  
Cox’s proportional hazard models were built to test the impact of confounding 
variables on survival (age, gender, performance status, pathological T-stage and N 
stage, CRM involvement). Hazard ratios (HR) and 95% confidence intervals (CI) were 
generated.  
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10.3 Results 
10.3.1. Demographics and treatment  
A total of 226 of 631 (35.8%) had evidence of persistent mrEMVI following CRT 
including 72 female and 154 male patients. The median age was 63.5 (IQR: 54.8- 72). 
158 patients had undergone adjuvant chemotherapy with 68 being observed only 
following surgery. This is shown in table 25. 
 
 
  Adjuvant chemotherapy Observation    
  N 158 N 68 Total P-value 
Performance status 0-1 145 61 206  
 2-3 13 7 20 0.14 
Gender Female 44 28 72  
 Male 114 40 154 0.09 
Pathological T-stage T0-2 32 18 50  
 T3-4 126 50 176 0.34 
Nodal status Negative 109 48 157  
 Positive 49 20 69 0.95 
CRM Negative 149 63 212  
 Positive 9 5 14 0.76 
 
 
Table 25 - Cohort characteristics split by the adjuvant chemotherapy 
 
10.3.2. Histopathology staging characteristics 
10.3.3. Comparison of adjuvant chemotherapy and observation groups  
Patients were grouped into whether or not they had received adjuvant chemotherapy 
(adjuvant versus observation). Both groups were matched in terms of age, 
performance status and final pathological staging characteristics (T and N stage, and 
CRM status). The majority of patients in both groups were of performance status 0 or 
1; and had locally advanced disease in terms of T-stage.   
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10.3.4. Survival analysis 
At a median follow-up of 26 months (2-84) there were 68 recurrences of which 12 
(17.6%) were local. The 3 year DFS rates for patients who received adjuvant 
chemotherapy was 74.6% and observation only 53.7% (Figure 26). (Mantel Cox Log 
Rank Test – p=0.02). On univariate analysis CRM involvement was a significant factor 
for reduced 3 year DFS (HR 2.564 95% CI 1.274-5.162) and but not on multivariate 
analysis. Pathological nodal status and performance status of 3 were found to be of 
borderline significance on univariate analysis (HR 1.587, 95% CI 0.983-2.562, p-value-
0.06; HR 3.298, 95% CI 1.009-10.780, p-value-0.05) but not on multivariate analysis. 
 
     Months 
Figure 26 – Kaplan Meier curve comparing DFS between adjuvant chemotherapy 
group with observation-only group 
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For the purposes of analysis, patients who received adjuvant chemotherapy were used 
as reference to test the significance of chemotherapy on disease recurrence. Adjuvant 
chemotherapy had a survival benefit on both univariate and multivariate analysis (HR 
0.569, 95% CI 0.352-0.919, p-value-0.021; HR 0.484, 95% CI 0.290-0.809, p-value 
=0.006). These results are seen in table 26.  
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  Univariable    Multivariable    
  HR 
95% CI 
lower 
95% CI 
upper P value HR 
95% CI 
lower 
95% CI 
upper P value 
Gender Female Ref    Ref    
 Male .857  .531 
 
1.384 0.528 .949  0.563 1.598 0.843 
Pathological T-stage T0 Ref    Ref    
 T1 1.258 0.141 11.266 0.837 1.633 .166 16.068 .674 
 T2 0.607 0.152 2.427 0.480 .822 .183 3.683 .798 
 T3 2.103 0.761 5.810 0.152 2.571 .771 8.577 .125 
 T4 1.729 0.488 6.131 0.396 1.270 .276 5.847 .759 
Pathological N-stage Negative Ref    Ref    
 Positive 1.587  .983  2.562 0.059 1.570  .921 2.677 .098 
CRM Negative Ref    Ref    
 Positive 2.564  1.274 5.162 0.008 3.753 1.547 9.107 0.03 
Performance status 0 Ref    Ref    
 1 .836  .509 1.373 .478 .860 .507 1.457 .574 
 2 1.050 .439  2.511 .913 1.029 .421 2.512 .950 
 3 3.298  1.009  10.780 .048 2.136 .609 7.497 .236 
Adjuvant chemotherapy No Ref    Ref    
 Yes 0.569 .352  .919 0.021 .484  .290 .809 .006 
 
 
Table 26 - Univariable and fully adjusted multivariable Cox’s proportional hazard models for 3 year disease free survival
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10.4 Discussion 
 
The main finding of the present study is that patients who receive adjuvant 
chemotherapy following CRT and curative surgery have a decreased risk of 
developing disease recurrence over three years. This was independent of age and 
performance status in addition to nodal disease. The hazard ratio for disease 
recurrence for patients receiving chemotherapy was 0.48. They also had a significantly 
improved disease-free survival at 3 years compared to patients undergoing clinical 
follow-up alone (74.6% versus 53.7%). Although the majority of patients in the study 
had adjuvant chemotherapy, approximately 30% did not implying there is a significant 
number of patients who may benefit from additional treatment. It is notable that nodal 
disease was not an independent factor for disease recurrence in matched patients 
who have previously undergone neo-adjuvant treatment and oncologically successful 
surgery.  
There remains a lack of consensus on the use of adjuvant chemotherapy following 
CRT. The current European and North American guidelines recommend that all 
patients with stage III and ‘high-risk’ stage II rectal cancers are offered adjuvant 
chemotherapy although this is not underpinned by a robust evidence base. However, 
the survival benefit of further treatment, with up to six months of 5-FU-based 
chemotherapy in patients who may have already had a significant response from pre-
operative treatment, is unknown and further confuses the issue. In fact paradoxically, 
there is some suggestion that patients who have had minimal response from 
neoadjuvant treatment indeed show no survival benefit following adjuvant 
chemotherapy (Janjan et al., 2001, Das et al., 2006, Collette et al., 2007). This has led 
to a variability in practise amongst clinicians described in Chapter 6. 
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Age is most commonly cited as a reason for not recommending or offering adjuvant 
treatment (Schrag et al., 2001, Potosky et al., 2002, Ayanian et al., 2003) however 
there is good evidence to show comparable outcomes for elderly patients who are 
given such treatment in both colon and rectal cancer (Sargent et al., 2001, Popescu 
et al., 1999). With an increasing elderly population and a drive towards improving 
outcomes for this group of patients, we will no doubt see a rise in the number of elderly 
patients being offered adjuvant treatment in the future. Another interesting point is that 
co-morbidity or performance status, which are often used as reasons why eligible 
patients did not receive adjuvant chemotherapy (Abraham et al., 2006). However it is 
important to appreciate that patients have already been through both neo-adjuvant 
treatment and major surgery which means that unless it is the initial treatment that has 
led to a decrease in performance status, this factor becomes redundant.  
The design of the present study and the subsequent analysis attempted to address 
some of these points which have previously explained the variability in practise with 
regards to adjuvant chemotherapy. EMVI can be considered to be a ‘high-risk’ factor 
and patients should be offered adjuvant treatment to reduce the risk of disease 
recurrence. The patients in the study were matched in terms of age, performance 
status and final staging which means the results of the multivariate analysis show a 
true independence for disease recurrence.   
The difficulties with relying solely on histopathology to detect EMVI following CRT has 
been described in earlier sections. If mrEMVI can be reliably identified in a 
reproducible manner then it seems sensible to use if for decision making. Using 
radiological characteristics to guide and inform treatment decision-making is 
universally done so with regards to neoadjuvant treatment. Extending this to adjuvant 
treatment seems a natural progression particularly if there is difficulty in interpreting 
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routine pathological analysis following CRT and there is a potential for patients who 
may benefit from further treatment to be missed. In addition to this, the results would 
be known to clinicians before surgery thus helping plan for future treatment and inform 
patients at an earlier stage. 
Limitations of the study include a lack of information regarding the decision-making 
process following surgery. Knowledge of whether treatment was not recommended or 
whether not offered would have given further understanding to any variability in 
practise. Also, there was no information regarding severity and extent of any operative 
complications. This is known to be a factor in delaying or withholding adjuvant 
treatment (Cheung et al., 2009) and may have played a role in this study. 
Understandably, if a patient has endured a challenging journey through the first 
phases of their treatment they are less likely to consider further therapy particularly if 
there is a risk of morbidity. Further limitations include that this is a retrospective study 
and which can impact on the accuracy of the follow-up data. The database at the Royal 
Marsden from which the data is extracted is comprehensive across all hospital 
specialties and is prospectively maintained but nevertheless there is still the potential 
for inaccurate follow-up data. This is not a randomized study which also means that 
the results are subject to bias. There was no sample size calculation so the results 
can suffer from a type 2 error. The numbers are small and it would be interesting to 
develop a randomized study using expected differences in three year DFS.  
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Chapter 11 
Extramural venous invasion (EMVI) is a potential imaging predictive 
biomarker of neoadjuvant treatment in rectal cancer 
 
Aim 
 
This study aimed to demonstrate that improvement in the degree of MRI-detected 
EMVI following CRT results in improved survival. Further, by relating the radiological 
improvement in EMVI to better outcomes in terms of disease recurrence and time to 
recurrence this would suggest that mrEMVI could be used as a predictive imaging 
biomarker. 
11.1. Introduction  
The challenges associated with solely relying on histopathology techniques to detect 
EMVI have been discussed in some detail in the preceding chapters. The pertinent 
issues include direct difficulties in interpreting the resection specimens, particularly 
following CRT and if only simple stains are used. Other issues include the delay in 
diagnosis – histopathological analysis is performed following surgery. And further, the 
results of the histopathological analysis do not provide a stratified measure of the 
severity of EMVI.  Some of the advantages of using MRI to detect EMVI have also 
been presented in preceding chapters. These include timing of detection, grading the 
severity and being able to demonstrate vascular anatomy in vivo and thus tumour 
invasion can be readily identified.  
EMVI may play a role in pre-operative risk-stratification and further, influence decisions 
with regard to adjuvant chemotherapy or more intensive neoadjuvant treatment. EMVI 
responds to CRT by causing vessel fibrosis which can be detected on MRI. These 
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radiological changes may result in improved survival. The prognostic effect of MRI-
detected EMVI (mrEMVI) has previously been examined (Smith et al., 2008a) and 
described in detail in earlier sections. The potential to grade regression of EMVI 
following neoadjuvant treatment means that it could be used as an imaging biomarker 
to measure effectiveness of such treatment.  
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11.2. Methods 
The patient selection has been described in Section 3.  Briefly, a retrospective analysis 
of prospectively collected data was conducted examining the staging and post-
treatment MRI scans of patients who had presented with primary rectal cancer and 
MRI evidence of EMVI. The MRI scans were re-reviewed to capture the additional data 
on changes in mrEMVI. 
The study fulfilled the relevant Reporting Recommendations for Tumour Marker 
Prognostic Studies (REMARK) criteria (McShane et al., 2005).  
11.2.1. The REMARK Criteria for reporting biomarkers 
The REMARK criteria were born out of a need to develop a standardised reporting tool 
for potential biomarkers. Several hundred reports have emerged investigating novel 
biomarkers to predict disease activity in cancer but the overwhelming majority have 
failed to translate into meaningful clinical application. 
Much of the reason behind this poor yield has been the lack of reporting criteria which 
has meant that many studies have not been replicated to reach the same conclusions. 
The REMARK guidelines are analogous to similar guidelines used for the reporting of 
randomized controlled trials or observational trails such as Consolidated Standard for 
Reporting Trials (CONSORT); and Standards for Reporting Diagnostic Accuracy 
Studies (STARD). The criteria include reporting of specifics of hypotheses, study 
design, methodology, results presentation and statistical analysis amongst others. The 
full REMARK guidelines are shown in Appendix C. 
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11.2.1. Chemoradiotherapy and post-operative chemotherapy regime 
The CRT regime is described in Chapter 4. The post-operative chemotherapy is also 
described in Chapter 4. The policy of our institution is to routinely give patients with 
stage III disease adjuvant chemotherapy in addition to patients who demonstrate high-
risk features on baseline imaging and therefore require pre-operative therapy. For 
patients with stage II disease following pre-operative treatment, a discussion is had 
between patient and oncologist regarding the benefits of further adjuvant treatment. 
11.2.3. Radiological mr-staging 
The local policy of our institution is for all patients with rectal cancer to routinely 
undergo local staging with MRI and for those patients who have CRT to have further 
MRI scans to assess treatment response. Each patient underwent a minimum of two 
MRI scans, before and after CRT, which were available for review. Where patients 
had undergone more than one post-CRT MRI scan, the most recent scan immediately 
prior to surgery was reviewed for the purposes of analysis.  
mrT-stage was categorised into either “good” or “poor” based on the extent of tumour 
spread into the mesorectum. “T-good” included all tumours staged as T3b or better 
whereas T3c or worse were recorded “T-poor”. mrN stage was categorised as either 
positive or negative, and mrCRM was considered positive if the tumour edge was 
within 1mm of the circumferential resection margin. These characteristics were 
recorded pre-treatment and post-treatment (mr- and ymr-stage).  
ymrEMVI status was recorded as either positive or negative (positive status was a 
score of 3 or 4 on the MRI-EMVI grading system described in earlier sections). Further 
MRI assessment for the extent and site of EMVI was recorded in addition to the degree 
of regression. This was categorised as large-vessel mrEMVI if tumour invasion was 
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identified into superior, middle or inferior rectal veins; or small-vessel disease if 
mrEMVI was seen into non-anatomical vessels. mrvTRG was used to categorise the 
degree of EMVI regression. The criteria for the mrvTRG score has been presented in 
earlier sections. The treatment response was measured by the degree of fibrosis 
present in the extramural vasculature. 
Fibrosis in contradistinction to tumour is characterised on MRI as dense low 
(dark/black) signal intensity rather than the nodular intermediate (relatively 
brighter/grey) signal intensity of tumour. This is best seen on post-CRT T2-weighted 
MRI, the areas of fibrosis have very low signal intensity, whereas areas of residual 
tumour have intermediate signal-intensity. The signal intensity of fibrosis is similar to 
that of the muscularis propria, and signal intensity of residual tumour is similar to that 
of baseline tumour.  
11.2.4. Histopathology staging 
Final histopathology staging (yp-stage) included T-stage; N-stage; EMVI status and 
CRM involvement.  
11.2.5. Statistical analysis 
The response of EMVI to CRT was measured using the mrvTRG scale described 
above. For the purposes of analysis, patients were categorised into two groups based 
on whether there had been more or less than 50% fibrosis seen within the lumen of 
the affected vessels – mrvTRG1-3 (good mr venous responder) and mrvTRG4-5 (poor 
mr venous responder). Survival included recurrence rates; site of recurrences; and 3 
year disease-free survival (DFS).  
Differences in staging characteristics between groups was analysed using Fisher’s 
exact test and Chi-squared, where appropriate. Survival curves for DFS were 
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calculated using the Kaplan Meier product limit method; differences between survival 
curves for mrvTRG levels were tested for significance using the Mantel-Cox log rank 
test. An event was radiological or pathological detection of recurrent/metastatic 
disease or death from any cause. Time to event was recorded from the start of 
treatment date. Multivariate analysis was performed using Cox regression for time to 
recurrence. A p-value of <0.05 was considered significant. Hazard ratios were 
recorded with 95% confidence intervals.  
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11.3. Results 
A total of 88 patients who were mrEMVI positive met the inclusion criteria and had MRI 
images available for review. 62 were included in the final analysis. Reasons for 
exclusion were metastatic disease on presentation, incomplete neoadjuvant 
treatment, and EMVI not evident on MRI review. 21 patients were female and 41 male. 
The median age was 68 (range 28-87).  
11.3.1. Pre-treatment mr-staging 
60 patients (97%) were staged as mrT-poor and 44 (71%) patients also had MR 
defined nodal disease at the time of diagnosis. mrEMVI was present in all 62 patients; 
of these, 50 (81%) had evidence of large-vessel mrEMVI. The height of the lower edge 
of the tumour from the anal verge was measured on MRI for each patient - 21 low 
rectal (0-5cm); 15 mid-rectal (6-10cm); 26 upper rectal (>10cm). The CRM was 
considered threatened on MRI if the tumour margin spread to within 1mm – same as 
histopathology criteria. 31 patients (50%) had a positive mrCRM. 
11.3.2. Post-treatment ymr-staging 
11.3.2.1. ymr-EMVI 
35 patients (56%) had more than 50% fibrosis of EMVI following CRT (“good venous 
responders”). This included 12 patients where there was complete fibrosis of EMVI 
(mrvTRG1) which is considered to be a change in EMVI status from positive to 
negative. 27 patients (44%) demonstrated less than 50% fibrosis of EMVI (“poor 
venous responders”).  
In the good venous responder, 20 of 35 patients showed evidence of large vessel 
EMVI; 2 patients had small-vessel and disease and 12 patients showed no evidence 
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of EMVI. In the poor venous responders, 26 of 27 patients had large-vessel EMVI and 
only 1 patient with small-vessel disease.    
11.3.2.2. Other staging characteristics 
Following CRT, 13 of 35 (37%) patients were now staged as T-poor; 11 patients had 
nodal disease (31%); and 5 patients (14%) showed that the CRM was still threatened 
or involved in the good venous responders. Of the 27 poor venous responders, 26 
were still T-poor (96%); 18 (67%) had nodal disease; and 17 (63%) had an involved 
CRM. The pre- and post-CRT staging characteristics are shown in table 27. 
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Staging characteristic 
 
Baseline staging 
n=62 
Post- CRT  
p-value MrvTRG 1-3 
n=35 
MrvTRG 4-5 
n=27 
 
mrT-stage 
Good (mrT1-T3b) 60 22 1  
<0.05 Poor (>mrT3b) 2 13 26 
 
mrN-stage 
0 18 24 9  
<0.05 1/ 2 44 11 18 
 
EMVI vessel type 
No evidence 0 12 0  
 
>0.05 (small and large vessel) 
Small vessel 12 3 1 
Large vessel 50 20 26 
 
mrCRM status 
Negative 31 30 10  
<0.05 Positive 31 5 17 
 
Table 27 – Pre and Post-treatment MRI staging characteristics (ymr-stage) 
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11.3.3. Histopathology staging 
The majority of the good venous responders were staged as ypT3 (17/35). One patient 
had a pathological complete response with no residual tumour found; 12 patients were 
staged as ypT2 and 5 patients were ypT4. For nodal staging – 11 patients were node-
negative and 24 patients had N1/N2 disease. The CRM was clear of tumour in all 
patients.  
In the poor venous responders group, one patient had a pathological complete 
response and there was one patient staged as ypT2. 22 patients had ypT3 stage and 
3 patients ypT4. 14 patients had node-negative disease whilst 13 patients had N1/N2 
disease. 2 patients had a positive CRM. These are shown in table 28. 
 
Staging characteristic No of patients p-value 
MrvTRG 1-3 MrvTRG 4-5 
 
 
ypT-stage  
pCR 1 1  
 
 
<0.05 
T2 12 1 
T3 17 22 
T4 5 3 
ypN-stage 0 24 13  
0.12 1/ 2 11 14 
ypCRM status Negative 35 25  
N/A Positive 0 2 
 
Table 28 – Post-treatment histopathological staging (yp-stage) 
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11.3.4. Survival analysis   
Only 3 patients (9%) developed recurrence from the good venous responders – 2 
hepatic; 1 local recurrence. 3-year disease-free survival (DFS) was 87.8%. In 
comparison 12 patients (44%) developed disease recurrence from the poor venous 
responders, with the majority being hepatic metastases – 7 hepatic; 3 pulmonary; 2 
local. 3-year DFS was 45.8%. A Mantel-Cox log-rank test comparing survival showed 
a statistically significant difference – p=0.013. The survival curves of the two groups 
are shown in figure 27. 
 
Figure 27 – Kaplan Meier curves for disease-free survival (DFS) for patients mrvTRG 
1-3 and mrvTRG 4-5 
mrvTRG 1-3 
mrvTRG 4-5 
mrvTRG 1-3 censored 
mrvTRG 4-5 censored 
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On multivariate analysis of specific patient and tumour characteristics using Cox 
regression, only regression of EMVI by more than 50% (mrvTRG1-3) was shown to 
be significant for improved disease-free survival and recurrence – p = 0.013. The 
hazard ratio of a patient developing recurrence following CRT and surgery if there was 
less than 50% fibrosis of EMVI was 5.748 (95% CI 1.442 – 22.905). This is shown in 
table 29. 
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Variable Hazard ratio 95% CI p-value 
 
Sex 
     Female 
      Male    
 
1.000 
1.479 
 
 
0.527 – 4.149 
 
 
0.458 
 
Height from anal verge 
           >5cm 
           <5cm 
 
1.000 
0.634 
 
 
0.248 – 1.620 
 
 
0.341 
 
EMVI regression 
      mrTRG 1-3 
      mrTRG 4-5 
 
1.000 
5.748 
 
 
1.442 – 22.905 
 
 
0.013 
 
ypT stage 
       T3b or better 
       T3c or worse 
 
1.000 
0.265 
 
 
0.067 – 1.052 
 
 
0.059 
 
ypN stage 
      N0 
      N1/2 
 
1.000 
2.255 
 
 
0.891 – 5.710 
 
 
0.086 
 
ypCRM status 
      negative             
      positive 
 
1.000 
1.197 
 
 
0.136 – 10.496 
 
 
0.871 
 
 
Table 29 – Multivariate analysis of prognostic factors for disease-free survival following neoadjuvant chemoradiation and TME surgery 
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11.4. Discussion 
 
This study has shown that good regression of mrEMVI with more than 50% fibrosis is 
associated with significant improvement in disease-free survival, independent of final 
pathological staging (T-stage, nodal status and CRM status). This finding was seen in 
56% of patients initially presenting with mrEMVI.  3-year disease-free survival (DFS) 
was only 45.8% when there was less than 50% fibrosis (poor venous responders) 
compared with 87.8% in good venous responders.  In addition, the recurrence rates 
were 9% for good mrEMVI versus 44% for poor mrEMVI responders. This is the first 
study to stratify the tumour regression grade of EMVI following neoadjuvant treatment 
using REMARK criteria for investigating imaging biomarkers. These results would 
suggest that mrEMVI could be used as a predictive imaging biomarker and that it is 
worthwhile targeting patients with mrEMVI for further oncological treatment such as 
neo-adjuvant chemotherapy rather than just chemo-sensitisation to elicit further down-
staging of mrEMVI, since those patients showing a significant degree of fibrosis of 
mrEMVI have improved survival.      
Using detailed MRI assessment enables more effective risk assessment and therefore 
therapeutic stratification early in the patient treatment pathway. The most important 
recognised factors that influence neoadjuvant treatment are depth of tumour 
penetration, and in particular the extent of spread into the mesorectum and beyond 
(T3-sub-stage and T4), and proximity of the tumour edge to the circumferential 
resection margin (CRM) – these have been described in earlier sections.  
The response to neoadjuvant treatment can be measured histopathologically by the 
use of tumour regression grades (Mandard et al., 1994, Suarez et al., 2008). The 
regression grading enables an assessment of response in terms of cytological 
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changes and stromal changes including fibrosis which have been show to correlate 
well against outcomes. There has been recent investigation in the use of MRI-based 
regression grades (mrTRG). Understanding how a tumour will respond to treatment 
using mrTRG scores pre-operatively, increases the chance that surgery will result in 
a successful oncological outcome and further allows for intensive oncological 
treatment if patients have not shown an adequate response. However there have been 
no specific investigation of response to mrEMVI as a predictive tool. 
The consistent depiction on MRI of the larger veins such as the superior and inferior 
rectal veins, aids identifying the type and size of vessel involved. MRI is therefore more 
accurate in identifying large-vessel EMVI than smaller-vessel disease (Smith et al., 
2008a).  We observed that the majority of patients had large-vessel disease initially 
and where there was less than 50% fibrosis of EMVI large-vessel disease 
predominated. This confirms the importance, first shown by Talbot, of large vessel 
disease over smaller vessel (Talbot et al., 1981). Whilst small-vessel EMVI may be 
more difficult to identify both radiologically and histopathologically, it may in fact be of 
little clinical consequence. 
Following CRT, 38 patients showed more than 50% fibrosis (mrvTRG score of 1-3). 
Interestingly, of these 38 patients, 12 patients showed complete regression of mrEMVI 
and would be reported as EMVI-negative on MRI - no evidence of EMVI. Only one 
patient who had become mrEMVI negative developed a recurrence – hepatic 
metastases. There was also improvement in all other prognostic factors as one would 
expect. As the study cohort all underwent CRT, it is, by definition, a high-risk group of 
patients. This can be seen by the baseline staging characteristics which show that 
almost all patients were staged as T-poor. In our institution, not all T3 patients are 
universally irradiated and nodal disease alone is not an indication for neo-adjuvant 
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therapy. In the mrvTRG 1-3 group, the majority of patients were staged T3 but the 
CRM was negative in all patients. Although there were a few patients who were 
radiologically staged to have CRM involvement following CRT on MRI, this information 
would have been known to the surgeon allowing them to make appropriate surgical 
decisions to ensure a clear margin. In the poor venous responders, T3 tumours 
predominated and the CRM was involved in 3 patients out of 28. More than half of 
patients still had nodal disease although this was not statistically relevant difference 
between the groups. Further, on multivariate analysis, nodal disease was not a 
significant factor and only mrvTRG grade was significant.    
These results suggest that EMVI regression is a prognostic indicator for disease 
recurrence in addition to being predictive as well. Patients who show little fibrosis of 
EMVI following CRT are more likely to develop metastatic disease. The hazard ratio 
of 5.748 is significant and suggests that if patients show minimal regression of EMVI 
following standard CRT that more intensive pre-operative chemotherapy to further 
treat EMVI may improve disease recurrence. These patients are at risk of developing 
metastases and should be considered for aggressive therapy pre- or post-operatively. 
This also raises the issue of more frequent follow-up as currently there is no universal 
consensus on rectal cancer surveillance after curative surgery. Whilst patients who 
are enrolled in trials have a defined follow-up strategy, the timing of imaging, serum 
CEA and colonoscopy varies from centre to centre. Patients who are identified to be 
high-risk of metastatic disease should be considered for more frequent follow-up, and 
in particular more frequent liver imaging.  
One of the perceived limitations of this study is the use of a specialist gastrointestinal 
radiologist to stage the MRI scans. It is not always possible for patients’ imaging 
studies to be reported by specialist radiologists and sub-specialisation has not been 
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accepted in the UK as yet. It has been previously shown in the Mercury study that 
technique and assessment of MRI can be standardised, particularly when a specific 
proforma-based system is adopted (Taylor et al., 2010, Taylor et al., 2008). Further, 
this is retrospective analysis which introduces bias. However the data collected was 
done so from routinely undertaken proforma reports for histopathology and the MRI 
scans were re-reviewed by the authors. The numbers in the study are also small as 
this is a pilot study. This introduces the possibility of bias and statistical error (type II). 
The development of the MARVEL trial (described in later chapters) will help 
prospectively validate these results.   
In summary, neoadjuvant therapy is known to improve survival and downstage 
disease in terms of depth of tumour spread, regional lymph node and CRM 
involvement. There have been no studies of the effect of chemoradiation on EMVI in 
terms of morphological change or effect on survival. This is the first study to quantify 
the radiological changes which occur in EMVI following CRT and how they relate to 
survival. Patients in whom there has been more than 50% fibrosis and regression of 
EMVI show significant improvement in disease-free survival. In patients where there 
has been less than 50% regression, consideration should be made for additional 
neoadjuvant therapy. The regression and fibrotic changes in EMVI following CRT are 
identifiable on MRI and by showing that mrEMVI treatment response correlates with 
improvement in disease recurrence, we suggest that it has a role as a predictive 
imaging biomarker. 
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Chapter 12  
Differences in molecular profile between ypEMVI negative and ypEMVI 
positive rectal cancer and the changes following neoadjuvant 
chemoradiotherapy 
 
Aim 
 
This study primarily focuses on a sub-type of advanced rectal tumours that exhibit 
EMVI and aims to characterise gene expression differences in malignant cells from 
these tumours compared to EMVI negative rectal tumours.  Identification of genes 
involved in the development pathway, in tumours expressing EMVI positive status, can 
allow the identification of potential therapies which could hope to prevent these genes 
(specifically microRNAs) from being over or unexpressed preventing vascular 
invasion. 
12.1. Introduction 
Numerous efforts using molecular profiling have attempted to categorize cancers such 
that patients with an increased risk of recurrence and metastasis can be identified. 
The behaviour of malignant cells lining rectum depends upon both genetic mutations 
and gene expression changes, which it may be possible to identify. This knowledge 
may mean that we can predict which cancers will respond to various drugs and 
treatments such as irradiation and spare some patients unnecessary morbidity. 
Pre-operative assessment and tumour staging is critical for recognising more 
aggressive and advanced colorectal tumours and can improve prognostic outcome, 
for example by using molecular methods. Inaccuracy of staging in some cases has led 
to some patients being staged with a low stage tumour when it is in fact a higher stage 
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tumour and therefore should get treatment intensification. This highlights the 
importance of accurate pre-operative staging in clinical management especially when 
identifying patients who would benefit from CRT. Molecular profiling will help ensure 
future accurate staging, most likely in conjunction with high resolution imaging 
techniques such as MRI.  
Responses of tumours to neoadjuvant CRT can be quite varied between patients and 
for some patients the little benefit of the neoadjuvant treatment regime is eclipsed by 
the significant adverse side-effects of the therapy (Birgisson et al., 2007). However for 
some patients, CRT prior to surgery can significantly reduce tumour size thus 
improving the chance of complete tumour removal during surgery. Therefore 
establishing a robust identification criteria for those who would benefit from CRT is 
also advantageous.  
Previous efforts using molecular markers alongside gene expression profiling have 
hoped to define patients with an increased risk of disseminated disease. With a large 
variation in the reported prevalence of EMVI in surgical resection specimens it 
indicates there are problems when assessing EMVI status. The preceding chapters 
have attempted to address this however there may be more novel ways in which EMVI 
could be detected. Identification of genetic markers and further understanding of the 
molecular mechanisms which lead to EMVI may aid in developing newer treatment 
strategies. The identification of new diagnostic and prognostic biomarkers for EMVI is 
needed to help characterise the tumour and complement treatment selection 
strategies.   
Deregulation of gene expression is a hallmark of cancer. With the technology available 
today, molecular and genetic profiling allows us to recognize and understand the 
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fundamental mechanisms, which regulate the behaviour of rectal cancer. MicroRNAs 
(microRNAs) have recently been described as “managers of gene expression” 
(Mirnezami et al., 2009) regulating biological processes including proliferation, cellular 
differentiation, apoptosis and stem cell self-renewal. MicroRNAs are short non-coding 
regulatory molecules which base-pair with the 3’ -UTR region of protein coding mRNAs 
resulting either in degradation of the mRNA or inhibition of translation. Primary or pri-
microRNAs are first transcribed in the nucleus by polymerase II, as long hairpin 
structures. These structures are processed by the ribonuclease ‘Drosha’ to form 
shorter double stranded pre-microRNAs. These pre-microRNAs are subsequently 
exported out of the nucleus where they are further trimmed by the endonuclease Dicer 
to produce short mature microRNAs. These 22-25 base pair duplexes are integrated 
into the RNA-induced silencing protein complex (RISC) (Bartel, 2004). Mature 
microRNAs escort the RISC to supress gene expression by binding to their target 
mRNA.   
So far more than 1400 microRNAs have been identified and are estimated to regulate 
up to 30% of the human genome. With microRNAs having hundreds of transcripts as 
direct or indirect targets and more than one microRNA having the ability to assemble 
on a single transcript, the possible regulatory potential by microRNAs is vast. Such 
deregulation of genes particularly those involved in tumour suppression, cell cycling, 
apoptosis and invasion can lead to cancer formation and progression. In recent years, 
significant advancement in microRNA research studies using high-throughput analysis 
of pathological samples has expanded our knowledge of a variety of cancers including 
colorectal cancer and breast cancer (Sorlie et al., 2006). Technology such as 
expression profiling using microarrays would allow the identification of any significant 
variations in microRNA gene expression between different sub-types of cancer such 
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as EMVI positive rectal cancer and EMVI negative tumours revealing new potential 
biomarkers and therapeutic targets.  
12.2. Methods 
12.2.1. Clinical Sample Selection 
The patient selection and tissue sampling is described in Section 3. Briefly, tissue 
samples used in this study were obtained from a licenced and approved tissue bank 
at Southampton General Hospital and the Royal Marsden Hospital. Formalin-fixed 
paraffin embedded (FFPE) rectal tumour resection blocks were selected from patients 
with locally advanced adenocarcinoma of the rectum and showing no evidence of 
distant metastases. Patients initially underwent a pre-operative MRI scan, prior to 
long-course chemoradiotherapy (LCRT) and then surgery. Patients were also 
subjected to a pre-operative MRI scan as part of their treatment plan. Both scans were 
assessed using a scoring proforma to resolve basic characteristics and the post-
treatment MRI scan was compared to the histopathology analysis of the surgical 
specimen.  
Tissue specimens of four subtypes were collected; EMVI positive tumours subdivided 
into lymph node positive or lymph node negative, and EMVI negative subdivided into 
lymph node positive or lymph node negative. The clinical and pathological information 
for patients within the criteria was recorded into a database. Written informed consent 
forms were obtained from each patient  
Samples were further analysed following laser micro-dissection and RNA extracted for 
analysis. These techniques are explicitly described in Section 3. 
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Results 12.3 
12.3.1. Demographics and tumour characteristics 
 
A total of 30 samples were selected for analysis. 12 EMVI-positive tumours were 
compared with 18 EMVI-negative. These samples were collected on the basis of MRI-
detected EMVI on post-CRT MRI scans (ymrEMVI status). The patient characteristics 
and tumour characteristics are shown in table 30. 
 
Sex Male 18 
Female 12 
Age Median 69.5 
Height from anal verge Low 8 
Middle 9 
Upper 13/01/1900 
T-stage Good 7 
Poor 23 
N-stage Negative 11 
Positive 19 
CRM status Negative 18 
Positive 12 
 
Table 30 – Patient demographics and MRI-based tumour characteristics 
12.3.2. Survival 
 
The recurrence rate of the EMVI-positive group was 7/12 (58.3%) versus 5/18 (27.8%). 
3-year DFS was 25.8% in the EMVI-positive group compared with 72.9% in the EMVI-
negative group (p<0.05). 
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12.3.3. MicroRNA analysis 
 
Comparison of the EMVI positive and EMVI negative sample demonstrated a 
difference in three microRNA sequences - hsa-miR-1277-5p; hsa-miR-4764-3p;  
hsa-miR-873-3p. The difference in expression was calculated as a ‘fold difference’ 
which corresponded to under- or over-expression of the sequence. This is shown in 
table 31.  
 
microRNA sequence Fold Difference 
EMVI positive EMVI negative 
hsa-miR-1277-5p 0.49 1.00 
 
hsa-miR-4764-3p 
 
2.33 1.00 
 
hsa-miR-873-3p 
 
0.49 1.00 
 
 
Table 31 – Difference in microRNA expression between EMVI positive and negative 
tumours. 
Comparison was also made between tumours which were node-negative or node-
negative (stage II versus stage III) tumours with evidence of EMVI. A further four 
sequences were identified that demonstrated differential expression. This is shown in 
table 32. 
microRNA sequence Node negative Node positive 
hsa-miR-1914-5p 
 
1 0.48 
 
hsa-miR-4666b 
 
1 3.74 
 
hsa-miR-4482-5p 
 
1 3.37 
 
hsa-miR-634 1 0.43 
 
 
Table 32 – Difference in microRNA expression between stage II and stage III 
tumours 
227 
 
12.4. Discussion 
The results of this study show that individual rectal cancer sub-types have distinct 
molecular profiles. Differences in expression were also demonstrated in three specific 
microRNA sequences between ypEMVI negative and ypEMVI positive tumours. Node-
positive and node-negative tumours were shown to have different expressions in four 
different and specific microRNA sequences. This study is the first to show that ypEMVI 
positive tumours have inherent biological profiles when compared to EMVI negative 
tumours, which adds to the differences in clinical outcomes that are already known. 
These differences can be identified in a unique gene signature through microRNA 
sequencing.  
Traditional techniques to detect tumour characteristics are being challenged in an 
attempt to discover increasingly accurate methods of risk-stratifying and ultimately 
treating patients with cancer. Following the lead of breast cancer where much 
excellent work has identified novel therapeutic targets, rectal cancer is now being 
investigated through molecular profiling techniques. The premise of detecting tumour 
characteristics through routine histopathological methods remains the ‘Gold Standard’ 
however we have shown in earlier chapters how high resolution imaging techniques 
such as MRI can complement this.  
High-throughput analysis of gene signatures is a more novel technique which has 
great potential. It allows clinicians to stratify patients on differences identified on a 
molecular level and thus more accurately than gross pathology methods. By linking 
these profiles to clinical outcome data, we are able to develop highly accurate 
surveillance and treatment strategies.  
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The clinical outcome data between node-negative and node-positive tumours is not 
disputed. The patients in this study whose tumours’ were further analysed had all 
undergone pre-operative CRT. The difference in microRNA expression between 
tumours with distinct nodal status following CRT is an important finding. This implies 
that despite CRT the tumours still have inherent biological differences which may 
result in specific clinical outcome patterns.  
Differences were also noted between the EMVI sub-types. Earlier chapters have 
demonstrated different clinical outcome data between these sub-types. The results of 
this study add to the clinical observations which show that EMVI is an important factor 
post-CRT. The use of the radiological and clinical data strengthens the case for 
discovering therapeutic targets based on EMVI status. The difference in expression 
between EMVI positive and negative tumours is a basis for therapy. If we can target 
the specific sequences which are unique to EMVI positivity we have the opportunity to 
improve survival.  
The next step in this process is to validate these results both internally and externally. 
Further, determining where the microRNA sequences act in known tumorigenesis 
pathways is important in developing future therapies. However there are certain 
limitations in this particular study. Firstly, the laser micro-dissection did not specifically 
identify areas of tumour where there was known EMVI. The sample were taken from 
tumour specimen but not correlated directly to extramural veins. This introduces the 
idea that specific areas of the tumour may have unique profiles and that the area 
containing extramural veins laden with cancer cells has a different profile than an area 
of tumour without veins. This is an important investigation for the future. For example, 
do the molecular profiles of liver metastases mimic those of EMVI positive tumours in 
general, or are they specifically related to the profile of tumour specimen within the 
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extramural veins? Secondly, this study only investigated the molecular profiles of 
patients following CRT. It would be interesting to know whether the profiles had 
changed following CRT by comparing samples before and after. This may help explain 
the mechanisms and target of CRT in individual patients.  
In summary, the results of this study are interesting and demonstrate that tumours with 
distinct morphological and radiological characteristics also have distinct molecular 
profiles. However, the clinical relevance and application of these results are a long 
way off. There needs to be further validation and investigation of EMVI sub-type. For 
example, verification with quantitative PCR followed by external validation. Further, 
there a number of new avenues which must be explored to confirm these results with 
greater accuracy and detail to ensure that the most appropriate therapeutic targets are 
manipulated.   
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Chapter 13 
Development of the ‘MARVEL’ Study – The Molecular and Radiological 
Evaluation of EMVI in Rectal Cancer 
 
Aim 
 
This prospective study will identify important differences between key rectal cancer 
tumour subtypes, and in turn will fuel the formulation of new hypotheses. Identification 
of reliable pathological markers of EMVI pathways (from both the primary tumour 
sample, but more importantly from the pre-operative biopsies) has real potential for 
taking us a step closer to more personalized management of rectal cancer by 
establishing prognostic biomarkers reflective of disease type, but also through the 
underlying biology that may be highlighted (with its promise of therapeutic translation).  
13.1. Introduction  
The preceding chapters have discussed in detail and presented results to explain that 
optimal treatment of rectal cancer relies on accurate pre-operative risk stratification 
and subsequent multidisciplinary management. Treatment decisions take place in the 
context of the MDT and involve clinicians from different specialities. The identification 
of adverse tumour characteristics underpins this strategy. EMVI is an example of this 
and has been shown in some detail to be a poor prognostic factor in rectal cancer that 
confers an increased risk of disease recurrence (Chapters 1 and 5). Traditionally, 
EMVI has been identified on histopathological analysis of surgical resection 
specimens alone. And as pathology has been historically considered to be the ‘gold 
standard’ for staging, diagnosis is not always possible on biopsy if one were to enquire 
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about the pre-operative EMVI status. Therefore there is over-reliance of post-operative 
specimens.  
CRT is widely accepted as beneficial to selected patients in terms of decreased risk 
of local recurrence. Until now, very little has been known about the long-term outcome 
and response to CRT of EMVI positive tumours. The results of the studies in earlier 
sections have helped better understand the morphological and clinical outcomes of 
such tumours. 
New analytic techniques using principles of miniaturization are becoming available for 
gene and molecular profiling. The use of microarrays can be readily applied to the 
profiling of rectal cancer. Using these techniques, it is possible to identify differences 
in the genetic profiles between EMVI positive and EMVI negative tumours and whether 
any changes are observed following CRT. This may then be correlated with clinical 
behaviour over the medium and long-term with regards to local recurrence, distant 
metastases and overall survival.  
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13.2. Methods 
13.2.1. Trial Design 
 
 
Figure 28 – Flowchart showing MARVEL trial design 
 
This will be a prospective study comparing two groups of patients undergoing the 
same treatment regime for locally advanced rectal cancer. The study aims to 
investigate the radiological and pathological effects of pre-operative CRT on EMVI in 
rectal cancer. The treatment regime for locally advanced tumours will be dictated by 
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the hospital – the study protocol does not interfere with local policy. However, pre-
operative treatment must include long-course CRT. Surgery must be considered 
curative and performed using total mesorectal excision (TME) principles. 
The primary objective will be to document a difference in relapse free survival (RFS) 
at 1 and 3 years between mrEMVI positive and mrEMVI negative rectal cancer. Our 
definition of RFS will include patients who are alive at the end of follow-up with no 
evidence of recurrence. Secondary endpoints include the rate of conversion of EMVI 
positive to negative following CRT and the response rates of EMVI tumours in relation 
to other adverse features such as T stage, nodal stage, CRM involvement and TRG. 
The final objective is to document the differences in the underlying profiles of EMVI 
positive and negative adenocarcinoma, and whether there is any change in these 
profiles following CRT and relate this to clinical outcome. By identifying differences 
between the underlying profiles relating to EMVI status, we will be able to propose 
potential therapeutic targets.  
13.2.2. Participants 
Patients will be identified at the multidisciplinary meeting (MDT) held at the local 
hospital. They must be able to undergo CRT followed by curative surgery. Recruitment 
will take place on a consecutive patient basis. As part of the staging process, it must 
be local policy to perform local staging with MRI and staging for distant disease with 
CT scan of the thorax, abdomen and pelvis. Patients will be divided into those who are 
EMVI positive or EMVI negative depending on the baseline staging MRI scan.  
Patients will be given the option to enrol in the study in the outpatient clinic (surgical 
or oncology) following the MDT meeting. This will occur in the local hospital and the 
local research team will carry out recruitment. Patients are free to consent to join the 
234 
 
trial on the same day they read the patient information sheet, as this trial is non-
interventional. This study will not require patients to undergo any additional or further 
investigations or procedures outside the treatment pathway. 
CRT would be given over a 3-month period followed by repeat MRI scanning to 
determine response and potential for surgery – the neoadjuvant treatment strategy will 
be in line with the current NICE proposals (Appendix XX). They will consent to allow 
analysis of their biopsy and surgical specimen, which may include genetic analysis. 
Patients in the trial will be treated as determined by the MDT responsible for their care. 
All staging information determined as part of this study will be made available to the 
MDT. The trial will have no impact on the treatment given to patients. 
Following recruitment, biopsy specimens will be retrieved and “banked” for analysis. 
Tissue blocks and slides from local units will be requested by the Royal Marsden 
Hospital once recruitment has been confirmed. All imaging studies will be performed 
at the local hospital and reported on the clinical reporting form (CRF) by a member of 
the research team. Once patients have completed pre-operative CRT they must 
undergo further MRI scanning as part of their treatment strategy to assess local 
response. These MRI scans will be reported on the CRF. Providing the patients are 
able to proceed to surgery they will continue in the trial. Central review of MRI scans 
will take place at the Royal Marsden Hospital, Sutton. Routine histopathology reporting 
will be performed by the local hospital and reported on the pathology CRF by a 
member of the research team. The surgical specimens will be retrieved and “banked” 
following surgery for pathological analysis. Clinical follow up will take place using 
routine outpatient consultations and any subsequent imaging as per local policy. 
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13.2.3. Inclusion Criteria 
• Locally advanced primary adenocarcinoma of the rectum (requiring pre-
operative treatment); diagnosed on tissue biopsy  
• Adult patients – over 18 years  
• Able to undergo curative (TME) surgery  
• Able to undergo MRI and CT with relevant contrast agent  
• Able to undergo LCRT  
Exclusion Criteria 
• Metastatic disease at presentation 
• Emergency diagnosis/treatment 
• Unable to undergo staging (MRI and CT) or treatment procedures 
(LCRT/surgery) 
 
13.2.4. Sample size 
The primary endpoint for this study is disease relapse at 3 years. There will be interim 
analysis at one year. This is a non-matched prospective case-control study. We have 
estimated relapse at year one for EMVI positive patients to be in the order of 33% and 
EMVI negative to be 16%. At year 3 we estimate 75% relapse in patients with EMVI 
positive rectal cancer compared with 35% of EMVI negative tumours. Using previous 
work, we estimate that 25% of EMVI positive rectal cancer becomes EMVI negative 
following CRT. Recruitment will take place over a two-year period, with an additional 
three years of follow-up. We anticipate a maximum of 5% loss to follow up at three 
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years. A total of 40% of all patients are expected to be EMVI positive prior to treatment. 
Based on these estimates, the study would have 91% power to show a difference in 
relapse rate with a total of 80 patients (48 EMVI negative and 32 EMVI positive), using 
a two-sided alpha of 0.05. 
The laboratory work is an observational hypothesis. There are no statistical 
calculations or power analyses that can be done at this time, as there isn’t any existing 
data that can be used to extrapolate from. If a biomarker is found, it would need to be 
internally and externally validated formally (in further studies).  
13.2.5. Analysis methods 
All time to event endpoints will be calculated using Kaplan-Meier methods. Cox 
regression will be used to estimate hazard ratios and 95% confidence intervals. All 
tests will be two-sided with alpha 0.05 unless otherwise stated. The primary endpoint 
of time to relapse will be measured from the date of surgery. Those patients who are 
found to have irresectable disease after CRT will be withdrawn from the trial. Patients 
who do not have successful resection (local disease remaining after surgery) will be 
included with relapse at time 0. Date of relapse in all other patients will be defined as 
the date of first positive diagnosis of local, nodal or distant relapse. Patients will be 
grouped as EMVI positive or negative according to their status pre-CRT, and relapse 
rates compared between the groups using a log- rank test. Relapse rates at 1 and 3 
years will be calculated for both groups, and overall, with 95% confidence intervals. 
Cox regression will be used to calculate a hazard ratio and 95% confidence interval. 
In patients with EMVI positive status pre-CRT, relapse rates will be compared between 
patients who remain positive following CRT, and those who achieve EMVI negative 
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status following CRT. Pathological T and N stage (from the surgical specimen) will be 
compared between the two groups using a Chi-squared or Fisher’s exact test. 
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13.4. Discussion 
This is a multicentre observational trial which is currently open to recruitment. One of 
the main objectives of this trial is to investigate the prognostic and predictive effect of 
EMVI following CRT. Whilst several studies have reported on the survival for specific 
tumour characteristics including CRM, T-stage, nodal disease and EMVI, whether or 
these conclusions apply following CRT is yet to be validated in large numbers. MRI 
has been recently shown to be effective in assessing CRT response but this needs to 
be done prospectively in such a trial. 
In earlier chapters we have seen that EMVI is becoming increasingly recognized as 
an important prognostic factor in rectal cancer. This has been shown to adversely 
affect survival for Stage II tumours as well as being a potential imaging biomarker. 
These initial studies support the need for a large-scale prospective trial and to 
determine whether oncological treatment strategies need to consider EMVI more 
directly. 
The results of this trial will be available in 2017. The Approval letter for the MARVEL 
trial is shown in Appendix D.  
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Chapter 14  
Conclusions  
14.1. Recent and current literature 
14.1.1. Optimal histopathological detection of pEMVI – the future. 
Since the commencement of this thesis in 2010, there have been other investigators 
who have examined the importance of EMVI in similar contexts. In earlier sections, the 
difficulty in accurately identifying EMVI using routine histopathological methods and 
stains has been explained. One of the controversies in the detection of pEMVI has 
been whether or not to use more specialised stains, particularly those which stain for 
elastin. This has now been examined in greater detail in the last few years.  
A large-scale retrospective study from Scotland examined more than 400 specimens 
of both colon and rectal cancer. They carried out a comparison of pEMVI detection 
rates between using an elastica stain and with normal routine H&E staining. The 3-
year survival were no different between the groups however the rate of detection 
improved from 18% to 58% (Roxburgh et al., 2010). They also found that staining for 
elastica improved the prognostic value of EMVI. A direct comparison between using 
H&E alone versus elastic staining and H&E in 53 patients demonstrated an increase 
in the area under the receiver operator curve (ROC) from 0.58, P = 0.293 (H&E alone) 
to 0.74, P = 0.003 for venous invasion detected using the elastica method. Although 
they have not examined rectal cancer specifically, they have also made the argument 
that accurate testing for EMVI is important so not to exclude patients from vital 
adjuvant therapy (Roxburgh and Foulis, 2011).  
240 
 
The experience of pathologists in Canada was reported by Messenger. A population-
based survey was sent to 361 pathologists that yielded a 64.9% response rate. The 
majority of respondents stated they reported EMVI in less than 10% of specimens and 
only 9.1% reporting detection rates above 20% (Messenger et al., 2011). Interestingly, 
special stains were also used if there was suspicion of EMVI but by just over 50% of 
pathologists. 
A further and more recent study from Toronto has further examined the utility of elastin 
stains. The investigators sent forty slides to six specialist gastro-intestinal (GI) and six 
non-specialist pathologists to look for EMVI. Initially they were only stained with H&E 
and subsequently resent following staining for elastin – Movat stained. The overall rate 
of detection improved from 19.6% to 46.4% (p>0.001). Further results from this study 
showed an improved detection rate for specialist GI pathologists and better inter-
observer agreement when Movat stain was used - H&E: κ=0.23 vs. Movat: κ=0.41 
(Kirsch et al., 2013).  
In a recent systematic review exploring the detection methods of pEMVI, the use of 
elastic stains were found to be beneficial with an overall detection rate of 43.6% (van 
Wyk et al., 2014). However rates of detection have been reported as high as 71% for 
all stages of disease in colorectal cancer (Roxburgh et al., 2014, Sejben et al., 2010). 
There appears to be a realisation that EMVI is an important consideration for adjuvant 
therapy and accurate detection is crucial to be able to offer patients optimal survival. 
Furthermore, there is also a shared concern that the current methods of detection are 
resulting in underestimates for the true prevalence of EMVI and therefore there is the 
real possibility that we may be denying patients optimal adjuvant treatment. The 
routine use of specialised stains, in particular elastin-based stains, will most likely 
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become the standard for histopathology. There is accumulating evidence that using 
elastin stains improves detection rates and it may be the case in the future that the 
use of these stains becomes incorporated into universal guidelines for pathologists. 
14.1.2. The use of MRI-based scales to measure CRT treatment response. 
In earlier chapters, the use of MRI to detect and grade EMVI in response to CRT has 
been shown as prognostically important. Indeed, it may be possible to use mrvTRG 
as a predictor of disease progression and to determine which patients require 
increased surveillance and intensified chemotherapy regimes. Such a scale has 
recently been shown to predict survival following CRT by using radiological changes 
to the tumour as a whole. 
Studies by the MERCURY Group have demonstrated the accuracy of the MRI-based 
TRG scale (mrTRG). A study in 2011 from the MERCURY Group examined the 
response to CRT of 111 patients with locally-advanced rectal cancer (Patel et al., 
2011b). They compared the tumour regression grading of MRI and histopathology. 
Further they investigated the use of MRI to predict ‘good’ and ‘poor’ responders using 
specific radiological criteria. MRI assessment of TRG was an independent predictor of 
poor survival and recurrence. Hazard ratios (HR) of 4.40 (95% CI, 1.65 to 11.7) and 
3.28 (95% CI, 1.22 to 8.80) were seen with ‘poor’ mrTRG for overall survival and 3-
year DFS, respectively. And for an MRI predicted CRM involvement was 
independently significant for local recurrence with HR of 4.25 (95% CI, 1.45 to 12.51). 
This compared to ypT stage and ypCRM status as independent predictors of 
recurrence and survival. 
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14.2. Final Conclusions and future perspectives 
The treatment for rectal cancer is evolving and consequently staging systems have 
followed to maintain accurate risk-stratification of patients. Historically, clinicians used 
evidence of tumour depth, nodal disease and metastatic spread to offer relatively 
simplified treatments, primarily involving surgical resection. However as more tumour 
features have been shown to be related to prognosis in addition to more detailed 
information becoming known about the more traditional adverse features, patients 
have been offered more tailored treatments.  
Most patients present with what is described as “locally advanced” disease, which 
means that the tumour has penetrated through the bowel wall into the surrounding 
mesorectum. These patients require radical resection of their tumours under the 
surgical principles set out in ‘total mesorectal excision’ (Heald et al., 1982). 
Furthermore, they are likely to benefit from additional oncological therapy. Tumour 
characteristics associated with this include features such as nodal disease and EMVI. 
Offering neoadjuvant CRT to patients is the most common treatment strategy for 
locally advanced tumours. However the proportion of patients who are likely to benefit 
from such treatment is not as clear as previously thought, and features such as EMVI 
may be underestimated at present. For example, most centres will pre-operatively 
irradiate tumours whose only adverse feature is involved mesorectal nodes under the 
assumption that these nodes are a risk for local recurrence. But considering the 
anatomy of lymphatic drainage in the mesorectum does not cross the mesorectal 
fascia and that optimal TME surgery will involve high ligation of the inferior mesenteric 
artery and excision en-bloc of the tumour, rectum and mesorectum attached to the 
vascular pedicle, it seems illogical to offer radiotherapy for this reason alone (Chand 
et al., 2013b).  
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The rationale for this approach is based on historical data which did not exclusively 
examine patients’ who had undergone optimal surgery in the CR07 trial for example. 
Indeed, in those patients who did undergo TME surgery the benefit of radiotherapy 
was marginal. Using neoadjuvant therapy more selectively will mean that patients who 
are more likely to benefit from the treatment are offered it whilst those who are less 
likely are not subject to the additional morbidity associated with an intensive treatment 
such as radiotherapy (Chand et al., 2013a).  
The future of rectal cancer treatment will be based on identifying those patients who 
are most at risk of disease recurrence and offering them more intensive treatment 
whilst at the same time not burdening patients who are unlikely to benefit from 
additional treatment with added morbidity. This policy of selective oncological 
treatment must be based on accurately identifying those adverse factors which are 
most associated with disease recurrence that can be treated with current therapies. 
EMVI may be one such feature and by using more accurate techniques and different 
approaches to detection, it will be possible to truly understand its prognostic relevance 
in rectal cancer. 
EMVI has become increasingly recognised as a poor prognostic factor and improving 
consistency of its definition along with more accurate detection has meant that its true 
prognostic value is being recognized. Although there is still no randomized trial 
evidence which definitively shows it to be a predictive factor in rectal cancer, there is 
growing level 2 and 3 evidence as described above. A review of the current literature 
shows a huge variation in detection rates over the years. The vast majority of these 
studies have been based on patients undergoing primary surgery with only a small 
proportion having adjuvant chemotherapy. The evolution in the management of rectal 
cancer has led to a greater number of patients being offered pre-operative CRT for a 
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period of 6-12 weeks. This has made these historical studies redundant in one aspect 
such that the prognostic effect of EMVI once it has been exposed to both 
chemotherapy and radiotherapy may not be the same as in those patients who have 
undergone primary surgery.  
A major advance in the detection of EMVI has been the increasing use of MRI. It has 
now become integral to the staging of rectal cancer and despite the popularity of endo-
anal ultrasound in the USA, MRI remains the mainstay of local staging for the majority 
of patients. Thus EMVI can be first detected at the time of initial staging at diagnosis 
compared with the historical studies described above, where the first time EMVI was 
detected was following surgery and analysis of the resection specimens by the 
pathologist. In addition, the role of MRI in the treatment pathway allows morphological 
changes in EMVI to be quantified and compared with the post-operative pathology. 
This has provided many exciting opportunities to understand the prognostic relevance 
of EMVI in the modern-era of rectal cancer management.  
MRI is routinely used to risk-stratify patients early in the management pathway and 
forms the basis of treatment-decision making for neoadjuvant CRT. The last decade 
has seen the acceptance of high-resolution MRI to inform clinicians with regards to 
decision-making. The identification of the CRM is the most important of adverse 
features. However, to varying degrees the identification of tumour spread into the 
mesorectum (T3 sub-stage) and nodal disease have also been reasons for 
neoadjuvant therapy. The results of trials have shown that neoadjuvant therapy in 
combination with TME surgery have improved the rates of local recurrence 
significantly, but this has not translated to an improvement in overall survival 
(Glimelius, 2013). The devastating effects of local recurrence have been dramatically 
reduced but it is the systemic disease which is leading to death from rectal cancer and 
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it is this which needs to be targeted in the future. Developing new strategies to reduce 
the risk of distant disease and ultimately improve overall survival must be the goal of 
future studies. It is unlikely that radiotherapy will have a significant role to play in this 
and the mainstay of treatment will be chemotherapy either in the adjuvant, or possibly, 
the neoadjuvant setting. The difficulty will be convincing patients that rather than opting 
for an operation after a period of chemoradiotherapy, that they should continue with a 
further six months of chemotherapy whilst alleviating their concerns of the risk of the 
disease becoming more advanced. Furthermore, there is a risk of over-treating 
patients and there must be sufficient robust evidence behind such a strategy. Aside 
from the side effects associated with a prolonged period of systemic chemotherapy, 
patients can be wary from protracted treatment particularly if this results in lethargy. 
This resistance from patients to continue with systemic chemotherapy has been seen 
in the post-operative setting whereby patients who have already undergone intensive 
pre-operative treatment followed by a major operation are reluctant to undergo further 
systemic treatment for a limited benefit (Khrizman et al., 2013).  
The survey conducted in Chapter 7 investigating the role of MRI in treatment decision-
making demonstrated the acceptance by most clinicians in using high quality imaging 
to guide decisions. Whilst MRI has an established role in influencing neoadjuvant 
therapy, it is encouraging that there is an appetite for its use in adjuvant treatment. 
Our institution has a policy of using a combination of pathological and radiological 
factors to decide on adjuvant treatment. For example, a stage II tumour which has no 
adverse features following CRT would normally not be offered adjuvant chemotherapy 
in most centres across Europe. Whilst the NCNN guidelines (NCNN, 2013) suggest 
that all patients who have undergone neoadjuvant therapy for locally advanced 
disease should be offered adjuvant chemotherapy regardless of pathological staging, 
246 
 
there is no evidence behind this stance and further it is difficult to explain this to 
patients in a quantifiable manner. In our institution, the initial staging MRI scans are 
re-visited to look for nodal disease; and if this proves to be positive for mesorectal 
nodes patients are offered further chemotherapy. Again, there is no evidence behind 
this but highlights the variability in practise shown in the survey results.  
Another aspect of this variability in practise is the perceived survival benefit of adjuvant 
treatments. Even within the oncology community, there is variation in the survival 
benefit offered by adjuvant chemotherapy which means patients are being told 
differing information about the same treatment. Until there is clear evidence and 
associated guidelines, patients will be offered potentially inaccurate information to 
base their decisions on – either under- or over-representing survival benefit.    
Interestingly, there remains a reluctance to use MRI following CRT for decision-making 
and a persistent reliance on pathology. Direct comparison of like-for-like (MRI versus 
MRI) seems to be the obvious and intuitive thing to do when it comes to guiding 
decision-making. The same MRI sequences and protocols are used for initial staging 
and for post-CRT imaging which is ideal for comparison of treatment effect and study 
of prognostic factors. The effect of tumour regression was originally derived in 
oesophageal cancer following neoadjuvant treatment (Mandard et al., 1994). There 
have been recent reports describing the accuracy of MRI-based regression grades on 
measuring the effect of treatment response in rectal cancer (Patel et al., 2011b). In 
these reports, an MRI-derived TRG scale (mrTRG) has been shown to be 
independently predictive of disease-free survival and overall survival. An argument 
against using such a scale is that once the patient has had surgery and been finally 
staged by pathology, the mrTRG scale is redundant. Yet there are associated 
difficulties in relying on pathology alone.  
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Firstly, there is no robust evidence to suggest that adjuvant chemotherapy following 
surgery in patients who have undergone neoadjuvant chemoradiation show any 
survival benefit. However, patients in whom there has been tumour regression 
following variable neoadjuvant chemotherapy regimes show improved survival. This 
would suggest that evaluating disease response by MRI and then deciding on further 
neo-adjuvant treatment may be a better strategy than the use of post-operative 
chemotherapy. Therefore, tumour features such as EMVI and their response to CRT 
could be objectively measured on MRI and used to decide whether further pre-
operative chemotherapy is beneficial.   
Secondly, using pathology alone may result in a significant number of patients with 
EMVI being missed. A major challenge in the detection method for patients has been 
the effect of CRT on the architectural features pathologists use to identify EMVI. 
Accurate detection of adverse features relies on standardisation of technique and 
definition, both of which are currently lacking in pathology. The gradual acceptance of 
pro-forma based reporting actively encourages the pathologist to seek out features 
such as EMVI and is no doubt the future of pathology reporting. However even with 
more accurate techniques than currently in routine use, much of the detection of EMVI 
is based around the identification of specific architectural features. The fibrosis which 
results from CRT produces anatomical distortion thus ‘hiding’ the presence of EMVI 
(Messenger et al., 2011).  
But before the correct techniques and definitions are applied to the specimens, it is 
important that they tumour is adequately sampled and that it is cut up in a manner 
which is optimal for EMVI identification. This has been exhaustively described by 
Quirke et al (Quirke and Morris, 2007). The pathologist can only look for EMVI in the 
specimen they have been provided - another disadvantage of using pathology alone. 
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All these problematic issues with identifying ypEMVI alone can be helped by the use 
of MRI. Certainly, a starting point would be to use MRI as a reference which would 
‘guide’ pathological analysis. Although, MRI interpretation post CRT has been labelled 
difficult by some, using the same criteria for identification EMVI can be accurately 
sought. It is also independent of the quality of the resection specimen and sampling 
by the pathologist. The entire rectum can be seen in-situ therefore giving a better 
picture of the anatomical relationship of the tumour and surrounding vasculature.  
Traditionally, the use of adjuvant chemotherapy and prognostication of patients 
following surgery has been based on studies involving primary surgery. Much of this 
evidence is still used in rectal cancer for which there is scarce data on the effect of 
CRT on tumour features. The effect of neoadjuvant therapy with the use of 
radiotherapy +/- chemotherapy in varying doses is clear on local recurrence. There is 
little dispute that local recurrence rates have fallen not simply because of improved 
surgical technique but the addition of pre-operative treatment. Yet the overall survival 
of these patients is unchanged. The interpretation must be that it is the systemic 
disease which ultimately affects survival which is not adequately treated by the use of 
radiation and limited chemotherapy. Therefore the role of adjuvant chemotherapy 
becomes very interesting. But how effective is chemotherapy in patients who have 
already undergone neoadjuvant CRT and can we continue to use the same pre-
treatment features to guide such treatment?  
If we relate the use of oncological treatment to the surgical anatomy of the rectum, it 
may give us some clues. The rectum as we have seen earlier is surrounded by an 
embryological fatty envelope. This acts as an oncological barrier which contains the 
lymphatic channels and nodes which can act as conduits for tumour cells. Many 
centres use the presence of tumour in these nodes as a reason to offer radiotherapy 
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prior to surgery. These nodes and their channels do not cross the mesorectal fascia 
and if good quality surgery under TME principles is performed, will be excised en-bloc 
with the tumour. The rationale for this treatment is based on studies in which TME 
surgery was not an inclusion criteria and thus specimen quality was variable (Chand 
et al., 2014). Alternatively, the veins outside the bowel wall do cross the mesorectal 
fascia and these too can act as conduits of disease progression. Could it be a 
possibility that post-CRT we are chasing the ‘wrong’ adverse feature and it is actually 
EMVI that we should be pursuing? 
The importance of EMVI and MRI-based detection of adverse features is being 
increasingly recognised. The main problem is that there is still no robust randomized 
evidence that shows that either (y)pEMVI or (y)mrEMVI are predictive factors for 
survival. It is unlikely that without this evidence that oncologists will be willing to treat 
patients on the basis of anecdotal evidence alone. The design of current trials has 
tried to address this question somewhat – for example, MARVEL (Chapter 13) has the 
opportunity to assess EMVI directly. The results of the survey above show the 
confusion. Even within a learned community there is a great variability in the benefit 
of chemotherapy in EMVI-positive patients and whether mrEMVI should be used as a 
prognostic factor for decision-making. In these situations, it is strong level 1 evidence 
in the form of a prospective randomized trial or meta-analysis that can provide 
guidelines.  
The discordance between mrEMVI and pEMVI remains problematic and may hinder 
the interpretation of future trials investigating the clinical relevance of EMVI. We have 
already described some of the reasons behind under-reporting in pathology 
particularly after CRT. However, the question of whether mrEMVI is a true reflection 
of venous invasion must also be addressed. Without direct correlation between optimal 
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histopathological analysis, mrEMVI will continue to suffer scepticism. One possibility 
is that mrEMVI may not be exactly the same as pEMVI. The radiological characteristics 
which define mrEMVI may be demonstrating some other phenomenon such as a 
combination of lymphovascular, perivascular and perineural invasion. If this is the 
case, perhaps looking at mrEMVI as an entirely separate prognostic factor may be 
more fair comparison. After all, whether mrEMVI and pEMVI are the same 
phenomenon or not, the results of these studies in addition to others continue to show 
mrEMVI as an independent marker of poor prognosis. On the other hand, if the 
discordance between mrEMVI and pEMVI are simply due to over-diagnosis of one 
versus under-diagnosis of the other, optimising definitions and techniques for both 
radiologists and pathologists should help to bridge this gap. Further work involving 
detailed correlation of tumour between MRI image slices and representative sample 
from the tissue blocks will aid development of consistent and accurate techniques. 
This work is currently being undertaken by our research group and is ongoing but is 
not included in this report.  
The issue of adjuvant chemotherapy for patients with EMVI will need further resolution. 
There are two main issues; firstly, there is component of the current staging systems 
that accounts for EMVI which means including this in the treatment discussion whether 
that be in the forum of the MDT or with patients alone is an additional conversation. 
Secondly, the fact that most tumours with EMVI will have associated poor prognostic 
features means that they will most likely undergo neoadjuvant CRT. The role of 
adjuvant chemotherapy in this setting is unclear as already discussed. This leads on 
to the need for a new, randomized trial where the survival benefit in patients post CRT 
that show evidence of persistent EMVI can be evaluated. The design of such a trial 
will be challenging and at minimum will suffer from a limited number of patients. To 
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accurately identify the predictive and prognostic effect of EMVI post CRT, patients will 
need to have been given a pathological stage II and show evidence of mrEMVI on the 
post CRT images. There will be only 300-400 patients per year that fit such a criteria 
and a sample size will be in the order of 400 patients to determine a 20% difference in 
3-year DFS at the 90% power level. This doesn’t preclude a trial but highlights some 
of the initial hurdles in the design phase.   
The role of biomarkers will continue to increase in the future and diversify to involve 
different disciplines, for example, molecular biology, imaging; biochemistry. A concern 
of some clinicians is that pushing more intensive treatments to poor prognosis tumours 
is over-treating patients with potentially little gain. Conversely, if a subset of patients 
with poor prognosis are ‘missing out’ on treatment because of under-diagnosis, we 
may be doing these patients a dis-service. More accurate identification of patients who 
are not only at significant risk of poor outcomes, but also will benefit the most from 
additional intensive treatment is the goal of biomarker medicine.  
The utility of biomarkers is in their ability to identify high-risk populations. It is unlikely 
that one particular sequence of cDNA, RNA or microRNA will be able to guide 
treatment for all patients and that combinations of adverse biomarkers will result in 
more accurate risk stratification. Studies which seek to validate molecular biomarkers 
and in particular microRNAs, report under- or overexpression being linked with 
survival. These sequences can then be targeted for therapeutic exploitation. Clearly, 
as with any pharmaceutical product that attempts to enter the market, stringent testing 
will need to be overcome to ensure that these sequences not only target cancels for 
reduction in aggressiveness but also do not affect normal host tissue leading to 
undesired consequences. This is a fundamental difference compared to imaging 
biomarkers which are able to identify high-risk populations and monitor disease 
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response to therapy but not currently a target for therapeutic purposes. This highlights 
the interaction between biomarkers of differing types (as explained in chapter 10). 
Whilst one type may seek to detect and monitor disease, another may be able to treat 
disease.  
On a more fundamental level, identifying changes in the underlying biology of tumour 
following treatment and linking these changes to survival allows targeting of specific 
areas of the tumour. This can be demonstrated in the changing of EMVI status which 
improves disease free survival but also has an underlying molecular change. If studies 
such as MARVEL are able to show these changes between the biopsies and resection 
specimens, we will be able to simplify further the targeting of microRNAs and gain a 
better understanding of the pathways involved in disease progression and metastases. 
The results of TMA studies above have identified specific sequences which are unique 
to EMVI tumours. Clearly, validation both internally and externally will be required 
before any consideration can be made of therapeutic translation but the results are 
encouraging. The use of such novel technologies is a must if we are to understand the 
natural biology of these diseases and will greatly enhance the large scale studies 
currently underway examining the clinical effects of different treatment groups and 
validation of prognostic markers of disease progression and survival. 
There is certainly a long way to go before unique microRNA sequences can be 
exploited therapeutically. microRNA 21 is considered by many to have the greatest 
potential of the current crop of microRNAs associated with colorectal cancer (Asangani 
et al., 2008). However, this along with other sequences such as those identified in the 
above study need accurate characterisation into the tumorigenesis and progression of 
disease pathways.  
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The pattern of recurrences highlights another important consideration in the general 
management strategies of high-risk EMI positive patients. The majority of recurrences 
occurred in the liver suggesting a preponderance for this site. Whilst the underlying 
pathways for liver metastases are still not fully known, there must be an anatomical 
association through the vasculature which leads to this phenomenon. The 
mechanisms of metastatic spread and thus the potential targets of treatment in the 
future still need further investigation however in the meantime, patients who are 
considered at risk of liver metastases should be offered more frequent follow-up. This 
may include shorter periods between imaging of the liver and clinical follow-up 
appointments in an attempt to identify potential disease recurrence at the earliest of 
stages. Therefore tailoring surveillance regimes based on an individual’s risk may be 
preferable compared with a more generalised approach. Currently, there is no 
universal consensus on follow-up for patients at risk of disease recurrence and 
strategies vary from unit to unit in terms of endoscopic, radiological and clinical follow-
up. Unifying a follow-up protocol will also give patients more confidence in their general 
treatment knowing that wherever they are treated they will receive similar surveillance.  
A further point which has possibly led to an underestimation of the significance of EMVI 
in influencing treatment strategies is the association with other known adverse 
features. A recent randomised study by Rullier et al, comparing neoadjuvant 
radiotherapy plus capecitabine to radiotherapy plus capecitabine plus oxaliplatin in T3-
4, M0 rectal cancer showed an association between a positive CRM and vascular 
invasion (Rullier et al., 2013). In patients with a positive CRM, 19.6% had vascular 
invasion compared with 6.2% of patients who did not have any evidence of invasion. 
This was found to be significant on multivariate analysis.  
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By definition, EMVI is found exclusively in locally advanced tumours in terms of tumour 
penetration and nodal disease. This means that these tumours would have been 
offered neoadjuvant therapy in any case, and as current regimes are standardised 
whether such tumour have EMVI or not will not change the management. Although 
this is an important limitation of EMVI as a prognostic factor influencing neoadjuvant 
treatment, it is adjuvant treatment where there is more potential for changing treatment 
strategies. With the current lack of strong evidence on the prognostic implications of 
tumour features following CRT, there is an opportunity to help define guidelines. To 
do this, and plan appropriate trials to validate hypotheses of EMVI being associated 
with disease recurrence and that EMVI can be treated by intensive chemotherapy 
regimes, there must be a fundamental shift away from traditional adverse features 
such as nodal disease. The QUASAR trial continues as the basis of evidence for many 
clinicians despite only a limited number of rectal cancers in the cohort studied and that 
no patients had CRT. However to isolate patients following CRT with only EMVI as a 
recognised adverse feature will be difficult. This has been explained above but briefly, 
there must be a universal consensus on EMVI detection and as the number of patients 
will be relatively small, any investigation will require a multicentre design. 
Approximately, 15000 patients are diagnosed with rectal cancer per year, however 
using results in the above studies for determining the prevalence of ymr/pEMVI, ypT3b 
or less, ypN0, CRM clear tumours will equate to around 300-400 patients only. 
Recruitment for such a trial will be difficult and require a multicentre design.  
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Appendix B 
 
Addressograph 
 
 
 
Pathology Reporting Form 
 
Pathologist: Date: 
 
Study Code: Surgeon: 
 
Patient initials: Operation date …/…/20... 
 
Date of Birth: Sex                M F 
 
 
Biopsy report 
 
Type:                                 Adenocarcinoma Mucinous 
 
Differentiation:                Poor Well/mod 
 
Comments:  
 
 
Histology 
 
Type: Adenocarcinoma         Yes           No 
 
Differentiation:(By predominate type)         Poor Well/Mod 
 
 Other tumour type (Please State) ……………………………………………. 
 
 
Maximum extramural spread of tumour 
 
 Above sphincters (from edge of muscularis propria) .….mm 
 At sphincters (from edge of internal sphincter) .….mm 
 
 
Minimum distance of tumour to CRM from outer edge of tumour .….mm 
 
 
Is the resection complete? (>1mm to the CRM) Yes No 
 
Metastatic Spread 
 
No of Nodes examined  …….. 
 
No. of 
 
positive nodes …….. 
 
 
 
Apical Node positive 
  
 
Yes     No 
 
 
Extramural Vascular invasion Yes No 
 
 
270 
 
Extra – nodal deposits seen Yes No 
 
 
CRM Involved Yes No 
 
Maximum length of margin involvement …………mm 
 
Mode of CRM Involvement: Direct                      Vascular 
 
 Node           Tumour Satellite  
 
 
Site of CRM Involvement                  At mesorectum                          Below 
                            Mesorectum 
            (at levators/sphincters) 
 
 
Tissue at CRM:                                     Normal tissue                       Fibrosis 
 
                                   Tumour 
 
Distance from dentate line to lower border of Mesorectum …………..mm 
 
 
 
Plane of resection 
 
Mesorectum (all specimens) 
 
Plane                       Muscularis propria  Intramesorectal   Mesorectal 
 
 
 
 
 
 
Post neoadjuvant therapy tumour regression 
 
 
No regression                          Minimal regression                   Moderate regression  
 
 
Good regression                      Total regression 
 
 
 
 
Other comments 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………… 
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